thiazoles has been researched along with Diabetes Mellitus, Type 2 in 809 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 207 (25.59) | 18.2507 |
| 2000's | 524 (64.77) | 29.6817 |
| 2010's | 69 (8.53) | 24.3611 |
| 2020's | 9 (1.11) | 2.80 |
| Authors | Studies |
|---|---|
| Bernal-Fernández, G; Castillo-Salazar, M; García-Jiménez, S; Hernández-DiazCouder, A; Mojica-Cardoso, C; Navarrete-Vázquez, G; Sánchez-Muñoz, F; Springall Del Villar, R; Toledano-Jaimes, C | 1 |
| Akhtar, T; Ehsan, M; Haroon, M; Mehmood, H; Musa, M; Tahir, E; Woodward, S | 1 |
| Ahmed, A; Ahsan Halim, S; Al-Harrasi, A; Bin Muhsinah, A; El-Seedi, HR; Irfan, M; Khan, A; Saeed, A; Tehzeeb, A; Ul Ain, Q; Ullah, S | 1 |
| Cui, ZN; He, M; Li, YJ; Li, YS; Shao, J | 1 |
| Ishii, Y; Kakefuda, R; Katsuda, Y; Maekawa, M; Ohta, T; Okuma, C; Sano, R; Sasase, T; Tadaki, H; Tomimoto, D; Yoshiuchi, H | 1 |
| Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z | 1 |
| Matsudaira, T; Nawano, M; Ohashi, R; Sugama, H; Takayama, H; Yanagisawa, H; Yasuda, K | 1 |
| Chandran, A; Drews, K; El Ghormli, L; Sylvetsky, AC; Talegawkar, SA; Welsh, JA | 1 |
| Mourad, AAE; Mourad, MAE | 1 |
| Aasen, T; Abdul Moin, NI; Abdul Wafi, S; Aboukameel, A; Abu-Bakar, N; Acharya, A; Ackermans, L; Adaramoye, O; Adarsh, KV; Adeosun, WA; Ahmad, NH; Ahmadi, F; Akanni, O; Akbar, M; Akbulak, RO; Akev, N; Akkaya, Ö; Al-Rashed, S; AlAbbad, S; Alabi, O; Alappat, BJ; Alcalá, S; Alcoutlabi, M; Aleppo, G; Alexander Ross, JB; Alexander, JH; Alexander, R; Alias, A; Alimba, C; Alken, FA; Allan, R; Alpers, M; Alsbou, EM; Amarasiri, SS; An, T; Anastasiadis, F; Anastassiadou, M; Anderson, KC; Andronikos, P; Anheyer, D; Annapurna, K; Anorlu, RI; Anten, MM; Anthopoulos, TD; Araujo-Castillo, RV; Aravamudhan, S; Arawwawala, LDAM; Arulsamy, N; Arunamata, A; Asghar, A; Asiri, AM; Aslanidou, T; Astrakhantseva, IV; Astutik, E; Attanayake, AP; Atwater, BD; Audureau, E; Augusto, S; Bakare, A; Banach, M; Bandelier, P; Banerjee, S; Barral, M; Bascuñán, J; Bates, FS; Bauer, NJC; Bayrak, BB; Beck, RW; Beckervordersantforth, J; Beeri, R; Begum, R; Beldi-Ferchiou, A; Bellingham, G; Ben-Tal, N; Bendib, I; Bergenstal, RM; Berger, MF; Bernasconi, G; Berry, S; Beuvon, F; Bi, WJ; Bi, Z; Bianconi, V; Bibi, I; Blank, BR; Bliemeister, E; Bobkowski, W; Bode, AM; Booth, CM; Bose, U; Boyd, K; Brancato, A; Brenmoehl, J; Brogi, E; Bronzo, P; Brooks, T; Brown, D; Brown, DN; Bruce, D; Buan, MEM; Bueno-Hernández, F; Bugielski, B; Bulavaitė, A; Buscagan, TM; Buxton, R; Caffaro, MM; Cai, Q; Cai, X; Cai, Y; Calhoun, P; Callander, N; Cambier, S; Camparo, P; Canales-Vargas, EJ; Canham, K; Cantu, J; Cao, J; Cao, JW; Cao, P; Cao, T; Cao, X; Caravella, BA; Carcadea, E; Carè, J; Carmichael, P; Carrasco Cabrera, L; Carteaux, G; Carvalho, PDS; Casarez, E; Cazorla, M; Celestrin, CP; Chakraborty, NK; Chan, B; Chandarlapaty, S; Chandgude, AL; Chang, CC; Chang, JH; Chang, X; Chang, Y; Chankhanittha, T; Chantanis, S; Chapovetsky, A; Chavan, S; Chen, B; Chen, D; Chen, F; Chen, G; Chen, H; Chen, J; Chen, K; Chen, KJ; Chen, KP; Chen, L; Chen, MA; Chen, Q; Chen, S; Chen, W; Chen, WF; Chen, X; Chen, Y; Cheng, D; Cheng, J; Cheng, Q; Cheon, GJ; Chiu, SC; Cho, CH; Cho, J; Choi, H; Choi, JS; Choi, YH; Christie, P; Chu, CH; Chu, Y; Chung, DH; Chung, F; Cline, JP; Cohen, A; Cohen, AD; Cohen, NJ; Comen, E; Compter, I; Cong, J; Cong, Z; Cooper, A; Cornud, F; Costa, C; Costa, S; Covey, A; Cowan, AM; Cramer, H; Cruz-Rivera, C; Cui, J; Cui, M; Cui, Y; Cui, YH; Culquichicón, C; Cushman, T; D'Auria, SJ; da Silva, J; Dalgediene, I; Danenberg, HD; Das, S; Dasgupta, K; Daubit, IM; de Oliveira, PD; de Prost, N; De Ruysscher, D; Dearman, K; Decato, D; Delfau-Larue, MH; Deng, L; Dhakate, SR; Dharuman, V; Di Costanzo, N; Dickler, MN; Dinehart, EE; Ding, D; Dinh, TK; Divya, KP; Djifack Tadongfack, T; Do, T; Domínguez-Roldan, R; Domínguez-Zambrano, E; Dömling, A; Donato, MD; Dong, JH; Dong, W; Dong, X; Dong, XR; Dong, Y; Dong, Z; Downs, M; Drutskaya, MS; Du, B; Du, F; Du, H; Du, L; Du, X; Duan, Z; Duangthip, D; Dunstand-Guzmán, E; Duong, F; Eckert, DJ; Edelhäuser, BAH; Eekers, DBP; Efendi, F; Efraimidis, P; Ehrenberg, H; Ehsanbakhsh, Z; Eickholt, C; Eksterowicz, J; El Mobadder, M; El-Araby, IE; El-Magd, MA; El-Tarabany, MS; Elgorban, AM; Engelmann, D; English, KL; Esfandiari, H; Eslami, B; Espinosa-Cuevas, A; Eswara, S; Faber, E; Fan, XH; Fan, Y; Fang, J; Fang, Z; Fantin, VR; Fei, P; Feng, G; Feng, H; Feng, J; Feng, X; Feng, XJ; Fennell, TR; Fernández-Moreira, V; Ferraz, ABF; Ferreras, KN; Flores, K; Flores-Pérez, I; Flox, C; Fluharty, FL; Fokouong Tchoffo, E; Folefack, GO; Foroutan, T; Fort, D; Fourati, S; Fousas, S; Frapard, T; Freguia, S; Friedman, DJ; Friedman, LS; Fu, D; Fu, Q; Fu, Y; Fujinami, S; Furihata, K; Gal, RL; Gan, H; Gao, C; Gao, F; Gao, R; Gao, SS; Gao, W; Gao, XC; Gao, Y; Gao, Z; Garozi, L; Ge, J; Georgiopoulos, A; Gerakiou, K; Ghazimirsaeed, SM; Ghazimirsaeed, ST; Gimeno, MC; Gjestad, R; Glurich, I; Goetchius, E; Goland, S; Goldstein, S; Gonçalves, CM; Gonçalves, H; Gong, Q; Gonzalez, D; Goplen, FK; Gorshkova, EN; Gotsman, I; Govindasamy, V; Granger, CB; Greco, L; Grigoriadou-Skouta, E; Grigoropoulos, P; Grivicich, I; Gromov, NV; Gruber, S; Grytczuk, M; Grzech-Leśniak, K; Gu, L; Gu, S; Gu, Z; Guadagnini, D; Guan, H; Guilliams, M; Guo, J; Guo, L; Gupta, A; Gupta, SK; Gurzu, S; Gutleb, AC; Haban, A; Hablitz, JJ; Hadisuyatmana, S; Hahn, S; Haiges, R; Hallal-Calleros, C; Hamed, M; Hammad, N; Hammer, N; Han, C; Hao, Y; Harnett, J; Has, EMM; Hassanpour, K; Hatzopoulos, D; Hawaldar, R; He, X; He, Y; He, YY; He, Z; Heberman, D; Heckl, D; Hegde, H; Henson, MA; Hernández-Velázquez, VM; Herrera, E; Hijazi, Z; Hirayama, K; Hirth, JM; Hoeben, A; Hohnloser, SH; Hong, M; Hood, K; Hoplock, LB; Hopman, WM; Horlbogen, LM; Hossein Rashidi, B; Hou, G; Hou, H; Hou, J; Hou, Y; Hu, J; Hu, W; Hu, X; Hua, W; Huang, G; Huang, H; Huang, J; Huang, T; Huang, W; Huang, Y; Huang, YD; Huang, Z; Hudis, CA; Hue, S; Huo, J; Hussain, M; Hvas, AM; Ichii, T; Ide Zeuna, J; Ilyas, S; Inoue, T; Iranzo, A; Irfan, M; Iwasa, Y; Iwashita, Y; Izgorodina, EI; J R, A; Jaber, WA; Jaborek, JR; Jacobus, SJ; Jadeja, SD; Jafarabadi, M; Jalan, D; Jamil, MI; Jarrah, S; Jarvis, D; Jayatilaka, KAPW; Jemal-Turki, A; Jeon, YK; Jeong, N; Jeong, SH; Jeong, SY; Jermy, M; Jhaveri, K; Ji, H; Ji, K; Ji, RY; Jiang, F; Jiang, J; Jiang, X; Jiang, Y; Jiao, Q; Jilani, K; Jiménez-Guerrero, P; Jin, L; Jo, YH; Johnson, JG; Johnson, ML; Jones, WS; Jose, S; Jularic, M; Jung, I; Jung, YJ; Jungen, C; Junttila, MR; Kache, S; Kahanovitch, U; Kalantzi, KI; Kallio, T; Kamnoedboon, P; Kang, CH; Kang, H; Kang, J; Kang, KW; Kapoor, P; Karmakar, D; Kartalis, A; Kauranen, P; Kazocina, A; Keikha, F; Keltai, M; Kershaw, SV; Kettani, M; Khalvati, S; Khandhar, S; Khosla, N; Kiely, CJ; Kim, CC; Kim, H; Kim, MJ; Kim, Y; Kim, YH; Kim, YT; Kimoto, E; Kiyu, A; Klatt, N; Kobayashi, M; Koh, J; Köhler, R; Kondadasula, SV; Kong, H; Kong, W; Kong, X; Kotidis, A; Kotwal, A; Kouvari, M; Kozhinov, AN; Kruger, D; Kuang, S; Kuang, Y; Kubota, M; Kuklik, P; Kumar, P; Kumar, SK; Kuo, YF; Kurup, SP; Kusuhara, H; Kuswanto, H; Lacouture, ME; Lambin, P; Lang, CC; Langroudi, FH; Lanman, RB; Larsen, OH; Laskin, J; Le, VH; Leach, M; Lee, BG; Lee, DF; Lee, DS; Lee, HJ; Lee, SB; Lee, YA; Lei, Y; Lekashvili, O; Lelj, F; Lemin, AS; Lemoine, J; Leuschner, R; Li, B; Li, BT; Li, C; Li, D; Li, F; Li, G; Li, H; Li, HW; Li, J; Li, M; Li, P; Li, Q; Li, S; Li, W; Li, X; Li, XY; Li, Y; Li, Z; Lian, Y; Liang, C; Liao, J; Liao, W; Liao, Y; Lin, D; Lin, W; Lin, YL; Lindbäck, J; Lindsay, AP; Ling, J; Linser, PJ; Liu, C; Liu, H; Liu, JJ; Liu, L; Liu, Q; Liu, SF; Liu, X; Liu, Y; Liu, Z; Liu, ZM; Lo Sterzo, C; Lo, ECM; Lobchuk, MM; Lodge, TP; Logotheti, S; Lonial, S; Lopes, G; Lopes, RD; Lopez, J; Lopez, SA; López-Santos, AL; López-Sendón, JL; Loring, Z; Louis, C; Lovita, AND; Lu, DZ; Lu, H; Lu, J; Lu, K; Lu, TT; Lu, Y; Luengo, A; Lum, LG; Luna, JM; Luo, L; Luo, R; Luo, T; Luo, X; Luo, Z; Lv, B; Lymperopoulos, N; Lyras, A; Lyu, Y; M Kannan, A; Ma, H; Ma, M; Ma, Q; Ma, S; Ma, WY; Ma, Y; Maalouf, E; Machado, FA; Maeda, K; Magrans, JO; Maharani, A; Maia, G; Mainwaring, RD; Maji, TK; Majumdar, K; Mannarino, MR; Mansuri, MS; Marinescu, SC; Markatos, G; Marquardt, S; Marraiki, N; Martens, C; Martínez, TJ; Marumo, K; Maruyama, H; Marwani, HM; Marzo, I; Masrati, G; Matamba, P; Mathialagan, S; Matys, J; Mayatra, JM; Mboua, PC; McArthur, T; McCrimmon, RJ; McIntosh, S; McSpadden, S; Medina-Campos, ON; Medvedovsky, AT; Mei, Z; Mekontso-Dessap, A; Menezes, AMB; Meng, J; Meng, P; Meng, Y; Menter, A; Mets, MB; Mets-Halgrimson, R; Metzger, T; Metzler-Nolte, N; Meyer, C; Mi, Y; Michailoviene, V; Mikrogeorgiou, A; Militz, H; Miller Iii, TF; Minarowska, A; Mir, S; Miron, I; Miyake, T; Moayer, F; Modi, S; Moeller, SJ; Mohamad, MN; Mohammed, EHM; Mokhonov, VV; Mondal, A; Moore, J; Moravcova, M; Mordi, IR; Mordi, NA; Mortensen, NP; Moscariello, C; Moser, J; Moynahan, ME; Mu, J; Mu, W; Mudduwa, LKB; Mukherjee, S; Mukhtar, A; Mulkey, DK; Murr, N; Mushtaq, Z; Muthuswamy, N; Mutlu, O; Muto, C; Myroforou, I; Na, KJ; Nabi, M; Nagornov, KO; Nagy, RJ; Naik, A; Nakajima, K; Nam, KT; Nam, YW; Namburath, M; Nammour, S; Namour, A; Namour, M; Nanan, S; Natsume, H; Nave, S; Naveed, A; Nazir, H; Ndubaku, C; Nedospasov, SA; Neradilek, MB; Newcomb, C; Nguépy Keubo, FR; Nguyen, M; Ning, J; Ning, Q; Noguchi, S; Nordahl, SHG; Nordfalk, KF; Norton, L; Noupoue, EM; Nouri, SS; Nowak, JK; Núñez, K; Oakes, K; Odegaard, JI; Ogorodnikova, OL; Ogunsuyi, O; Oh, HK; Oh, HR; Oh, KH; Ohgi, K; Okunade, KS; Oliveira, AG; Olorunfemi, G; Olsen, ML; Olson, BA; Omari, KW; Ondruschka, B; Orfali, R; Orkopoulos, A; Orlowski, RZ; Oser, SM; Oser, TK; Özcan, M; Padilla, V; Paeng, JC; Pajuelo-Lozano, N; Pal, SK; Palmieri, S; Palomeque, E; Pan, W; Panagiotakos, DB; Pandey, M; Pang, D; Pang, Q; Pangarah, CA; Panny, A; Paparella, A; Papirio, S; Papouskova, K; Parang, K; Park, HJ; Park, IK; Park, S; Parker, TL; Parkhomenko, A; Parmon, VN; Parsons, B; Parsons, J; Patel, PR; Patil, S; Patsourakos, NG; Patterson, KC; Pavlidis, P; Pedernera, M; Pedersen, R; Pedraza-Chaverri, J; Pellegrini, M; Peña-Chora, G; Pereira, EDM; Pereira, MADS; Peretz, A; Perez-Padilla, R; Perlman, GY; Perona, R; Petras, C; Phuntsho, S; Picada, JN; Pinder, TA; Piper, LFJ; Pirozzi, F; Pirro, M; Pleckaityte, M; Ploutz-Snyder, LL; Ploutz-Snyder, R; Pogorzelski, A; Poles, L; Postma, AA; Prager, A; Prakash, J; Punn, R; Pützer, BM; Qi, J; Qi, MC; Qi, Y; Qian, J; Qian, Y; Qiang, L; Qiu, J; Qu, Y; Rabiu, KA; Rahighi, S; Rahman, MM; Rahmani, B; Rajkumar, SV; Ramanathan, R; Raras, TYM; Rashi, Y; Rasool, G; Rathore, MG; Ratnawati, R; Ratola, N; Raucci, U; Ray, SK; Razavi, P; Razazi, K; Razek, S; Razi, SS; Reback, M; Reddy, K; Rees, DC; Reginatto, FH; Reich, H; Reis-Filho, JS; Ren, X; Ren, Y; Renner, G; Rey, G; Reymen, B; Riaz, M; Ricci, A; Richardson, PG; Richter, C; Riga, M; Ritchie, C; Rivoal, S; Roberts, W; Robson, ME; Rocha, GZ; Rodrigues, AD; Rogach, AL; Rojas, A; Rosenberg, A; Rosenberg, E; Rosenheck, RA; Roslan, K; Rothenberger, C; Rouschop, KMA; Rubagumya, F; Ryan, CM; Ryder, JW; Saad, MJA; Sacan, O; Sacchi, A; Sahebkar, A; Saini, A; Sainz, B; Sajo, EA; Sakizadeh, J; Saleh, AA; Salgado Júnior, IB; Salvi, R; Samoylova, YV; Samuni, A; Sanchez, DM; Sanchez-Perez, I; Santos, M; Sarapulova, A; Sardot, T; Saud, N; Sauerbier, P; Scaltriti, M; Schaeffer, B; Schalk, DL; Scherschel, K; Schijven, MP; Schreuder, HWR; Schuhmacher, M; Schultz-Lebahn, A; Schwarzl, J; Scott, JM; Sebayang, SK; Seeger, ZL; Segabinazi Peserico, C; Selenica, P; Serio, A; Seruga, B; Shah, A; Shah, C; Shah, PD; Shahrokh Tehraninezhad, E; Shan, A; Shao, Z; Sharma, AMR; Sharma, RK; Shen, J; Shen, R; Shi, X; Shi, Y; Shi, ZE; Shih, YC; Shimohata, H; Shimpi, N; Shin, SH; Shon, HK; Shuvy, M; Siddique, AB; Siegbahn, A; Sikandar, M; Silvani, Y; Singh, A; Singh, AK; Singh, D; Singh, JS; Singh, KP; Singh, M; Situ, B; Skipper, MT; Skouloudi, M; Sloane, BF; Smyrnioudis, N; Snyder, MA; Söhnchen, C; Solis Condor, R; Solit, DB; Someya, S; Song, H; Song, J; Song, W; Song, Y; Sorokina, KN; Soshi, S; Soyer, P; Spitschak, A; Sreekrishnan, TR; Srinivasan, M; Staruschenko, A; Steel, A; Stefan-van Staden, RI; Stein, AM; Strayer, H; Struthers, AD; Su, H; Su, Q; Su, X; Sudore, RL; Sugimura, H; Sugiyama, Y; Sujuti, H; Sumner, SJ; Sun, B; Sun, D; Sun, H; Sun, J; Sun, JY; Sun, X; Sun, Y; Sun, Z; Sung, YC; Surenaud, M; Sutimantanapi, D; Suwandaratne, NS; Swaroop, S; Sychrova, H; Syed, A; Szczepanik, M; Szederjesi, J; Szodorai, R; Tacy, TA; Tadelle, RM; Takayasu, M; Tammeveski, K; Tan, H; Tan, M; Tang, HX; Tang, S; Tang, X; Tanokura, M; Tao, F; Tao, H; Tarafdari, A; Tarín-Carrasco, P; Tasson Tatang, C; Teixeira, JP; Thakur, A; Theobald, A; Thevenot, P; Thomaidis, K; Tian, J; Tillib, SV; Toma, C; Tomita, M; Tonchev, I; Tong, F; Toy, W; Trypuć, M; Tselepis, AD; Tsetseris, L; Tsikouri, GE; Tsikouris, EI; Tsoplifack, CB; Tsoumani, ME; Tsujimoto, R; Tsybin, YO; Tu, J; Tu, TM; Turco, M; Turkyilmaz, IB; Uddin, MJ; Ung, J; Unsihuay, D; Utsunomiya, T; Vagenende, B; Vaishnav, J; Valdes, C; Validad, MH; Valle, J; van Ginkel, MPH; van Grevenstein, WMU; Vanderpuye, V; Vasan, N; Vasilenko, EA; Vasques, GJ; Vavoulis, P; Verani, A; Veziroglu, E; Viegas, A; Vitali, MG; Vitsas, G; Voccio, JP; Vogiatzidis, C; Volow, A; Volpin, F; Vourvahis, M; Wagner, LI; Walkowiak, J; Wallace, R; Wallentin, L; Wan, D; Wan, L; Wan, T; Wang, C; Wang, F; Wang, FN; Wang, H; Wang, J; Wang, L; Wang, Q; Wang, S; Wang, T; Wang, W; Wang, X; Wang, XW; Wang, Y; Wang, YS; Wang, Z; Ward, J; Ward, L; Waseem, R; Watson, DF; Weber, P; Wehrmeister, FC; Wei, CH; Wei, H; Wei, L; Wei, Q; Wei, Y; Weinstock, RS; Weiss, M; Welborn, M; Wen, L; Wen, LM; Wen, Q; Wen, Z; Wesseling, P; Westerbergh, J; White, K; Wick, MP; Willems, S; Wiyasa, IWA; Wójciak, R; Wolkenhauer, O; Won, HH; Wong, J; Woo, YC; Wood, LS; Wu, CT; Wu, CY; Wu, D; Wu, G; Wu, J; Wu, K; Wu, M; Wu, Q; Wu, T; Wu, W; Wu, X; Wu, XT; Wu, Y; Xi, D; Xi, J; Xiang, W; Xiang, Y; Xiao, M; Xiao, Z; Xie, H; Xie, Q; Xie, S; Xie, X; Xing, M; Xing, YL; Xu, C; Xu, X; Xu, Y; Xu, Z; Xue, F; Xue, XD; Yaglioglu, HG; Yamada, H; Yamashita, M; Yan, W; Yan, Z; Yanardag, R; Yang, D; Yang, H; Yang, K; Yang, QQ; Yang, R; Yang, S; Yang, T; Yang, X; Yang, Y; Yao, H; Yao, Y; Yari, D; Yassin, MT; Ye, C; Ye, J; Ye, Q; Yildiz, EA; Ying, S; Yoon, H; Yu, D; Yu, K; Yu, N; Yu, PL; Yuan, C; Yuan, D; Yuan, LJ; Yuan, Z; Yuen, N; Zagatto, AM; Zakaria, Y; Zalewski, AM; Zamora, S; Zavorotinskaya, T; Zeid, JL; Zeinoun, T; Zeng, C; Zerby, HN; Zhan, X; Zhang, A; Zhang, D; Zhang, E; Zhang, F; Zhang, H; Zhang, J; Zhang, L; Zhang, M; Zhang, P; Zhang, Q; Zhang, QY; Zhang, RG; Zhang, S; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, CK; Zhao, H; Zhao, J; Zhao, K; Zhao, Q; Zhao, S; Zhao, T; Zhao, XQ; Zhao, Y; Zhao, Z; Zheng, J; Zheng, L; Zheng, Y; Zhou, B; Zhou, G; Zhou, L; Zhou, T; Zhou, X; Zhu, C; Zhu, J; Zhu, Y; Zhu, ZQ; Zhuang, T; Zimmermannova, O; Zin, NNINM; Zisimos, K; Zoghebi, KA; Zonder, JA; Zou, C; Zwirner, J | 1 |
| Bel, JS; Khaper, N; Lees, SJ; Tai, TC | 1 |
| Allémann, E; Dumoulin, M; Forge, V; Heinrich-Balard, L; Lux, F; Marquette, C; Morfin, JF; Pansieri, J; Plissonneau, M; Rivory, P; Saraiva, MJ; Stransky-Heilkron, N; Tillement, O; Toth, E | 1 |
| Chen, J; Cheng, Y; Duan, W; Shen, X; Shi, X; Wang, Z; Yu, L; Zhang, H; Zhou, J | 1 |
| Davis, TP; Ding, F; Kakinen, A; Ke, PC; Nowell, CJ; Pilkington, EH; Sun, Y; Wang, B; Wang, M; Xing, Y | 1 |
| Hsieh, CY; Li, CY; Lu, CH; Ou, HT; Yang, CY | 1 |
| Adil, M; Ali, MR; Basheer, AS; Bawa, S; Hassan, MQ; Paudel, YN; Shah, S; Sharma, M; Siddiqui, A | 1 |
| Fukasawa, R; Hanyu, H; Higuchi, M; Ishii, K; Ogawa, Y; Shimada, H; Shimizu, S; Suhara, T; Takenoshita, N; Umahara, T | 1 |
| Chiba, K; Ishimoto, Y; Matsumoto, K; Takahashi, K; Tanaka, N; Watanabe, A; Yoshitomi, T | 1 |
| Chen, Y; Deng, L; Hu, L; Li, Z; Liu, B; Xu, Y; Zhang, L; Zhou, Z | 1 |
| Feng, B; Tang, C; Wang, Y; Zhang, L; Zhou, Y | 1 |
| Cheng, P; Liu, T; Shao, HG; Sun, YC | 1 |
| Copeland, KC; Dhaliwal, R; El Ghormli, L; Geffner, ME; Higgins, J; Levitsky, LL; Nadeau, KJ; Shepherd, JA; Weinstock, RS; White, NH | 1 |
| Danhof, M; DeJongh, J; Karim, A; Ploeger, BA; Scott, G; Stringer, F; Urquhart, R | 1 |
| Bahramikia, S; Yazdanparast, R | 1 |
| Kapurniotu, A; Velkova, A; Yan, LM | 1 |
| Aicher, TD; Boyd, SA; Chicarelli, MJ; Condroski, KR; DeWolf, WE; Hinklin, RJ; Lee, PA; Lee, W; Singh, A; Thomas, L; Voegtli, WC; Williams, L | 1 |
| Drimba, L; Hári, P; Hegedűs, C; Kovács, D; Málnási-Csizmadia, A; Németh, J; Peitl, B; Sári, R; Simon, Z; Szilvássy, Z | 1 |
| Coggan, AR; Gropler, RJ; Herrero, P; Lyons, MR; McGill, JB; Peterson, LR; Recklein, C; Saeed, IM; Schechtman, KB | 1 |
| Danhof, M; DeJongh, J; Scott, G; Stringer, F | 1 |
| Abedini, A; Cao, P; Raleigh, DP; Schmidt, AM; Tu, LH; Wang, H; Zhang, X | 1 |
| Baldi, JC; Hofman, PL; Manning, PJ; Walker, RJ | 1 |
| Boyd, S; deSchoolmeester, J; Dossetter, AG; Goldberg, FW; Groombridge, SD; Gutierrez, PM; Kemmitt, PD; Robb, GR; Scott, JS; Sjögren, T; Swales, JG; Turnbull, AV; Wild, MJ | 1 |
| Joo, H; Joo, K; Jung, KH; Kwon, SR; Lim, MJ; Park, W | 1 |
| Fukuda, S; Ito, M; Morinaga, H; Ohta, T; Sakata, S | 1 |
| Advani, SL; Cummins, CL; Gilbert, RE; Kepecs, DM; Schroer, SA; Thai, K; Woo, M; Zhang, Y | 1 |
| Cai, XL; Chen, YL; Gu, W; Hong, TP; Ji, LN; Li, CJ; Qiu, MC; Shan, ZY; Tian, HM; Xue, YM; Yang, HZ; Yang, JK; Zhao, JJ | 1 |
| Viles, JH; Younan, ND | 1 |
| Gudas, LJ; Jessurun, J; Tang, XH; Trasino, SE | 1 |
| Cheng, JT; Ku, PM; Lee, KS; Niu, CS; Niu, HS | 1 |
| Frost, NL; Gates, KS; Llufrio, EM; Parsons, ZD; Ruddraraju, KV | 1 |
| Huang, W; Jiao, L; Li, Z; Pan, M; Qian, H; Qiu, Q; Su, X; Wang, X; Xu, X | 1 |
| El Ghormli, L; Hirst, K; Ievers-Landis, CE; Linder, B; Marcus, MD; van Buren, DJ; Walders-Abramson, N; Wilfley, DE; Zeitler, P | 1 |
| Arslanian, S; Bacha, F; Caprio, S; El Ghormli, L; Goland, R; Haymond, MW; Levitsky, L; Nadeau, KJ; White, NH; Willi, SM | 1 |
| Schlein, M | 1 |
| Chang, E; Chiang, GC; Ganzer, C; Hu, J; Isaacson, R; Kuceyeski, A; Pandya, S; Ravdin, L; Schulman, A; Sobel, V; Vallabhajosula, S | 1 |
| Adil, M; Akhtar, MS; Ali, MR; Bawa, S; Paudel, YN; Shah, S; Sharma, M; Wadhwa, R | 1 |
| Billin, AN | 1 |
| Hjemdahl, P; Li, N; Ostenson, CG; Razmara, M | 1 |
| Baum, L; Chan, JC; Gu, XM; Guan, J; He, L; Lai, FM; Sui, Y; Tong, PC; Wong, HK; Zhao, HL | 1 |
| Balabolkin, MI; Klebanova, EM; Kreminskaia, VM; Kuzin, AG; Mamaeva, GG; Tel'nova, ME | 1 |
| Cho, WJ; Jena, BP; Jeremic, AM | 1 |
| Bemis, JE; Carney, DP; Disch, JS; Gagne, DJ; Jirousek, MR; Lambert, PD; Lavu, S; Lynch, AV; Milne, JC; Ng, PY; Nunes, JJ; Olefsky, JM; Perni, RB; Schenk, S; Smith, JJ; Vu, CB | 1 |
| Barile, E; Chen, LH; Chen, V; Dahl, R; De, SK; Emdadi, A; Machleidt, T; Murphy, R; Pellecchia, M; Riel-Mehan, M; Stebbins, JL; Yuan, H | 1 |
| Andersen, B; Bagger, MA; Behrens, C; Brand, CL; Christensen, IT; Guldbrandt, M; Jeppesen, CB; Jørgensen, AS; Knudsen, LB; Kodra, JT; Lau, J; Madsen, P; Nishimura, E; Pridal, L; Valcarce-Aspegren, C; Ynddal, L | 1 |
| Cheng, AY; Josse, RG | 1 |
| Pal, M | 1 |
| Benardeau, A; Benz, J; Gubler, M; Haap, W; Hebeisen, P; Huber, W; Joseph, C; Kitas, E; Kuhn, B; Mohr, P; Paehler, A; Ruf, A; Sanchez, RA; Schott, B; Tozzo, E; Wessel, HP | 1 |
| Fukuda, S; Ito, M; Matsushita, M; Morinaga, H; Nakagawa, Y; Ohta, T; Sakata, S; Tanaka, M | 1 |
| Bizzarro, FT; Corbett, WL; Dvorozniak, MT; Grimsby, J; Grippo, JF; Guertin, KR; Haynes, NE; Hilliard, DW; Holland, GW; Kester, RF; Mahaney, PE; Matschinsky, FM; Qi, L; Railkar, A; Sarabu, R; Spence, CL; Tengi, J | 1 |
| Feng, Y; Leng, Y; Li, F; Zhang, A; Zhang, Y; Zhu, Q | 1 |
| Grasso, DM; La Rosa, C; Marletta, G; Scalisi, S; Sciacca, MF; Zhavnerko, G | 1 |
| Abedini, A; Meng, F; Plesner, A; Raleigh, DP; Verchere, CB | 1 |
| Lu, J; Xie, Z; Zhang, H; Zhang, WJ; Zhang, Y; Zhou, G | 1 |
| Aggarwal, S; Bhardwaj, TR; Kumar, M; Thareja, S | 1 |
| Akiyama, TE; Berger, JP; Bergeron, R; Castriota, GA; Chapman, KT; de Jesus, RK; Doebber, TW; Ellsworth, KP; Feng, Z; Lassman, ME; Levorse, DA; Li, C; Mills, SG; Owens, KA; Pasternak, A; Tang, H; Wu, MS; Yan, Y; Yang, L; Zhang, BB | 1 |
| Cashion, DK; Dang, Q; DaRe, J; Erion, MD; Fan, Y; Gibson, T; Jacintho, JD; Jiang, T; Kasibhatla, SR; Lemus, R; Li, H; Li, W; Liu, Y; Potter, SC; Sun, Z; Taplin, F; Tian, F; van Poelje, PD | 1 |
| Fujimori, S; Hada, T; Hisashi, Y; Hosoya, T; Kamatani, N; Kenjiro, K; Kohri, K; Matsuzawa, Y; Nakamura, T; Naoyuki, K; Shin, F; Takanori, U; Tatsuo, H; Tetsuya, Y; Toshikazu, H; Toshitaka, N; Ueda, T; Yamamoto, T; Yamanaka, H; Yuji, M | 1 |
| Acusta, AP; Ambery, PD; Bilezikian, JP; Borges, JL; Cobitz, AR; Fitzpatrick, LA; Grosse, M; Jones-Leone, AR; Nino, AJ | 1 |
| Hanley, AJ; Harris, SB; Retnakaran, R; Ye, C; Zinman, B | 1 |
| Noormägi, A; Palumaa, P; Primar, K; Tõugu, V | 1 |
| Davies, HA; Madine, J; Middleton, DA | 1 |
| Schmidt, BM; Wagner, AD | 1 |
| Hao, M; Ji, M; Li, G; Li, Y; Luo, F; Ren, H; Yang, L; Zhang, S; Zhang, X | 1 |
| Kaushik, S; Khan, A; Lindenmayer, JP; Parakadavil, M; Smith, RC; Tedeschi, F; Yusim, A | 1 |
| Doubova, SV; Flores-Hernández, S; Mino-León, D; Reyes-Morales, H | 1 |
| Fassot, C; Freidja, ML; Henrion, D; Loufrani, L; Tarhouni, K; Toutain, B | 1 |
| Bacharaki, D; Dimitriadis, GD; Marathias, KP; Markakis, KP; Mazioti, M; Raptis, AE; Raptis, SA; Vlahakos, DV | 1 |
| Cao, D; Chen, J; Chen, L; Chen, T; Huang, L; Liang, X; Liu, J; Ma, L; Peng, A; Peng, F; Qiu, J; Qiu, N; Wang, G; Wei, Y; Xiang, M; Xu, Q; Yang, Z | 1 |
| Gulati, V; Harding, IH; Palombo, EA | 1 |
| Choi, R; Chung, CH; Hyun, M; Kim, GT; Kim, S; Lee, EY; Lee, MY; Seok, S | 1 |
| Araki, E; Furukawa, N; Kawaguchi, T; Kikukawa, Y; Ono, K; Shimomura, T; Suzushima, H; Watanabe, Y | 1 |
| Aragno, M; Benetti, E; Collino, M; Fantozzi, R; Mastrocola, R; Rogazzo, M; Thiemermann, C; Yaqoob, MM | 1 |
| Saksida, T; Sandler, S; Stojanovic, I; Stosic-Grujicic, S; Timotijevic, G | 1 |
| Engelen, L; Schalkwijk, CG; Stehouwer, CD | 1 |
| Cheng, B; Gong, H; Huang, K; Li, C; Li, T; Sun, Y; Zhang, X; Zheng, L | 1 |
| Hering, BD | 1 |
| Gao, X; Gao, Y; Jia, P; Li, G; Lin, H; Luo, B; Pan, C; Shi, H; Tian, H; Xing, X; Zhao, Y; Zhou, L | 1 |
| Braddon, J; Phillips, P | 1 |
| Goa, KL; Wagstaff, AJ | 1 |
| Aso, Y; Inukai, T; Takanashi, K; Takemura, Y; Tayama, K | 1 |
| McNeely, MJ; Yang, SH | 1 |
| Chen, H; Freed, MI; Greenberg, AS; Haffner, SM; Weston, WM; Williams, K | 1 |
| Mohan, V; Vidhya, S | 1 |
| Häring, HU; Stumvoll, M | 1 |
| Chakrabarti, R; Hiriyan, J; Kumar, MP; Kumar, SK; Mamidi, NV; Misra, P; Rajagopalan, R; Rao, CS; Suresh, J; Vikramadithyan, RK | 1 |
| Foley, JE; Gatlin, MR; Rosenstock, J; Shen, SG | 1 |
| Beck-Nielsen, H; Eirich, A; Grimmsmann, T; Klein, HH; Levin, K; Meyer, MM; Perwitz, N | 1 |
| Azen, SP; Berkowitz, K; Buchanan, TA; Goico, J; Hodis, HN; Kjos, SL; Marroquin, A; Ochoa, C; Peters, RK; Tan, S; Xiang, AH | 1 |
| Kubo, K | 1 |
| Alamy, SS; Jarskog, LF; Lieberman, JA; Sheitman, BB; Spivak, B | 1 |
| Brant, BP; Garvey, WT; Kennedy, A; Rogers, NL; Wallace, P; Willi, SM | 1 |
| Goldstein, BJ | 4 |
| Petersen, KF; Shulman, GI | 1 |
| Reusch, JE | 2 |
| Aljada, A; Dandona, P | 1 |
| Lebovitz, HE | 1 |
| Weissman, P | 1 |
| Heise, M; Kreider, M | 1 |
| Hevener, AL; Javorschi, S; Kruszynska, YT; Norman, RA; Olefsky, JM; Sinha, M; Yu, JG | 1 |
| Avilés-Santa, ML; Raskin, P; Strowig, SM | 1 |
| Berry, RA; Freed, MI; Greene, DA; Haffner, SM; Heise, MA; Herman, WH; Holman, RR; Jones, NP; Kahn, SE; Lachin, JM; Levy, D; Viberti, G; Zinman, B | 1 |
| Dove, A | 1 |
| Iwatani, M; Wasada, T | 1 |
| Guan, HP; Jensen, MV; Lazar, MA; Li, Y; Newgard, CB; Steppan, CM | 1 |
| Barnett, AH | 1 |
| Blanco, J; Robles, NR | 1 |
| Bronson, RT; Drori, S; Edelmann, W; Eng, C; Girnun, GD; Gonzalez, FJ; Kucherlapati, R; Mueller, E; Nambiar, P; Rosenberg, DW; Sarraf, P; Smith, WM; Spiegelman, BM | 1 |
| Herrmann, A; Hesselbarth, N; Hippius, M; Hoffmann, A; Kuschel, U | 1 |
| Endo, A; Furuse, Y; Hisatome, I; Igawa, O; Ikawa, S; Kato, M; Kinugawa, T; Ogino, K; Osaki, S; Shigemasa, C; Shimoyama, M; Uchida, K | 1 |
| Langer, O | 1 |
| Biswas, N; Carey, DG; Cowin, GJ; Doddrell, DM; Galloway, GJ; Jones, NP; Richards, JC | 1 |
| Noda, M | 1 |
| Yamanouchi, T | 2 |
| Toyota, T | 2 |
| Sugiyama, Y | 1 |
| Hiratani, K; Iwata, M; Kobayashi, M | 1 |
| Oka, Y | 1 |
| Hosaka, D; Imai, Y; Kawazu, S; Ohmura, E | 1 |
| Kitaoka, H | 2 |
| Kadowaki, T; Yamauchi, T | 1 |
| Levitt, O; Merlob, P; Stahl, B | 1 |
| Parker, JC | 1 |
| Aleksunes, LM; Reagan, LA; Vergara, CM; Wang, F | 1 |
| Biswas, N; Brunzell, JD; Cohen, BR; Freed, MI; Kreider, MM; Marcovina, SM; Ratner, R | 1 |
| Dandona, P; Dole, JF; Freed, M; Murphy, K; Patel, J; Patwardhan, R; Rendell, M; St John Sutton, M | 1 |
| German, JB; Leiter, EH; Pan, HJ; Reifsnyder, PR; Watkins, SM | 1 |
| Bradley, C | 1 |
| Kudzma, DJ | 1 |
| Afaq, A; Blonde, L; Pathak, R | 1 |
| Montague, CT; Tugwood, JD | 1 |
| Göke, B; Parhofer, KG | 1 |
| Fernando, OB; Ovalle, F | 1 |
| Sakura, H | 1 |
| Chalasani, N; Cummings, OW; Pinto, AG | 1 |
| Chawla, S; Takiya, L | 1 |
| Göke, B; Scherbaum, WA | 1 |
| LaCivita, KA; Villarreal, G | 1 |
| Hällsten, K; Knuuti, J; Lönnqvist, F; Nuutila, P; Oksanen, A; Rönnemaa, T; Sipilä, H; Viikari, J; Viljanen, T; Virtanen, KA | 1 |
| Gin, H; Rigalleau, V | 2 |
| Craft, S; Watson, GS | 1 |
| Andersen, B; Brand, CL; Fleckner, J; Fledelius, C; Gotfredsen, CF; Hansen, BF; Sauerberg, P; Sturis, J; Wassermann, K; Ye, JM | 1 |
| Mizushige, K; Noma, T; Tsuji, T | 1 |
| Weldy, DL | 1 |
| Solignac, M | 1 |
| Prous, JR; Silvestre, JS; Vázquez, M | 1 |
| Belz, U; Herling, AW; Juretschke, HP; Kalisch, J; Kleinschmidt, E; Kramer, W; Kuhlmann, J; Neumann-Haefelin, C; Stein, M | 1 |
| Armstrong, DU; Chinnapongse, S; King, AB | 1 |
| Asnani, S; Fonseca, VA; Gouda, BP | 1 |
| Dubois, M; Pattou, F; Schoonjans, K; Vantyghem, MC | 1 |
| Hällsten, K; Huupponen, R; Janatuinen, T; Knuuti, J; Lönnqvist, F; Lönnroth, P; Nuutila, P; Parkkola, R; Rönnemaa, T; Viljanen, T; Virtanen, KA | 1 |
| Hayashi, Y; Imaeda, K; Itoh, M; Kamiya, F; Kato, T; Miyachi, N; Okayama, N; Shimizu, M; Takeuchi, T; Takeuchi, Y | 1 |
| Bloomgarden, ZT | 4 |
| Ben Khalifa, F; Chow, WH; Menon, PS; Quimpo, JA; Vongthavaravat, V; Waitman, JN; Wajchenberg, BL | 1 |
| Iida, KT; Iwama, Y; Kamata, K; Kawakami, Y; Mokuno, H; Shimada, K; Shimano, H; Sone, H; Suzuki, M; Toyoshima, H; Watanabe, Y; Yamada, N | 1 |
| Bakris, G; Freed, MI; Heise, M; Porter, LE; Viberti, G; Weston, WM | 1 |
| Grossman, E | 1 |
| Astrup, A; Larsen, TM; Toubro, S | 1 |
| Froehlich, J; Hombach, V; Ittner, J; Koenig, W; Marx, N; Scharnagl, H; Schmidt, A; Siam, L; Wierse, G | 1 |
| Apolito, RA | 1 |
| Abou-Elenin, K; Caballero, AE; Hamdy, O; Horton, ES; Lim, SC; Logerfo, FW; O'Connor, C; Saouaf, R; Veves, A | 1 |
| Smith, SA; Tadayyon, M | 1 |
| Aroda, V; Bandukwala, R; Baxi, S; Carter, L; Ciaraldi, TP; Henry, RR; Kong, AP; Mudaliar, SR; Phillips, SA | 1 |
| Grellner, WJ; Harris, WS; Isley, WL; Klein, S; Miles, JM; Windsor, S; Wooldridge, D | 1 |
| Blüher, M; Lübben, G; Paschke, R | 1 |
| Adams, AD; Berger, JP; Doebber, TW; Hu, Z; Jones, AB; MacNaul, KL; Moller, DE; Santini, C; Yuen, W | 1 |
| Plosker, SM | 1 |
| Gong, WC; Jun, JK; Mathur, R | 1 |
| Passaro, MD; Ratner, RE | 1 |
| Kohno, M; Miyatake, A; Mizushige, K; Murakami, K; Noma, T; Tsuji, T | 1 |
| Nesić, V; Stefanović, V; Stojimirović, B | 1 |
| Viberti, GC | 1 |
| Fischer, S; Hanefeld, M | 1 |
| Festa, A; Gyimesi, A; Herz, M; Jermendy, G; Johns, D; Kerenyi, Z; Pavo, I; Schluchter, BJ; Shestakova, M; Shoustov, S; Tan, MH; Varkonyi, TT | 1 |
| Inoue, T; Kashiwabara, A; Kawasaki, T; Ogata, N; Sawashige, K; Sekino, N; Yamanouchi, T | 1 |
| Jones, NP; Jones, TA; Sautter, M; Van Gaal, LF | 1 |
| Graham, DJ; Green, L; Nourjah, P; Senior, JR | 1 |
| Tafuri, S; Wang, M | 1 |
| Basu, A; Kudva, YC; Zangeneh, F | 1 |
| Froehlich, J; Hombach, V; Imhof, A; Ittner, J; Koenig, W; Maerz, W; Marx, N; Schmidt, A; Siam, L; Wierse, G | 1 |
| Eguchi, T; Hino, T; Hisamochi, A; Ide, T; Koga, H; Koga, Y; Kumashiro, R; Kuwahara, R; Murashima, S; Ogata, K; Sata, M; Shishido, S; Tanaka, E; Ueno, T | 1 |
| Carter, L; Ciaraldi, TP; Henry, RR; Mudaliar, SR; Reehman, N; Wilmsen, HM | 1 |
| Moses, R | 2 |
| Tuepker, J | 1 |
| Bouche, C; Goldfine, AB | 1 |
| Chow, WH; Davies, C; Jiang, J; Li, GW; Pan, CY; Shi, HL; Sun, XC; Tian, H; Yang, WY; Zhu, XX | 1 |
| Boudoulas, H; Osei, K; Schuster, DP; Sparks, EA; Stakos, DA; Wooley, CF | 1 |
| Furukawa, H; Haruyama, H; Izumi, T; Koga, T; Koishi, R; Matsushita, Y; Miyoshi, K; Nakamura, K; Shimizu, M; Sugawara, M; Takahashi, T; Tomita, A; Watanabe, I; Yasumo, H | 1 |
| Bernal, MR; Calle-Pascual, AL; Fernández-Cruz, A; Goldfine, A; Horton, E; Jarolim, P; Libby, P; Nuzzo, R; Schönbeck, U; Varo, JJ; Varo, N; Veves, A; Vicent, D | 1 |
| Barnett, AH; Grant, PJ; Hitman, GA; Mather, H; Pawa, M; Robertson, L; Trelfa, A | 1 |
| Osawa, K; Ota, T | 1 |
| Chu, N; Ciaraldi, TP; Cui, L; Henry, RR; Ju, Y; Kim, D; Kong, A; Mathieu-Costello, O; Mudaliar, S | 1 |
| Aneja, A; El-Atat, F; McFarlane, SI; Muniyappa, R | 1 |
| Bajaj, M; Cersosimo, E; DeFronzo, RA; Glass, L; Hardies, LJ; Miyazaki, Y; Pratipanawatr, T; Pratipanawatr, W; Suraamornkul, S | 1 |
| Drexler, AJ | 1 |
| Wyne, KL | 1 |
| Miller, JL | 3 |
| Bell, DS | 1 |
| Bell, DS; Braunstein, S; Drexler, AJ; Miller, JL; Nuckolls, JG; Wyne, KL | 1 |
| Cabré, A; Camejo, G; Hultén, LM; Norén, K; Pedreño, J; Svensson, L; Vallvé, JC; Wiklund, O | 1 |
| Ahn, YB; Cha, BY; Kang, SK; Ko, SH; Lee, KW; Son, HS; Son, HY; Song, KH; Yoo, SJ; Yoon, KH | 1 |
| Boden, G; Cheung, P; Fried, SK; Mozzoli, M | 1 |
| Foster, JR; Pickavance, LC; Widdowson, PS; Wilding, JP; Williams, G | 1 |
| Chen, H; Cobitz, AR; Goldstein, BJ; Hand, LM | 1 |
| Rochester, CD; Samuel, J | 1 |
| Camp, HS | 1 |
| Calkin, AC; Cooper, ME; Thomas, MC | 1 |
| Duran, S; Escobar-Jiménez, F; Godin, C; Grossman, LD; Hardin, PA; Hawkins, F; Herz, M; Johns, D; Konkoy, CS; Lochnan, H; Reviriego, J; Tan, MH | 1 |
| Görtz, A; Lander, T; Reblin, T; Seidel, D; Stein, D | 1 |
| Diamant, M; Heine, RJ | 1 |
| Stumvoll, M | 1 |
| Debard, C; Frayn, KN; Humphreys, SM; Karpe, F; Langin, D; Tan, GD; Tiraby, C; Vidal, H | 1 |
| Ballary, C; Desai, A | 1 |
| Halimi, S | 3 |
| Bell, CF; Botteman, MF; Braunstein, SN; Devine, ST; Ramsdell, JW; Stephens, JM | 1 |
| Bizzarro, FT; Chu, CA; Coffey, JW; Corbett, WL; Dvorozniak, MT; Grimsby, J; Grippo, JF; Guertin, KR; Haynes, NE; Hilliard, DW; Kester, RF; Magnuson, MA; Mahaney, PE; Marcus, L; Matschinsky, FM; Qi, L; Sarabu, R; Spence, CL; Tengi, J | 1 |
| Chen, J; Di, F; He, R; Wang, D; Wang, Y; Yang, J; Yang, M; Yuan, S; Zhu, X | 1 |
| Odaka, H; Suzuki, M | 1 |
| Satoh, J | 1 |
| Bandyopadhyay, G; Beeson, M; Dizon, M; Farese, RV; Gomez-Daspet, J; Grebenev, D; Kanoh, Y; Miura, A; Powe, J; Sajan, MP; Standaert, ML | 1 |
| DeFronzo, RA; He, H; Mandarino, LJ; Miyazaki, Y | 1 |
| Lai, LC | 1 |
| Ibuki, M; Katayama, M; Mizoguchi, S; Morioka, S; Nagai, K; Shiratori, K; Takagi, T; Tamita, K; Tanabe, K; Tani, T; Yamabe, K; Yamamuro, A; Yoshikawa, J | 1 |
| Hollingdal, M; Juhl, CB; Lönnqvist, F; Prange, A; Pørksen, N; Schmitz, O | 1 |
| Ito, S; Ogawa, S; Takeuchi, K | 1 |
| Kim, HS; Kim, MS; Koh, EH; Lee, KU; Park, HS; Park, JY; Youn, JH; Youn, JY | 1 |
| Ayyobi, AF; Brunzell, JD | 1 |
| Iles, A | 1 |
| Abrahmsen, LB; Alberts, P; Ashkzari, M; Bergqvist, E; Björkstrand, E; Edling, NH; Engblom, LO; Fiedler, M; Forsgren, M; Klingström, G; Larsson, C; Nilsson, C; Nilsson, CE; Norling, S; Ohman, B; Selen, G | 1 |
| Kennedy, FP | 1 |
| Garg, A; Kermani, A | 1 |
| Gaillard, T; Habash, D; Osei, K; Rhinesmith, S; Schuster, D | 1 |
| Barringhaus, KG; Chen, M; Czarnik, AC; Hesselbacher, S; Ley, K; Nadler, J; Phillips, JW; Sanders, JM; Sarembock, IJ; Yang, Z | 1 |
| Dagogo-Jack, S | 1 |
| Cooper, M; Forbes, J; Jerums, G; Osicka, T; Panagiotopoulos, S | 1 |
| Narce, M; Poisson, JP | 1 |
| Chyun, DA; Johnson, BF; Law, G; Nesto, RW; Pfeifer, MA; Slater, WR; Vinik, AI; Wackers, FJ; Young, LH | 1 |
| Nakamura, M; Nishida, M | 1 |
| Del Prato, S; Volpe, L | 1 |
| Citrome, L; Volavka, J | 1 |
| Bailey, CJ; Day, C | 1 |
| Arch, JR; Augstein, P; Cawthorne, MA; Demuth, HU; Heinke, P; Hoffmann, T; Meyer, A; Sennitt, MV; Stocker, C; Subramanian, A; Wargent, E | 1 |
| Butte, AJ; Hoberman, S; Joshi, M; Levy, J; Pappo, J; Pollard, J | 1 |
| Sarabu, R | 1 |
| Dang, Q; Erion, MD; Jiang, T; Kasibhatla, SR; Lipscomb, WN; Potter, SC; Reddy, KR; Reddy, MR; van Poelje, PD | 1 |
| Barrett, DG; Brenner, MB; Briggs, SL; Delaunois, A; Durbin, JD; Efanov, AM; Giese, U; Gil, GS; Gromada, J; Guo, H; Radloff, M; Sewing, S; Wang, Y; Weichert, A; Zaliani, A | 1 |
| Demuth, HU; McIntosh, CH; Pederson, RA | 1 |
| Beconi, MG; Biftu, T; Chan, CC; Edmondson, S; Eiermann, GJ; Feeney, WP; He, H; Ippolito, DE; Kim, D; Lankas, GR; Leiting, B; Lyons, KA; Ok, HO; Patel, RA; Petrov, AN; Pryor, KA; Qian, X; Reigle, L; Roy, RS; Thornberry, NA; Weber, AE; Woods, A; Wu, JK; Zaller, D; Zhang, X; Zhu, L | 1 |
| Cho, L; Dumasia, R; Eagle, KA; Kline-Rogers, E; May, N; Mukherjee, D | 1 |
| Sawyer, TS; Spiller, HA | 1 |
| Feng, ZQ; Guo, YS; Guo, ZR; Li, YQ; Song, HR | 1 |
| Cozzone, D; Debard, C; Disse, E; Husson, B; Laville, M; Ricard, N; Vidal, H; Vouillarmet, J | 1 |
| Araújo Veloso, C; Bosco, A; Calsolari, MR; Cunha, EP; Martins Chaves, M; Nogueira-Machado, JA; Oliveira Medina, L | 1 |
| Cobitz, A; Garber, A; Huang, C; Rood, J; Rosenstock, J | 1 |
| Biswas, N; Chou, H; Cobitz, A; Garber, A; Rood, J; Rosenstock, J | 1 |
| Calsolari, MR; Chaves, MM; de Abreu Borges, E; Isoni, CA; Medina, LO; Nogueira-Machado, JA; Veloso, CA | 1 |
| Kanna, B; Pokharna, H | 1 |
| Bailey, CJ; Chen, H; Donaldson, J; Home, PD; Stewart, MW | 1 |
| Al-Khalili, L; Garcia-Roves, PM; Guigas, B; Krämer, DK; Krook, A; Leng, Y | 1 |
| Garber, A | 1 |
| Perlis, RH | 1 |
| Alimena, G; Breccia, M; Cannella, L; Frustaci, A; Muscaritoli, M; Stefanizzi, C | 1 |
| Bartberger, MD; Castro, VM; Chen, M; Emery, M; Fotsch, C; Gustafsson, S; Hale, C; Hickman, D; Homan, E; Johansson, L; Jordan, SR; Komorowski, R; Li, A; Matsumoto, G; McRae, K; Moniz, G; Orihuela, C; Palm, G; Veniant, M; Wang, M; Williams, M; Zhang, J | 1 |
| Gupta, R; Marek, P; Raleigh, DP | 1 |
| Kaku, K; Kaneko, T; Nagasaka, Y; Nakamura, K | 1 |
| Cawthorne, MA; Coyle, PJ; Holder, JC; Holman, GD; Kirkham, DM; Kozka, IJ; Lister, CA; Smith, SA; Young, PW | 1 |
| Kliewer, SA; Lehmann, JM; Moore, LB; Smith-Oliver, TA; Wilkison, WO; Willson, TM | 1 |
| Ikegami, H; Masuo, K; Mikami, H; Ogihara, T; Rakugi, H | 1 |
| Beerdsen, P; Joyce, M; Ludvik, B; Nolan, JJ; Olefsky, J | 1 |
| Keen, H | 1 |
| Cantello, BC; Cawthorne, MA; Cottam, GP; Duff, PT; Haigh, D; Hindley, RM; Lister, CA; Smith, SA; Thurlby, PL | 1 |
| Akazawa, S; Kawasaki, E; Matsumoto, K; Okuno, S; Takao, Y; Takino, H; Uotani, S; Yamaguchi, Y; Yamasaki, H; Yano, M | 1 |
| Braithwaite, SS; Colca, JR; Hofmann, C; Hotamisligil, GS; Lorenz, K; Palazuk, BJ; Spiegelman, BM | 1 |
| Iwanishi, M; Kobayashi, M | 1 |
| Bleasdale, JE; Swanson, ML | 1 |
| Vondrácková, D | 1 |
| Castle, CK; Colca, JR; Melchior, GW | 1 |
| van Haeften, TW; Wolffenbuttel, BH | 1 |
| Fukuda, M; Matsuda, M; Ohashi, Y; Ohguro, N | 1 |
| Umeda, F | 1 |
| Boden, G; Chaiken, RL; Eckert-Norton, M; Gelfand, RA; Lebovitz, HE; Pasmantier, R; Ryan, I | 1 |
| Bailey, P; Cullinan, CA; Doebber, TW; Flier, JS; Frederich, R; Graziano, MP; Hey, PJ; Leibowitz, MD; Lollmann, B; Smith, RG; Strader, CD; Szalkowski, DM; White-Carrington, S; Wu, M; Zhang, B | 1 |
| Amano, N; Ebara, T; Hirano, T; Hozumi, T; Ishida, Y; Kazumi, T; Odaka, H; Yoshino, G | 1 |
| Akanuma, Y; Iwamoto, Y; Kaneko, T; Kosaka, K; Kuzuya, T; Shigeta, Y | 2 |
| Kuehnle, HF | 1 |
| Beck-Nielsen, H; Berthezene, F; Boulton, AJ; Donoghue, S; Kumar, S; Lettis, S; Muggeo, M; Persson, B; Spinas, GA; Stewart-Long, P | 1 |
| Clark, DA; Genereux, PE; Gibbs, EM; Hulin, B; Lewis, DM; Newton, LS | 1 |
| Azen, S; Berkowitz, K; Buchanan, TA; Dunn, ME; Goico, J; Kjos, SL; Marroquin, A; Peters, R; Xiang, A | 1 |
| Melander, A | 1 |
| Henry, RR | 2 |
| Burant, CF; Polonsky, KS; Pugh, W; Sreenan, S; Sturis, J | 1 |
| Kawamori, R; Yoshii, H | 1 |
| Olefsky, JM; Saltiel, AR | 1 |
| Connell, J; Petrie, J; Small, M | 1 |
| Giacca, A; Kawamori, R; Lekas, M; Matsuhisa, M; Rodgers, CD; Shi, ZQ; Vranic, M; Wan, C | 1 |
| Cornicelli, JA; Davis, JA; O'Rourke, CM; Saltiel, AR | 1 |
| Antonucci, TK; Driscoll, JH; Faja, BW; Ghazzi, MN; Huang, SM; Perez, JE; Whitcomb, RW | 1 |
| Kondo, M; Sakane, N; Yoshida, T | 1 |
| Bischoff, ED; Boehm, MF; Cesario, RM; Crombie, DL; Davies, PJ; Hamann, LG; Heyman, RA; Jow, L; Mondon, CE; Mukherjee, R; Nadzan, AM; Paterniti, JR | 1 |
| Bressler, R; Johnson, DG | 1 |
| Reddy, SS; Speerhas, RA; Vidt, DG | 1 |
| Diani, A; Messina, JL; Murray, FT; Sangani, GA; Wachowski, MB; Weinstock, RS | 1 |
| Aikawa, E; Demura, H; Demura, R; Imaki, T; Naruse, K; Naruse, M; Nishikawa, M; Seki, T; Tanabe, A; Yoshimoto, T | 1 |
| Connor, SC; Hughes, MG; Lister, CA; Moore, G; Smith, SA | 1 |
| Flórez, H | 1 |
| Linday, LA | 1 |
| Ishikawa, S; Iwamoto, Y; Kuzuya, T; Nagasaka, S; Saito, T | 1 |
| Kondo, M; Yokoo, S; Yoshida, T; Yoshioka, K | 1 |
| Teter, ML | 1 |
| Santiago, JV | 1 |
| Katayama, S | 1 |
| Anichini, R; Ferrannini, E; Foot, E; Gastaldelli, A; Pecori, N; Seghieri, G; Sironi, AM; Vichi, S | 1 |
| Cwik, C; Mishra, SK; Postlethwaite, AE; Rajanna, B; Solomon, SS | 1 |
| Meier, CA | 1 |
| Foley, J; O'Doherty, R; Stein, D | 1 |
| Eastmond, R; Foot, EA | 1 |
| Mizukami, J; Taniguchi, T | 1 |
| Hirsch, IB; Purnell, JQ | 1 |
| Burant, CF; Davidson, NO; Graves, RA; Hirano, K; Lohmiller, J; Lukens, J; Ross, S; Sreenan, S; Tai, TA | 1 |
| Iwamoto, Y | 1 |
| Matsumoto, K; Miyake, S; Tominaga, Y; Ueki, Y; Yano, M | 1 |
| Campagnola, M; Cominacini, L; Davoli, A; Ferrannini, E; Foot, E; Fratta Pasini, A; Garbin, U; Lo Cascio, V; Sighieri, G; Sironi, AM | 1 |
| Akatsuka, H; Arakawa, K; Homma, K; Iijima, I; Inamasu, M; Kawanami, S; Matsumoto, M; Okumura, K; Ozeki, M; Saiga, Y; Watanabe, A; Yasuda, K | 1 |
| Baba, S; Kaneko, T | 1 |
| Hari, J | 1 |
| Zurlinden, J | 1 |
| Buchanan, TA; Burant, CF; Cline, G; Gumbiner, B; Hsueh, WA; Inzucchi, S; Kelley, D; Maggs, DG; Nolan, J; Olefsky, JM; Polonsky, KS; Shulman, GI; Silver, D; Valiquett, TR | 1 |
| Levi, M; Shimabukuro, M; Unger, RH; Zhou, YT | 1 |
| Lisi, DM | 1 |
| Abel, R; Alvey, CW; Koup, JR; Loi, CM; Randinitis, EJ; Young, MA | 1 |
| Kazierad, DJ; Koup, JR; Loi, CM; Randinitis, EJ; Sedman, AJ; Vassos, AB | 1 |
| Lefèbvre, PJ; Scheen, AJ | 2 |
| Kahn, SE; Porte, D; Prigeon, RL | 1 |
| Inoue, D; Koshiyama, H; Minamikawa, J; Yamauchi, M | 1 |
| Inzucchi, SE; Maggs, DG; Page, SL; Rife, FS; Shulman, GI; Spollett, GR; Walton, V | 1 |
| Fonseca, V; Graveline, JF; Raskin, P; Schwartz, S | 1 |
| Imura, H | 1 |
| Bethge, H; Häring, HU | 1 |
| Baba, S; Eguchi, H; Hozumi, T; Ikeda, M; Ishida, Y; Kaneko, T; Kawamori, R; Kubota, M; Omori, Y; Sasaki, H; Sato, A; Shichiri, M; Tominaga, M; Uehara, M; Wasada, T; Yamasaki, Y | 1 |
| Azen, SP; Berkowitz, K; Buchanan, TA; Kjos, S; Peters, RK; Xiang, A | 1 |
| Bornkessel, B | 1 |
| Butler, PC; Eberhardt, NL; Kudva, YC; Mueske, C | 1 |
| Spiegelman, BM | 1 |
| Chen, C | 1 |
| Buckingham, RE; Chattington, PD; Naderali, EK; Walker, AB; Williams, G | 1 |
| Abrams-Carter, L; Ciaraldi, TP; Henry, RR; Mudaliar, S; Nikoulina, SE; Park, KS | 1 |
| Inoue, D; Koshiyama, H; Minamikawa, J; Tanaka, S; Yamauchi, M | 1 |
| Akiba, M; Hosokawa, T; Kakimoto, N; Kobayashi, H; Kumon, H; Morimitsu, Y; Nakamura, K; Osawa, T; Oya, T | 1 |
| Gitlin, N; Juarbe, HM; Julie, NL; Lim, KN; Spurr, CL | 1 |
| Brunt, EM; Isley, WL; Neuschwander-Tetri, BA; Oki, JC; Phillips, NJ; Quiason, SG; Ramrakhiani, S | 1 |
| Eastmond, R; Eckland, DJ; Lettis, S; Young, MA | 1 |
| Hirano, T; Kazumi, T; Yoshino, G | 1 |
| Gorson, DM | 2 |
| Rusk, MH | 1 |
| Bethel, MA; Feinglos, MN | 1 |
| Abrams-Carter, L; Ciaraldi, TP; Henry, RR; Lindgren, K; Mudaliar, S; Nikoulina, SE; Park, KS; Tufari, SR; Veerkamp, JH; Vidal-Puig, A | 1 |
| Riddle, MC | 2 |
| Buse, JB; Faja, BW; Gumbiner, B; Mathias, NP; Nelson, DM; Whitcomb, RW | 1 |
| Kobayashi, I; Mori, M; Sato, N; Shimizu, H; Shimomura, Y; Tsuchiya, T | 1 |
| Ghazzi, MN; Horton, ES; Venable, TC; Whitcomb, RW; Whitehouse, F | 1 |
| Barnett, AH; Kumar, S; Lettis, S; Prange, A; Schulze, J | 1 |
| Fonseca, VA; Ghazzi, MN; Huang, SM; Valiquett, TR; Whitcomb, RW | 1 |
| Arisaka, T; Ikebuchi, M; Ikeda, M; Kanda, T; Kawamori, R; Kinoshita, J; Kubota, M; Matsuhisa, M; Mochizuki, K; Niwa, M; Tohdo, R; Wada, M; Yamasaki, Y | 1 |
| Skyler, JS | 1 |
| Akanuma, Y; Kaneko, T; Kosaka, K; Kuzuya, T; Shigeta, Y | 1 |
| Hashimoto, S; Hirayama, R; Kato, M; Kurosaki, E; Shikama, H; Shimokawa, T; Watanabe, Y | 1 |
| Amin, NM; Benjamin, E; Finnegan, J; Pershadsingh, HA; Sproul, JA | 1 |
| Aicher, TD; Balkan, B; Bell, PA; Brand, LJ; Cheon, SH; Deems, RO; Fell, JB; Fillers, WS; Fraser, JD; Gao, J; Kahle, GG; Knorr, DC; Leone, CL; Nadelson, J; Simpson, R; Smith, HC | 1 |
| Aoto, M; Arakawa, K; Ikezawa, K; Inamasu, M; Ishihara, T; Saito, A | 1 |
| Kotchen, TA; Sonnenberg, GE | 1 |
| Ishii, S; King, P; Pickavance, L; Tanaka, H; Widdowson, PS; Williams, G | 1 |
| Ott, P; Ranek, L; Young, MA | 1 |
| Arai, K; Hori, M; Imano, E; Kajimoto, Y; Kanda, T; Motomura, M; Nakatani, Y; Nishida, T; Yamasaki, Y | 1 |
| Fujita, Y; Kuwao, S; Saigenji, K; Shibuya, A; Takahashi, H; Takeuchi, H; Watanabe, M | 1 |
| Howard, BV; Howard, WJ | 1 |
| Kametani, T; Koshida, H; Shibata, K | 1 |
| Gura, T | 1 |
| de Groen, PC; Dinneen, SF; Vella, A | 1 |
| Bajji, AC; Bhushan, V; Chakrabarti, R; Kishore, PH; Lohray, BB; Rajagopalan, R; Rajesh, BM; Rao, VV; Reddy, AS; Reddy, KA; Reddy, KV; Saibaba, V | 1 |
| Fujimoto, S; Ikeda, H; Ishida, H; Kajikawa, M; Kato, S; Mizuno, N; Mukai, E; Nishimura, M; Odaka, H; Seino, Y; Yamada, Y | 1 |
| Cimons, M | 1 |
| Matsui, K; Nagao, K; Shibata, T; Shinkai, H; Wakitani, K; Yonemori, F | 1 |
| Fonseca, VA; Granberry, MC | 1 |
| Romanelli, AM; Umland, EM | 1 |
| Chait, A; Crawford, RS; Henry, RR; Mudaliar, SR | 1 |
| Faulds, D; Plosker, GL | 1 |
| Caro, JF; Kolaczynski, JW | 1 |
| Awata, T; Chen, S; Katayama, S; Kosegawa, I; Negishi, K | 1 |
| Day, C | 1 |
| Bobbioni, E; Buysschaert, M; Frith, L; Starkie, M | 1 |
| Barettino, D; Moreno, L | 1 |
| Stern, MP | 1 |
| Bell, DS; Ovalle, F | 3 |
| Genda, A; Michishita, I; Minagawa, F; Nozue, T | 1 |
| Horikoshi, H; Ikeda, Y; Mori, Y; Murakawa, Y; Okada, K; Tajima, N; Yokoyama, J | 1 |
| Blonde, L; Guthrie, RD; Sandberg, MI | 1 |
| Balfour, JA; Plosker, GL | 1 |
| Dandona, P; Izzo, JL; Sung, BH; Wilson, MF | 1 |
| Hoekstra, JB; Kuck, EM; Wagenaar, LJ | 1 |
| Liu, H; Oates, PJ; Ramasamy, R; Schaefer, S | 1 |
| DeFronzo, RA | 2 |
| Andres, E; Blicklé, JF; Brogard, JM; Neyrolles, N | 1 |
| Hirose, H; Katsukawa, F; Kawai, T; Oguchi, S; Oguma, Y; Ohashi, N; Saruta, T; Shimada, A; Takei, I; Tokui, M; Watanabe, K | 1 |
| Henney, JE | 1 |
| Gallwitz, B; Schmidt, WE | 1 |
| Krentz, AJ | 1 |
| Feinglos, MN; Hughes, AT; Luna, B | 1 |
| Buse, JB | 2 |
| DeMacker, PN; Smits, P; Stalenhoef, AF; Tack, CJ | 1 |
| Ginsberg, H; Plutzky, J; Sobel, BE | 1 |
| Paul, M | 1 |
| Collier, G; Zimmet, P | 1 |
| Oberpichler-Schwenk, H | 1 |
| Kruszynska, YT; Mulford, MI; Olefsky, JM; Yu, JG | 1 |
| Itoh, Y; Miyashita, Y; Murano, T; Sasaki, H; Shirai, K; Totsuka, M; Watanabe, H | 1 |
| Hunabiki, A; Kasuga, M; Morita, S | 1 |
| Ito, MK; Lin, JC | 1 |
| Smits, P; Tack, CJ | 1 |
| Clausson, P; Heinemann, L; Heise, T; Hirschberger, S; Rave, K | 1 |
| Abe, Y; Fukui, T; Hosomi, N; Kimura, S; Kiyomoto, H; Matsuo, H; Mizushige, K; Noma, T; Yao, L; Yu, Y | 1 |
| Hashizume, K; Sakurai, A | 1 |
| Banner, BF; Bonkovsky, HL; Kohlroser, J; Mathai, J; Reichheld, J | 1 |
| Brillon, D; Brown, DL | 1 |
| Diamond, RH; Forman, LM; Simmons, DA | 1 |
| Al-Salman, J; Arjomand, H; Kemp, DG; Mittal, M | 1 |
| Kuritzky, L; Quillen, DM; Samraj, GP | 1 |
| Bergkulla, S; Ebeling, P; Koistinen, HA; Koivisto, VA; Nissén, M; Rönnemaa, T; Salmela, P; Saltevo, J; Teppo, AM; Viikari, J | 1 |
| Yanase, T | 1 |
| Adachi, H; Amano, S; Bamba, T; Fujiyama, Y; Fukano, M; Okabe, H; Sato, J; Yamamoto, K | 1 |
| Booth, AM; Caldwell, SH; Iezzoni, JC | 1 |
| Caro, JJ; Copley-Merriman, C; Flegel, KM; Kavanagh, PL; Klittich, WS; O'Brien, JA; Raggio, G; Shomphe, LA; Sigler, C | 1 |
| Gomis, R; Jones, NP; Patwardhan, RN; Squatrito, S; Wolffenbuttel, BH | 1 |
| Caro, J; Wishner, KL | 1 |
| Malet, PF; Malik, AH; Prasad, P; Saboorian, MH; Thiele, DL | 1 |
| Hamaguchi, T; Hanafusa, T; Matsuzawa, Y; Nakajima, H | 1 |
| Kuzuya, T | 2 |
| Ikeda, H; Murase, K; Sugiyama, Y | 1 |
| Toyota, T; Ueno, Y | 1 |
| Shimizu, N | 1 |
| Haruta, T; Iwata, M; Kobayashi, M | 1 |
| Kameda, N; Oka, Y; Okuya, S | 1 |
| Kanazawa, Y; Kawano, M | 1 |
| Iwamoto, Y; Iwatani, M; Kamatani, N; Wasada, T | 1 |
| Kuzuya, H; Nakano, T; Yamada, K | 1 |
| Haneda, M; Isshiki, K; Kikkawa, R; Koya, D | 1 |
| Okazaki, R | 1 |
| Fujita, T; Fukumoto, S; Hirota, Y; Miura, M; Okazaki, R; Taguchi, M; Takeuchi, A; Tanaka, K; Toriumi, M | 1 |
| Hirayama, R; Kurosaki, E; Nakano, R; Shibasaki, M; Shikama, H; Shimaya, A | 1 |
| Larmore, SS | 1 |
| Lefèbvre, PJ; Letiexhe, MR; Paquot, N; Scheen, AJ | 1 |
| SoRelle, R | 1 |
| Bass, NM; Chow, H; Davern, TJ; Freise, C; Lee, WM; Masharani, U; Murphy, EJ; Shakil, AO; Shick, L | 1 |
| Fonseca, V; Patwardhan, R; Rosenstock, J; Salzman, A | 1 |
| Bailey, CJ; Nattrass, M | 1 |
| Juul Holst, J | 1 |
| Cole, ST; Freed, MI; Patwardhan, R; Rappaport, EB; Raskin, P; Yan, Y | 1 |
| Baker, AL; Dolehide, K; Hart, J; Schiano, T | 1 |
| Hirata, K; Ishida, T; Murao, S; Takahara, J | 1 |
| Bedoucha, M; Boelsterli, UA; Sigrist, S | 1 |
| Arch, JR; Buckingham, RE; Cai, XJ; Lister, CA; Pickavance, L; Wilding, J; Williams, G; Wilson, S | 1 |
| Brown, MN | 1 |
| Deacon, LF; Jones, NP; Nolan, JJ; Patwardhan, R | 1 |
| Gonzalez, R; Grinsell, JW; Lardinois, CK; Michaels, JR; Sare, JS; Starich, GH; Swislocki, A | 1 |
| Abe, Y; Aki, Y; Fukui, T; Kimura, S; Mizushige, K; Noma, T | 1 |
| Kato, K; Midorikawa, S; Sato, W; Watanabe, T; Yamada, D | 1 |
| Kadowaki, T | 1 |
| King, AB | 1 |
| Frias, JP; Kruszynska, YT; Olefsky, JM; Yu, JG | 1 |
| Mabuchi, H; Murase, Y; Wakasugi, T; Yagi, K | 1 |
| Cowley, H; Cox, PJ; Harris, AM; Hollis, FJ; Miller, AK; Ryan, DA; Vousden, M | 1 |
| McCarty, MF | 1 |
| Fonseca, V; Foyt, HL; Shen, K; Whitcomb, R | 1 |
| Izumiya, Y; Usuda, R; Yokoyama, M; Yoshizawa, M | 1 |
| Chapman, H; Gould, GW; Lister, CA; Maier, VH; Melvin, DR; Murphy, GJ | 1 |
| Kruszynska, YT; Olefsky, JM; Sobel, BE; Yu, JG | 1 |
| Bailey, CJ | 2 |
| Walker, M | 1 |
| Bledsoe, RK; Gampe, RT; Kliewer, SA; Lambert, MH; Milburn, MV; Miller, AB; Montana, VG; Willson, TM; Xu, HE | 1 |
| Bakris, G | 1 |
| Westerbacka, J; Yki-Järvinen, H | 1 |
| Berger, S; Jovanovic, L; Raskin, P; Ratner, R; Schwartz, S; Woo, V | 1 |
| Boudinot, FD; Ferguson, DC; Hoenig, M; Michels, GM | 1 |
| Krische, D | 1 |
| Böhm, S | 1 |
| Azen, SP; Berkowitz, K; Buchanan, TA; Goico, J; Kjos, SL; Marroquin, A; Ochoa, C; Peters, RK; Xiang, AH | 1 |
| Cline, GW; Dufour, S; Inzucchi, S; Krssak, M; Petersen, KF; Shulman, GI | 1 |
| Iwamoto, Y; Iwatani, M; Kamatani, N; Katsumori, K; Wasada, T; Watanabe-Takahashi, C | 1 |
| Kirk, JK; Michielutte, R; Pearce, KA; Summerson, JH | 1 |
| Matsuo, H; Mizushige, K; Murakami, K; Noma, T; Ohmori, K; Yao, L | 1 |
| Einecke, D | 1 |
| Bailey, CJ; Krentz, AJ; Melander, A | 1 |
| Miyamori, I; Oida, K; Takahashi, S | 1 |
| Charpentier, G; Riveline, JP; Varroud-Vial, M | 1 |
| Füchtenbusch, M; Schatz, H; Standl, E | 1 |
| Akazawa, S; Eguchi, K; Ito, M; Kawasaki, E; Sun, F | 1 |
| Hishinuma, T; Mizugaki, M; Yamazaki, T | 1 |
| Baum, U | 1 |
| Olefsky, JM | 1 |
| Ludvik, B | 1 |
| Moller, DE; Zhang, BB | 1 |
| Gorman, C | 1 |
| Akiyama, T; Fukumitsu, KI; Jia, DM; Nakamura, H; Otsuki, M; Tabaru, A | 1 |
| Stiefelhagen, P | 2 |
| Filz, HP | 1 |
| Murphy, E; Nolan, JJ | 1 |
| Fujiwara, T; Horikoshi, H | 1 |
| Jerkins, TW | 1 |
| Akasaka, T; Honda, Y; Hozumi, T; Morioka, S; Takagi, T; Yamamuro, A; Yoshida, K | 1 |
| Aronoff, S; Braithwaite, S; Egan, JW; Mathisen, AL; Rosenblatt, S; Schneider, RL | 1 |
| Chen, L; Cohen, SE; Kahn, CR | 1 |
| Abe, S; Akiyama, T; Jia, DM; Otsuki, M; Tabaru, A | 1 |
| Ducobu, J; Sternon, J | 1 |
| Bolesta, S; Malinowski, JM | 1 |
| Johnson, JH; McCarthy, KJ; Routh, RE; Shaw, W; Walsh, K; Welbourne, TC | 1 |
| Esterbauer, H; Fürnsinn, C; Neschen, S; Oberkofler, H; Patsch, W; Waldhäusl, W | 1 |
| Holder, JC; Murphy, GJ | 1 |
| Campbell, IW | 1 |
| Bryan, J | 1 |
| Blumenthal, RS; Nass, CM | 1 |
| Abe, N; Hirayama, H; Makino, N; Sugano, M; Yonemoch, H | 1 |
| Cheatham, WW; Glazer, NB | 1 |
| Henry, RR; Mudaliar, S | 1 |
| Bachmann, O; Häring, HU; Kausch, C; Krützfeldt, J; Machicao, F; Matthaei, S; Rett, K; Rettig, A; Stumvoll, M; Witke, A | 1 |
| Fonseca, VA; Granda-Ayala, R; Lee, TR; Parulkar, AA; Pendergrass, ML | 1 |
| Egan, JW; Einhorn, D; Mathisen, AL; Rendell, M; Rosenzweig, J; Schneider, RL | 1 |
| Meneilly, GS; Tessier, D | 1 |
| Funk, WB; Lenhard, MJ | 1 |
| Lloyd, SJ; Thomas, ML | 1 |
| Altan, VM; Ari, N; Karasu, C; Ozçelikay, AT; Sahilli, M; Yöntem, O | 1 |
| Blackburn, G | 1 |
| Ahima, RS; Bailey, ST; Banerjee, RR; Bhat, S; Brown, EJ; Lazar, MA; Patel, HR; Steppan, CM; Wright, CM | 1 |
| Khan, MA; Lockheart, MS; Neafus, KL; St Peter, JV; Vessey, JT | 1 |
| Grunberger, G; Miller, E; Patwardhan, R; Phillips, LS; Rappaport, EB; Salzman, A | 1 |
| Abe, T; Nagai, Y; Nomura, G | 1 |
| Tooke, J | 1 |
| Reasner, CA | 1 |
| Anderson, RJ; Patel, J; Rappaport, EB | 1 |
| Donnelly, R | 1 |
| Garber, AJ | 1 |
| Johnson, WT; Stephens, TW; Yakubu-Madus, FE | 1 |
| Adachi, Y; Araki-Sasaki, R; Furuta, M; Gabazza, EC; Hori, Y; Katsuki, A; Murata, K; Sumida, Y; Tsuchihashi, K; Yano, Y | 1 |
| Lawrence, JM; Reckless, JP | 2 |
| Robinson, S; Schachter, M; Valabhji, J | 1 |
| Buckingham, RE; Lister, CA; Smith, SA; Toseland, CD | 1 |
| Ebeling, P; Koistinen, HA; Koivisto, VA; Teppo, AM | 1 |
| Gunawan, I; Malamas, MS; McCaleb, M; Mihan, B; Sredy, J; Sullivan, D | 1 |
| Glass, CK | 1 |
| Collins, AR; Hsueh, WA; Jackson, S; Kintscher, U; Law, RE; Meehan, WP; Noh, G; Palinski, W; Wakino, S | 1 |
| Dole, JF; Freed, MI; Lebovitz, HE; Patwardhan, R; Rappaport, EB | 1 |
| Dharmalingam, M; Kumar, P | 1 |
| Banerji, MA; Lebovitz, HE | 1 |
| Auwerx, J; Rocchi, S | 1 |
| Akanuma, Y; Hagura, R; Hara, K; Ito, C; Kadowaki, T; Komeda, K; Kubota, N; Miki, H; Tamemoto, H; Terauchi, Y; Tobe, K; Yamauchi, T | 1 |
| Awad, J; Schindel, B; Schindel, Y | 1 |
| Burant, C; Corpe, C; Sreenan, S | 1 |
| Kumar, S; Valsamakis, G | 1 |
| Bandyopadhyay, G; Farese, RV; Kanoh, Y; Sajan, MP; Standaert, ML | 1 |
| Benjasuratwong, Y; Boonyavarakul, A; Bunnag, P; Chandraprasert, S; Chanprasertyotin, S; Deerochanawong, C; Nitiyanant, W; Puavilai, G; Sriussadaporn, S; Suthijumroon, A; Suwanwalaikorn, S | 1 |
| Medina, G; Puig, AJ; Sewter, C | 1 |
| Gottlieb, S | 1 |
| Unger, RH; Zhou, YT | 1 |
| Matthews, DR | 2 |
| Ellingboe, J; Gunawan, I; Han, S; Hu, B; Largis, E; Li, Z; Malamas, M; Mulvey, R; Oliphant, A; Sum, FW; Tillett, J; Wong, V | 1 |
| Caldwell, SH; Hespenheide, EE; von Borstel, RW | 1 |
| Hata, S; Ikemoto, S; Inoue, Y; Katoh, S; Matsushima, M; Tajima, N; Yokoyama, J | 1 |
| Porterfield, LM | 1 |
| Akiyama, T; Fukumitsu, KI; Jia, DM; Otsuki, M; Tabaru, A | 1 |
| Peters, AL | 1 |
| Cusi, K; DeFronzo, RA; Ferrannini, E; Glass, L; Mahankali, A; Mahankali, S; Mandarino, LJ; Matsuda, M; Miyazaki, Y | 1 |
| Janka, HU | 1 |
| Clark, A; Fraser, PE; Gross, M; Higham, CE; Jaikaran, ET; Serpell, LC; Zurdo, J | 1 |
| Foyt, HL; Ghazzi, MN; Owens-Grillo, JK; Valiquett, TR; Whitcomb, RW; Yale, JF | 1 |
| Buckingham, RE; Finegood, DT; Kojwang, D; Leonard, T; McArthur, MD; Thomas, MJ; Topp, BG | 1 |
| Huijberts, MS; Sels, JP; Wolffenbuttel, BH | 1 |
| Baba, T; Hashimoto, S; Neugebauer, S; Shimada, K; Watanabe, T; Yamada, D | 1 |
| Koshiyama, H; Kuwamura, N; Nakamura, Y; Shimono, D | 1 |
| Feinglos, MN; Luna, B | 1 |
| Bragg, T | 1 |
| Chamie, K; Perfetti, R | 1 |
| Rybka, J | 1 |
| Pfohl, M | 1 |
| Richter, B | 1 |
| Akutsu, H; Funada, J; Otani, T; Sekiya, M; Suzuki, J; Watanabe, K | 1 |
| Gale, EA | 2 |
| Drexler, AJ; Robertson, C | 1 |
| Dole, JF; Freed, MI; Raskin, P; Rendell, M; Riddle, MC; Rosenstock, J | 1 |
| Beattie, P; Harrigan, RA; Nathan, MS | 1 |
| Levine, RA; Sobel, BE | 1 |
| Kitabchi, AE; Umpierrez, GE | 1 |
| Scheen, AJ | 3 |
| Ebihara, L; Koide, H; Nakamura, T; Sekizuka, K; Shimada, N; Suzuki, S; Ushiyama, C | 1 |
| Inoue, Y; Momose, T; Moritan, T; Nagai, R; Ohtomo, K; Tateno, M; Yokoyama, I; Yonekura, K | 1 |
| Aljada, A; Assian, E; Dandona, P; Garg, R; Ghanim, H; Hamouda, W; Mohanty, P | 1 |
| Koshiyama, H; Kuwamura, N; Minamikawa, J; Nakamura, Y; Shimono, D | 1 |
| Egan, JW; Kipnes, MS; Krosnick, A; Mathisen, AL; Rendell, MS; Schneider, RL | 1 |
| Laws, A | 1 |
| Reaven, GM | 1 |
| Blicklé, JF | 2 |
| Girard, J | 3 |
| Burge, MR; Colleran, K; Sood, V | 1 |
| Marcus, AO | 1 |
| Boccuzzi, SJ; Fox, J; Kim, J; Shah, AB; Sung, JC; Wogen, J | 1 |
| Iwamoto, Y; Kanamuro, R; Maruyama, S; Teno, S; Yanagisawa, K | 1 |
| Klonoff, DC | 1 |
| Glazer, NB; Miskin, B; Prince, MJ; Robertson, KE; Rosenblatt, S | 1 |
| Csermely, P; Jermendy, G | 1 |
| Maeda, K | 1 |
| Hombach, V; Marx, N | 1 |
| Chapman, H; Clapham, JC; Holder, JC; Lister, CA; Moore, GB; Piercy, V; Smith, SA | 1 |
| Algenstaedt, P; Hamann, A | 1 |
| Palazzolo, MR; Solomon, SS; Usdan, LS | 1 |
| Jazet, IM; Meinders, AE | 1 |
| Calvo Romero, JM; Lima Rodríguez, EM | 1 |
| Andreelli, F; Charbonnel, B; Girard, J; Hanaire-Broutin, H; Mauvais-Jarvis, F | 1 |
| Al-Majali, K; Betteridge, DJ; Kaplan, F | 1 |
| Travaglini, MT; Werner, AL | 1 |
| Haneda, M; Kikkawa, R; Koya, D | 1 |
| Akanuma, Y; Ezaki, O; Fukayama, M; Hori, W; Ide, T; Itai, A; Kadowaki, T; Kagechika, H; Kamon, J; Kato, S; Kimura, S; Komeda, K; Kubota, N; Miki, H; Motojima, K; Murakami, K; Nagai, R; Shudo, K; Terauchi, Y; Tobe, K; Tsuboyama-Kasaoka, N; Tsuchida, A; Waki, H; Yamauchi, N; Yamauchi, T | 1 |
| Hara, M; Koide, H; Nakamura, T; Osada, S; Shimada, N; Ushiyama, C | 1 |
| Hanefeld, M | 1 |
| Morris, AD | 1 |
| Brunetti, P | 1 |
| Diemont, WL; van Grootheest, AC | 1 |
| Birkeland, KI | 1 |
| Häring, H; Stumvoll, M | 1 |
| Finegood, DT; Topp, BG | 1 |
| Zinman, B | 1 |
| Badimon, JJ; Crandall, JP; Fallon, JT; Fuster, V; Heflt, G; Herson, P; Lev, EI; Osende, JI; Rabito, P; Rauch, U; Rodriguez, OJ; Vidhun, R; Zaman, A | 1 |
| Chilcott, J; Lloyd Jones, M; Tappenden, P; Wight, J | 1 |
| Kohno, M; Miyatake, A; Mizushige, K; Murakami, K; Noma, T; Ohmori, K; Tsuji, T | 1 |
| Yoshimasa, Y | 1 |
| Hotta, N | 1 |
| Kitamura, R; Tanaka, Y | 1 |
| Lervang, HH | 1 |
| Beck-Nielsen, H; Brock, B; Madsbad, S; Schmitz, OE | 1 |
| Blaak, EE; Borghouts, LB; Hesselink, MK; Keizer, HA; Saris, WH; Schaart, G; Schrauwen, P | 1 |
| Funakoshi, A; Hayashi, H; Ichikawa, M; Kanai, S; Miyasaka, K; Sato, Y | 1 |
| Bedoucha, M; Boelsterli, UA | 1 |
| Baxi, S; Caulfield, M; Chu, NV; Ciaraldi, TP; Henry, RR; Kim, DD; Kong, AP; Loviscach, M; Mudaliar, S; Plodkowski, R; Reitz, R | 1 |
| Flemmer, M; Scott, J | 1 |
| Chilcott, J; Jones, ML; Tappenden, P; Wight, JP | 1 |
| Ebihara, I; Koide, H; Nakamura, T; Osada, S; Shimada, N; Ushiyama, C | 1 |
| Aguilar-Salinas, CA; Cesarman, G; Chavira-López, IJ; Fanghänel-Salmón, G; Gallegos-Martínez, J; Gómez-Diaz, RA; Gómez-Pérez, FJ; Guillén, LE; López, A; Salinas-Orozco, S; Sánchez-Reyes, L; Tamez, R; Torres-Acosta, EM; Vázquez-Chávez, C | 1 |
| Inzucchi, SE | 1 |
| Holmboe, ES | 1 |
| Cusi, K; DeFronzo, RA; Glass, L; Mahankali, A; Mahankali, S; Mandarino, LJ; Matsuda, M; Miyazaki, Y; Triplitt, C | 1 |
| McCormick, M; Quinn, L | 1 |
| Mouri, H; Nakanuma, Y; Okai, T; Sawabu, N; Yamaguchi, Y | 1 |
| Akasaka, T; Katayama, M; Morioka, S; Takagi, T; Tamita, K; Yamabe, K; Yamamuro, A; Yoshida, K | 1 |
| Chu, N; Ciaraldi, TP; Henry, RR; Kahn, BB; Kim, D; Kim, YB; Kong, A; Mohideen, P; Mudaliar, S | 1 |
| Chen, CL; Chuang, LM; Funahashi, T; Jeng, CY; Matsuzawa, Y; Tai, TY; Tanaka, S; Wang, JP; Wu, TJ; Yang, WS | 1 |
| Hashimoto, Y; Nakahara, K | 1 |
| Jensen, MD; Shadid, S | 1 |
| Camejo, G; Ljung, B; Oakes, N | 1 |
| Davis, AO; Klein, S; McGill, JB; Racette, SB | 1 |
| Dohi, Y; Gotoa, T; Hakamata, M; Hayashi, K; Sato, K; Takase, H; Toriyama, T; Ueda, R | 1 |
| Marra, F; Pastacaldi, S | 1 |
| Kleinwechter, H | 1 |
| Berg, AH; Berger, J; Charron, MJ; Chatterjee, K; Combs, TP; Doebber, T; Gertz, BJ; Gottesdiener, KM; Larson, PJ; Moller, DE; O'Rahilly, S; Savage, DB; Scherer, PE; Tanen, M; Wagner, JA; Wang, WJ; Weiss, S; Zhang, BB | 1 |
| Lotz, N | 1 |
| Chase, MP; Yarze, JC | 1 |
| Montague, CT | 1 |
| Befroy, D; Cline, GW; Dufour, S; Enocksson, S; Hundal, RS; Inzucchi, SE; Lebon, V; Mayerson, AB; Petersen, KF; Shulman, GI | 1 |
| DeFronzo, RA; Matsuda, M; Miyazaki, Y | 1 |
| Armstrong, D; Baxi, S; Caulfield, M; Chu, NV; Deutsch, R; Henry, RR; Kim, DD; Kong, AP; Mudaliar, SR; Reaven, PD; Reitz, R | 1 |
| Groop, L; Ridderstråle, M | 1 |
| Hirose, H; Ishii, T; Kawai, T; Matsubara, K; Oguma, Y; Okazaki, Y; Saruta, T; Takei, I; Taniyama, M; Tomita, M; Yamamoto, Y | 1 |
| Kuritzky, L; Quillen, DM | 1 |
| Lindberg, M | 1 |
| Baba, S | 1 |
| Abe, N; Hirayama, H; Makino, N; Yano, K; Yonemochi, H | 1 |
| Kram, MT; Lefkowitch, JH; May, LD; Rubin, DE | 1 |
| Nierenberg, DW | 1 |
| Inzucchi, SE; Mayerson, AB | 1 |
| Ardecky, RJ; Bean, JS; Bensch, WR; Bilakovics, JM; Broderick, CL; Brooks, DA; Brozinick, JT; Dana, SL; Etgen, GJ; Johnson, WT; Kauffman, RF; Liu, S; McCarthy, JR; Misener, EA; Montrose, CR; Ogilvie, KM; Oldham, BA; Paterniti, JR; Rito, CJ; Shuker, AJ; Tyhonas, JS | 1 |
| Khan, MA; St Peter, JV; Xue, JL | 1 |
| Demant, T | 1 |
| Abe, T; Ishibashi, S; Ishikawa, S; Kawakami, A; Kusaka, I; Nagasaka, S; Nakamura, T; Saito, T | 1 |
| Adachi, Y; Araki-Sasaki, R; Furuta, M; Gabazza, EC; Hori, Y; Katsuki, A; Nakatani, K; Sumida, Y; Tanaka, T; Yano, Y | 1 |
| Boyle, PJ; King, AB; Lau, H; Magar, R; Marchetti, A; Martin, J; Olansky, L | 1 |
| Tolman, KG | 1 |
| Yale, JF | 1 |
| Mykkänen, L | 1 |
| Tan, MH | 1 |
| Göke, B; Lehrke, M; Otto, C | 1 |
| Berrebi-Bertrand, I; Bril, A; Buckingham, RE; Delerive, P; Khandoudi, N; Staels, B | 1 |
| Freed, MI; Kreider, M; Lebovitz, HE | 1 |
| Christiansen, AL; Madsbad, S | 1 |
| Lawrence, IG | 1 |
| Greenberg, AS; Pittas, AG | 1 |
| Culhane, NS; Graves, R | 1 |
| Legro, RS | 1 |
| Grossman, LD | 1 |
| Coyle, D; Lee, KM; O'Brien, BJ | 1 |
| Coyle, D; Palmer, AJ; Tam, R | 1 |
| Henriksson, F | 1 |
| Valensi, P | 1 |
| Scheen, A | 1 |
| Cohen-Solal, A | 1 |
| O'Moore-Sullivan, TM; Prins, JB | 1 |
| Cusi, K; DeFronzo, RA; Hardies, J; Mahankali, A; Mahankali, S; Mandarino, LJ; Matsuda, M; Miyazaki, Y | 1 |
| Auwerx, J; Picard, F | 1 |
| Kaneko, T; Li, J; Qin, LQ; Sato, A; Wang, PY; Wang, Y | 1 |
| Verspohl, EJ; Weiland, F | 1 |
| Einhorn, D; Glazer, NB; Hershon, K; Rosenstock, J; Yu, S | 1 |
| Armstrong, DU; King, AB | 1 |
| Kane, JP | 1 |
| Smith, U | 1 |
| Kiayias, JA; Lakka-Papadodima, E; Theodosopoulou, E; Vlachou, ED | 1 |
| de Koning, EJ; Lemay, J; Martens, FM; Rabelink, TJ; Visseren, FL | 1 |
| Akarca, C; Barton, DM; Baskar, V; Buch, HN; Kamalakannan, D; Singh, BM | 1 |
| Anderson, JW; Frederich, RC; Konz, EC; Reynolds, LR | 1 |
| Egawa, K; Iwanishi, M; Kobayashi, M; Shigeta, Y | 1 |
| Banga, JD; Hendriksen, PH; Oey, PL; van Dam, PS; Wieneke, GH | 1 |
| Colca, JR; Hofmann, CA | 1 |
| Gumbiner, B; Nolan, JJ; Olefsky, JM; Suter, SL; Wallace, P | 1 |
| Clark, DA; Dambek, PJ; Goldstein, SW; Hulin, B; Kappeler, WH; Lamphere, CH; Lewis, DM; McDermott, RE; Rizzi, JP | 1 |
| Awata, T; Inooka, G; Iwamoto, Y; Kumakura, S; Kuzuya, T; Matsuda, A; Shiraishi, I | 1 |
| Colca, JR; Hofmann, C; Lorenz, K | 1 |
| Akanuma, Y; Iwamoto, Y; Kajinuma, H; Kasuga, M; Kosaka, K; Kuzuya, T; Shigeta, Y; Takebe, K; Yamanouchi, T; Yoshida, S | 1 |
| Fujita, T; Ikeda, H; Shimura, Y; Sugiyama, Y; Taketomi, S | 1 |
| Andrews, KM; Gibbs, EM; Hutson, NJ; Kreutter, DK; Stevenson, RW | 1 |
| Jirkovsky, I; McCaleb, ML; Nowicki, JW; Zask, A | 1 |
259 review(s) available for thiazoles and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses | 2021 |
Mirabegron: The most promising adipose tissue beiging agent.
Topics: Acetanilides; Adipose Tissue; Adipose Tissue, White; Animals; Diabetes Mellitus, Type 2; Energy Metabolism; Humans; Obesity; Thiazoles | 2021 |
Insulin Formulation Characterization-the Thioflavin T Assays.
Topics: Amyloid; Benzothiazoles; Biological Assay; Diabetes Mellitus, Type 2; Drug Design; Fluorescent Dyes; Humans; Hypoglycemic Agents; Insulin; Thiazoles | 2017 |
PPAR-beta/delta agonists for Type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home.
Topics: Animals; Atherosclerosis; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dyslipidemias; Glucose; Humans; Insulin Resistance; Lipoproteins; PPAR delta; PPAR-beta; Propionates; Thiazoles | 2008 |
Medicinal chemistry approaches for glucokinase activation to treat type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Design; Enzyme Activation; Glucokinase; Humans; Hypoglycemic Agents; Molecular Structure; Pyridines; Thiazoles | 2009 |
Protein tyrosine phosphatase 1B inhibitors: a molecular level legitimate approach for the management of diabetes mellitus.
Topics: Acetophenones; Amino Acid Sequence; Animals; Benzoates; Benzofurans; Biphenyl Compounds; Blood Glucose; Catalytic Domain; Catechols; Chromones; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Fluorides; Humans; Insulin; Insulin Resistance; Insulin Secretion; Janus Kinase 2; Models, Molecular; Naphthoquinones; Peptidomimetics; Phosphates; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Pyridazines; Receptor, Insulin; Signal Transduction; STAT3 Transcription Factor; Thiazoles; Thiazolidinediones; Thiophenes; Vanadium Compounds | 2012 |
[Hyperuricemia, gout, pseudogout and concomitant diseases].
Topics: Allopurinol; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Chondrocalcinosis; Comorbidity; Diabetes Mellitus, Type 2; Febuxostat; Gout; Gout Suppressants; Guideline Adherence; Humans; Hypertrophy, Left Ventricular; Hyperuricemia; Interleukin 1 Receptor Antagonist Protein; Kidney Failure, Chronic; Thiazoles; Xanthine Oxidase | 2011 |
Current therapeutic interventions in the glycation pathway: evidence from clinical studies.
Topics: Animals; Atherosclerosis; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Enzyme Inhibitors; Evidence-Based Medicine; Female; Glycation End Products, Advanced; Guanidines; Humans; Hyperglycemia; Male; Pyridoxamine; Thiamine; Thiazoles; Treatment Outcome | 2013 |
Oral hypoglycaemics. When not to use what.
Topics: Acarbose; Acidosis, Lactic; Aged; Contraindications; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Hypoglycemic Agents; Male; Metformin; Pioglitazone; Renal Insufficiency; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |
Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus.
Topics: Administration, Oral; Aged; Area Under Curve; Diabetes Mellitus, Type 2; Drug Interactions; Half-Life; Humans; Hypoglycemic Agents; Intestinal Absorption; Liver; Middle Aged; Randomized Controlled Trials as Topic; Rosiglitazone; Structure-Activity Relationship; Thiazoles; Thiazolidinediones; Treatment Outcome | 2002 |
Glitazones: clinical effects and molecular mechanisms.
Topics: Adipose Tissue; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Obesity; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
Insulin resistance as the core defect in type 2 diabetes mellitus.
Topics: Adipose Tissue; Diabetes Mellitus; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Obesity; Risk Factors; Thiazoles | 2002 |
Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Fatty Acids; Glucose; Glycogen; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Magnetic Resonance Spectroscopy; Muscle, Skeletal; Signal Transduction; Thiazoles | 2002 |
Current concepts in insulin resistance, type 2 diabetes mellitus, and the metabolic syndrome.
Topics: Coronary Disease; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin; Insulin Resistance; Metabolic Syndrome; Physical Fitness; Risk Factors; Thiazoles; Thrombosis; Vasodilation | 2002 |
A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and atherosclerosis.
Topics: Anti-Inflammatory Agents; Arteriosclerosis; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Inflammation; Insulin; Insulin Resistance; Thiazoles | 2002 |
Rationale for and role of thiazolidinediones in type 2 diabetes mellitus.
Topics: Administration, Oral; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Metabolic Syndrome; Thiazoles | 2002 |
Reappraisal of the pharmacologic approach to treatment of type 2 diabetes mellitus.
Topics: Administration, Oral; Antihypertensive Agents; Biguanides; Diabetes Mellitus, Type 2; Glucosamine; Hormone Replacement Therapy; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Insulin Resistance; Sulfonylurea Compounds; Thiazoles | 2002 |
[Uric acid metabolism and insulin resistance in type 2 diabetes].
Topics: Cardiovascular Diseases; Chromans; Diabetes Mellitus, Type 2; Humans; Hyperuricemia; Insulin Resistance; Thiazoles; Thiazolidinediones; Troglitazone; Uric Acid | 2002 |
Insulin-sensitizing agents--thiazolidinediones (glitazones).
Topics: Administration, Oral; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Approval; Europe; Humans; Hyperglycemia; Insulin; Insulin Resistance; Islets of Langerhans; Thiazoles; Thiazolidinediones; United Kingdom | 2002 |
[Antidiabetic agents and renal insufficiency].
Topics: Administration, Oral; Animals; Blood Glucose; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerulonephritis; Humans; Hyperglycemia; Hypoglycemic Agents; Inactivation, Metabolic; Insulin; Insulin Resistance; Kidney; Kidney Failure, Chronic; Liver; Renin-Angiotensin System; Thiazoles | 2002 |
When diet fails: insulin and oral hypoglycemic agents as alternatives for the management of gestational diabetes mellitus.
Topics: Administration, Oral; Biguanides; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetes, Gestational; Enzyme Inhibitors; Female; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Practice Guidelines as Topic; Pregnancy; Sulfonylurea Compounds; Thiazoles; Treatment Failure | 2002 |
[Primary prevention of diabetes mellitus by pharmacological intervention].
Topics: Acarbose; Angiotensin-Converting Enzyme Inhibitors; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Lactones; Metformin; Orlistat; Pravastatin; Primary Prevention; Ramipril; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
[Insulin sensitizer drugs--review].
Topics: Adipose Tissue; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
[Glitazone--a new drug for type 2 diabetes].
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Lipid Metabolism; Pioglitazone; Thiazoles; Thiazolidinediones | 2002 |
[Mechanisms of thiazolidinedione derivatives for hypoglycemic and insulin sensitizing effects].
Topics: Animals; Arteriosclerosis; Diabetes Mellitus; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Ligands; Lipid Metabolism; Obesity; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
[Pioglitazone].
Topics: Animals; Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Edema; Humans; Hypoglycemic Agents; Insulin Resistance; Lipid Metabolism; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Necrosis Factor-alpha | 2002 |
[Rosiglitazone (BRL-49653)].
Topics: Animals; Carbohydrate Metabolism; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin Resistance; Lipid Metabolism; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Treatment Outcome | 2002 |
[Combination therapy of insulin sensitizer, thiazolidinedione drugs, and sulfonylurea].
Topics: Blood Glucose; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
[Efficacy of combination therapy of alpha-glucosidase inhibitor and insulin sensitizer in patients with type 2 diabetes].
Topics: Acarbose; Animals; Biguanides; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Insulin Resistance; Pioglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
[Mechanisms by which PPAR gamma modulators regulate insulin sensitivity].
Topics: Adipocytes; Animals; Apoptosis; Cell Differentiation; CREB-Binding Protein; Diabetes Mellitus, Type 2; Drug Design; Humans; Hypoglycemic Agents; Insulin Resistance; Nuclear Proteins; Polymorphism, Genetic; Receptors, Cytoplasmic and Nuclear; Thiazoles; Trans-Activators; Transcription Factors | 2002 |
Oral antihyperglycemic agents during pregnancy and lactation: a review.
Topics: Administration, Oral; Biguanides; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Lactation; Milk, Human; Pregnancy; Pregnancy in Diabetics; Pregnancy Outcome; Sulfonylurea Compounds; Thiazoles | 2002 |
Troglitazone: the discovery and development of a novel therapy for the treatment of Type 2 diabetes mellitus.
Topics: Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
Management of rosiglitazone-induced edema: two case reports and a review of the literature.
Topics: Body Weight; Clinical Trials as Topic; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diuresis; Edema; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Middle Aged; Obesity; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |
The glitazones: a new treatment for type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Dosage Forms; Drug Monitoring; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; United Kingdom | 2002 |
Effects of thiazolidinediones for early treatment of type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Thiazoles; Thiazolidinediones; United States | 2002 |
Thiazolidinediones in the treatment of managed care patients with type 2 diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hyperlipidemias; Hypoglycemic Agents; Inflammation; Insulin Resistance; Islets of Langerhans; Managed Care Programs; Mice; Outcome Assessment, Health Care; Thiazoles; Thiazolidinediones; United States | 2002 |
Biology and toxicology of PPARgamma ligands.
Topics: Diabetes Mellitus, Type 2; DNA-Binding Proteins; Humans; Hyperlipidemias; Hypoglycemic Agents; Inflammation; Insulin Resistance; Ligands; Microbodies; Nuclear Proteins; Receptors, Cytoplasmic and Nuclear; Repressor Proteins; Thiazoles; Thiazolidinediones; Transcription Factors; Zinc Fingers | 2002 |
Thiazolidinediones: a review of their benefits and risks.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Risk Factors; Thiazoles; Thiazolidinediones | 2002 |
[Combination therapy with biguanides].
Topics: Acarbose; Biguanides; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Metformin; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Treatment Outcome; Troglitazone | 2002 |
Therapeutic options for the management of type 2 diabetes mellitus.
Topics: 1-Deoxynojirimycin; Adult; Diabetes Mellitus, Type 2; Disease Management; Education, Medical, Continuing; Education, Pharmacy, Continuing; Glucosamine; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Insulin Aspart; Managed Care Programs; Metformin; Thiazoles; Thiazolidinediones; United States | 2002 |
Oral anti diabetic polychemotherapy in type 2 diabetes mellitus.
Topics: Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Thiazoles; Thiazolidinediones | 2002 |
The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment.
Topics: Alzheimer Disease; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Pioglitazone: cardiovascular effects in prediabetic patients.
Topics: Animals; Aorta; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Fibrosis; Humans; Hypoglycemic Agents; Muscle, Smooth, Vascular; Myocardium; Pioglitazone; Prediabetic State; Thiazoles; Thiazolidinediones | 2002 |
Experimental approaches to study PPAR gamma agonists as antidiabetic drugs.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Humans; Hypoglycemic Agents; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
Effects of thiazolidinediones on cardiovascular risk factors.
Topics: Arteriosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Fibrinolysis; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Insulin Resistance; Risk Factors; Thiazoles; Vascular Resistance; Weight Gain | 2002 |
[Thiazolidinediones in type 2 diabetes. Role of peroxisome proliferator-activated receptor gamma (PPARgamma)].
Topics: Adipocytes; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Gene Expression Regulation; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides | 2002 |
Rosiglitazone reduces blood pressure and urinary albumin excretion in type 2 diabetes: G Bakris et al.
Topics: Albuminuria; Blood Pressure Determination; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Hypertension; Hypoglycemic Agents; Kidney Failure, Chronic; Male; Prognosis; Risk Assessment; Risk Factors; Rosiglitazone; Sensitivity and Specificity; Thiazoles; Thiazolidinediones | 2003 |
PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy?
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Obesity; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors | 2003 |
Insulin sensitisation in the treatment of Type 2 diabetes.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adrenergic beta-3 Receptor Agonists; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Humans; Hydroxysteroid Dehydrogenases; Hypoglycemic Agents; Insulin; Insulin Resistance; Islets of Langerhans; Metformin; Peptide Fragments; Protein Precursors; Randomized Controlled Trials as Topic; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Thiazoles; Transcription Factors | 2003 |
Polycystic ovary syndrome and insulin resistance.
Topics: Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Polycystic Ovary Syndrome; Prevalence; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; United States; Women's Health | 2003 |
Combination oral agent and insulin therapy for type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones | 2001 |
Treatment of insulin resistance in uremia.
Topics: Anemia; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Diabetes Mellitus, Type 2; Erythropoietin; Humans; Hyperparathyroidism; Hypoglycemic Agents; Insulin Resistance; Phosphoric Diester Hydrolases; Pyrophosphatases; Recombinant Proteins; Renal Dialysis; Thiazoles; Thiazolidinediones; Uremia | 2003 |
Rosiglitazone: potential beneficial impact on cardiovascular disease.
Topics: Albuminuria; Arteriosclerosis; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hyperglycemia; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Insulin Resistance; Obesity; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Male; Metformin; Middle Aged; Obesity; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Modulation of PPARgamma activity with pharmaceutical agents: treatment of insulin resistance and atherosclerosis.
Topics: Animals; Arteriosclerosis; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Models, Biological; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors | 2003 |
Insulin sensitizers.
Topics: Biguanides; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Ligands; Thiazoles; Thiazolidinediones | 2003 |
Repaglinide in combination therapy.
Topics: Carbamates; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Metformin; Pioglitazone; Piperidines; Postprandial Period; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome; Troglitazone | 2002 |
Prevention of type 2 diabetes: are we ready?
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Lactones; Life Style; Lipase; Metformin; Orlistat; Thiazoles; Thiazolidinediones; Troglitazone | 2003 |
Lessons learned from landmark trials of type 2 diabetes mellitus and potential applications to clinical practice.
Topics: Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Risk Factors; Thiazoles; Thiazolidinediones | 2003 |
The need for reappraisal of type 2 diabetes mellitus management.
Topics: Diabetes Mellitus, Type 2; Gluconeogenesis; Humans; Hypoglycemic Agents; Insulin Resistance; Metabolic Syndrome; Primary Prevention; Risk Factors; Thiazoles; Thiazolidinediones | 2003 |
Insulin resistance syndrome. Description, pathogenesis, and management.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metabolic Syndrome; Risk Factors; Thiazoles; Thiazolidinediones | 2003 |
Beneficial effects resulting from thiazolidinediones for treatment of type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Thiazoles; Thiazolidinediones | 2003 |
Constructing an algorithm for managing type 2 diabetes. Focus on role of the thiazolidinediones.
Topics: Administration, Oral; Algorithms; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Combination agents for diabetes.
Topics: Adult; Diabetes Mellitus, Type 2; Drug Combinations; Female; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Metformin; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Thiazolidinediones in diabetes: current status and future outlook.
Topics: Animals; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Evaluation, Preclinical; Humans; Hypoglycemic Agents; Lipids; Thiazoles; Weight Gain | 2003 |
MK-767. Kyorin/Banyu/Merck.
Topics: Animals; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Contraindications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Thiazoles; Thiazolidines | 2003 |
Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Thiazolidinediones -- some recent developments.
Topics: Adipose Tissue; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Cyclic AMP-Dependent Protein Kinases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Receptors, Cytoplasmic and Nuclear; Thiazoles; Transcription Factors | 2003 |
[Therapeutic strategies for type 2 diabetes].
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hyperglycemia; Hypoglycemic Agents; Metabolic Syndrome; Phenotype; Practice Guidelines as Topic; Thiazoles | 2003 |
[Hypertension and insulin resistance in obese type 2 diabetic Wistar fatty rat].
Topics: Animals; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 2; Disease Models, Animal; Hyperinsulinism; Hypertension; Hypoglycemic Agents; Insulin Resistance; Obesity; Pioglitazone; Rats; Rats, Wistar; Thiazoles; Thiazolidinediones | 2003 |
[Insulin-sensitizing agents: metformin and thiazolidinedione derivatives].
Topics: Adipocytes; Adiponectin; Cyclic AMP-Dependent Protein Kinases; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glycerol Kinase; Humans; Hypertension; Hypoglycemic Agents; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Metformin; Obesity; Proteins; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors | 2003 |
Prevention of type 2 diabetes.
Topics: Acarbose; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Exercise; Female; Humans; Hypoglycemic Agents; Male; Obesity; Risk Factors; Risk Reduction Behavior; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia.
Topics: Abdomen; Adipose Tissue; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Metabolic Syndrome; Niacin; Thiazoles; Thiazolidinediones | 2003 |
Ethnic disparities in type 2 diabetes: pathophysiology and implications for prevention and management.
Topics: Blood Circulation; Diabetes Mellitus, Type 2; Environmental Exposure; Female; Genetic Predisposition to Disease; Humans; Hypoglycemic Agents; Incidence; Insulin; Life Style; Male; Metabolic Syndrome; Obesity; Prevalence; Risk Factors; Thiazoles; Thiazolidinediones; United States | 2003 |
Evolving concepts in advanced glycation, diabetic nephropathy, and diabetic vascular disease.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Enzyme Inhibitors; Forecasting; Glycation End Products, Advanced; Guanidines; Humans; Protein Kinase C; Ramipril; Renin-Angiotensin System; Thiazoles | 2003 |
Rosiglitazone plus metformin: combination therapy for Type 2 diabetes.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Combinations; Humans; Hypoglycemic Agents; Metformin; Rosiglitazone; Thiazoles; Thiazolidinediones | 2004 |
The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diabetes Mellitus, Type 2; Dibenzothiazepines; Drug Administration Schedule; Humans; Hyperprolactinemia; Mental Disorders; Olanzapine; Patient Compliance; Piperazines; Practice Guidelines as Topic; Prescription Fees; Quetiapine Fumarate; Quinolones; Risk Assessment; Risperidone; Thiazoles; Torsades de Pointes; Treatment Outcome; Weight Gain | 2004 |
Avandamet: combined metformin-rosiglitazone treatment for insulin resistance in type 2 diabetes.
Topics: Contraindications; Diabetes Mellitus, Type 2; Drug Combinations; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Thiazoles; Treatment Outcome | 2004 |
Type 2 diabetes--therapy with dipeptidyl peptidase IV inhibitors.
Topics: Animals; Blood Glucose; Clinical Trials, Phase II as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Drug Evaluation, Preclinical; Humans; Membrane Proteins; Models, Molecular; Protease Inhibitors; Pyrrolidines; Rats; Substrate Specificity; Thiazoles; Xanthines | 2005 |
Role of PPAR- gamma agonist thiazolidinediones in treatment of pre-diabetic and diabetic individuals: a cardiovascular perspective.
Topics: Diabetes Mellitus, Type 2; Humans; PPAR gamma; Prediabetic State; Thiazoles; Thiazolidinediones | 2005 |
Toxicology of oral antidiabetic medications.
Topics: Diabetes Mellitus, Type 2; Drug Overdose; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Sulfonylurea Compounds; Thiazoles | 2006 |
[Advances in the study of glucokinase and small molecule glucokinase activators].
Topics: Animals; Binding Sites; Blood Glucose; Diabetes Mellitus, Type 2; Enzyme Activation; Enzyme Activators; Glucokinase; Humans; Hypoglycemic Agents; Molecular Conformation; Phosphorylation; Sulfones; Thiazoles | 2006 |
Treatment of bipolar disorder: the evolving role of atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Arrhythmias, Cardiac; Benzodiazepines; Bipolar Disorder; Diabetes Mellitus, Type 2; Dibenzothiazepines; Drug Evaluation; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Humans; Hyperprolactinemia; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles; Treatment Outcome; Weight Gain | 2007 |
Prevention of complications in non-insulin-dependent diabetes mellitus (NIDDM).
Topics: Acarbose; Aldehyde Reductase; Biguanides; Diabetes Mellitus, Type 2; Glucose; Guanidines; Humans; Hyperglycemia; Hypertension; Hypoglycemic Agents; Insulin; Lipids; Prospective Studies; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Trisaccharides; United Kingdom | 1995 |
Potential role of thiazolidinediones in older diabetic patients.
Topics: Aged; Aging; Animals; Benzopyrans; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin Resistance; Japan; Mice; Pioglitazone; Randomized Controlled Trials as Topic; Rats; Thiazoles; Thiazolidinediones; Troglitazone | 1995 |
New therapeutic agents for the treatment of NIDDM.
Topics: Animals; Carbonates; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Resistance; Molecular Structure; Prevalence; Thiazoles | 1996 |
Oral antidiabetic drugs: an overview.
Topics: Biguanides; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Glucose Intolerance; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Sulfonylurea Compounds; Thiazoles | 1996 |
Effects of troglitazone on insulin sensitivity.
Topics: Animals; Blood Glucose; Blood Pressure; Chromans; Diabetes Mellitus, Type 2; Glucose Intolerance; Glucose Tolerance Test; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Obesity; Thiazoles; Thiazolidinediones; Troglitazone | 1996 |
[Drug therapy in subjects with impaired glucose tolerance].
Topics: Acarbose; Biguanides; Chromans; Diabetes Mellitus, Type 2; Glucose Intolerance; Glycoside Hydrolase Inhibitors; Hypoglycemic Agents; Insulin Resistance; Metformin; Pioglitazone; Risk Factors; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Trisaccharides; Troglitazone | 1996 |
Thiazolidinediones in the treatment of insulin resistance and type II diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Gene Expression Regulation; Humans; Insulin Resistance; Lipids; Receptors, Cytoplasmic and Nuclear; Thiazoles; Transcription Factors | 1996 |
Pharmacological regulation of blood glucose levels in non-insulin-dependent diabetes mellitus.
Topics: Acarbose; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Metformin; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Trisaccharides; Troglitazone | 1997 |
Troglitazone: a new antihyperglycemic agent.
Topics: Chromans; Diabetes Mellitus, Type 2; Gluconeogenesis; Humans; Hypoglycemic Agents; Insulin Resistance; Thiazoles; Thiazolidinediones; Troglitazone | 1997 |
[Steps toward the primary prevention of type II diabetes mellitus. Various epidemiological considerations].
Topics: Adult; Aged; Chromans; Comorbidity; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diet, Reducing; Exercise; Female; Glucose Tolerance Test; Humans; Hypertension; Hypoglycemic Agents; Life Style; Male; Metformin; Middle Aged; National Institutes of Health (U.S.); Obesity; Prediabetic State; Risk Factors; Thiazoles; Thiazolidinediones; Troglitazone; United States | 1997 |
Troglitazone.
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Thiazoles; Thiazolidinediones; Troglitazone | 1997 |
[Treatment of hypertension associated with diabetes mellitus].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cerebrovascular Disorders; Chromans; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Insulin Resistance; Metformin; Obesity; Risk Factors; Thiazoles; Thiazolidinediones; Troglitazone | 1997 |
Thiazolidinediones.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Thiazoles | 1997 |
Novel pharmacological approaches to the prevention and treatment of non-insulin-dependent diabetes mellitus.
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Nicotinic Acids; Obesity; Tetrahydronaphthalenes; Thiazoles | 1997 |
New oral therapies for type 2 diabetes.
Topics: Acarbose; Administration, Oral; Algorithms; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Thiazoles; Thiazolidinediones; Trisaccharides; Troglitazone | 1997 |
[Clinical efficacy of Pioglitazone (AD-4833)].
Topics: Blood Glucose; Clinical Trials, Phase II as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Pioglitazone; Thiazoles; Thiazolidinediones | 1997 |
[Alpha-glucosidase inhibitor and insulin sensitizer combination therapy in NIDDM].
Topics: Acarbose; Animals; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Inositol; Insulin Resistance; Pioglitazone; Thiazoles; Thiazolidinediones; Trisaccharides; Troglitazone | 1997 |
[Combination therapy of insulin sensitizer and sulfonylurea].
Topics: Blood Glucose; Chromans; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Pioglitazone; Protein Precursors; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Troglitazone | 1997 |
Meta-analysis of steady-state pharmacokinetics of troglitazone and its metabolites.
Topics: Age Factors; Area Under Curve; Body Weight; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Sex Factors; Smoking; Thiazoles; Thiazolidinediones; Troglitazone | 1997 |
Oral antidiabetic agents. A guide to selection.
Topics: Administration, Oral; Aged; Diabetes Mellitus, Type 2; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Metformin; Sulfonylurea Compounds; Thiazoles | 1998 |
[The thiazolidinones--a new therapeutic agent for type 2 diabetes].
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Thiazoles | 1998 |
[Thiazolidindiones in type II diabetes mellitus].
Topics: Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Hypoglycemic Agents; Insulin Resistance; Thiazoles; Thiazolidinediones; Troglitazone | 1998 |
PPAR-gamma: adipogenic regulator and thiazolidinedione receptor.
Topics: Adipocytes; Adipose Tissue; Animals; Cell Differentiation; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Ligands; Receptors, Cytoplasmic and Nuclear; Thiazoles; Transcription Factors | 1998 |
Troglitazone: an antidiabetic agent.
Topics: Adult; Aged; Antihypertensive Agents; Biological Availability; Chromans; Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Interactions; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Thiazoles; Thiazolidinediones; Troglitazone; Vasodilator Agents | 1998 |
Treatment of type 2 diabetes mellitus.
Topics: Biguanides; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Diet, Diabetic; Exercise Therapy; Glycoside Hydrolase Inhibitors; Health Care Costs; Humans; Hypoglycemic Agents; Insulin; Patient Compliance; Patient Participation; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Troglitazone | 1998 |
Learning to use troglitazone.
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Thiazoles; Thiazolidinediones; Troglitazone | 1998 |
New therapeutic approaches to reversing insulin resistance.
Topics: Animals; Cardiovascular Diseases; Chromans; Diabetes Mellitus, Type 2; Humans; Hypertension; Hypoglycemic Agents; Insulin Resistance; Thiazoles; Thiazolidinediones; Troglitazone; Vasodilator Agents | 1998 |
Insulin resistance syndrome: options for treatment.
Topics: Arteriosclerosis; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Microvascular Angina; Obesity; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
Cardiovascular effects of troglitazone.
Topics: Blood Pressure; Cardiovascular Diseases; Cardiovascular System; Cholesterol, LDL; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Risk Factors; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
Troglitazone: a review of its use in the management of type 2 diabetes mellitus.
Topics: Adult; Aged; Animals; Area Under Curve; Chromans; Diabetes Mellitus, Type 2; Drug Interactions; Glucose; Glyburide; Half-Life; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
Insulin resistance: site of the primary defect or how the current and the emerging therapies work.
Topics: Adipose Tissue; Appetite Depressants; Diabetes Mellitus, Type 2; Female; Fenfluramine; Humans; Hypoglycemic Agents; Imidazoles; Insulin Resistance; Ligands; Metformin; Thiazoles; Thiazolidinediones | 1998 |
Thiazolidinediones: a new class of antidiabetic drugs.
Topics: Administration, Oral; Animals; Carbohydrate Metabolism; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Lipid Metabolism; Thiazoles | 1999 |
[Thiazolidenediones, diabetes and adipogenesis].
Topics: Diabetes Mellitus; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Obesity; Receptors, Cytoplasmic and Nuclear; Thiazoles; Transcription Factors | 1999 |
Rosiglitazone.
Topics: Animals; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Insulin; Islets of Langerhans; Polypharmacy; Rosiglitazone; Thiazoles; Thiazolidinediones | 1999 |
Troglitazone. Is it all over?
Topics: Animals; Blood Glucose; Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypertriglyceridemia; Hypoglycemic Agents; Insulin Resistance; Liver Function Tests; Male; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
Pharmacologic therapy for type 2 diabetes mellitus.
Topics: Acarbose; Administration, Oral; Algorithms; Carbamates; Chromans; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Insulin; Metformin; Piperidines; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Trisaccharides; Troglitazone | 1999 |
[Current status of the treatment of type 2 diabetes mellitus. The revival of insulin-resistance drugs].
Topics: Administration, Oral; Chromans; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Exercise; Fenfluramine; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Lactones; Lipase; Metformin; Orlistat; Peroxisome Proliferators; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes.
Topics: Administration, Oral; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
[Insulin resistance: therapeutic approaches].
Topics: Combined Modality Therapy; Diabetes Mellitus, Type 2; Exercise Therapy; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Metformin; Thiazoles | 1999 |
The use of insulin secretagogues in the treatment of type 2 diabetes.
Topics: Acarbose; Carbamates; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Metformin; Peptide Fragments; Piperidines; Protein Precursors; Risk Factors; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
The use of insulin alone and in combination with oral agents in type 2 diabetes.
Topics: Acarbose; Blood Glucose; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Metformin; Self Care; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
A review of metabolic and cardiovascular effects of oral antidiabetic agents: beyond glucose-level lowering.
Topics: Antioxidants; Blood Coagulation; Cardiovascular Diseases; Cardiovascular System; Cholesterol, LDL; Chromans; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Metformin; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
[Mechanisms and clinical effects of pioglatizone as a new agent for the treatment of type-2 diabetes].
Topics: Animals; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Multicenter Studies as Topic; Pioglitazone; Thiazoles; Thiazolidinediones | 1999 |
Clinical efficacy of metformin against insulin resistance parameters: sinking the iceberg.
Topics: Animals; Blood Glucose; Cardiovascular Diseases; Chromans; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Resistance; Leptin; Male; Metformin; Rats; Risk Factors; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
[Etiology and therapy of insulin resistance].
Topics: Animals; Arteriosclerosis; Biguanides; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertension; Insulin Resistance; Life Style; Obesity; Risk Factors; Thiazoles; Thiazolidinediones; Tumor Necrosis Factor-alpha | 1999 |
New drugs for diabetes.
Topics: Carbamates; Chromans; Cyclohexanes; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Nateglinide; Phenylalanine; Piperidines; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
Oral pharmacologic management of type 2 diabetes.
Topics: 1-Deoxynojirimycin; Acarbose; Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Metformin; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; United States | 1999 |
Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration.
Topics: Chromans; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liver; Liver Failure; Male; Middle Aged; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
New directions in type 2 diabetes mellitus: an update of current oral antidiabetic therapy.
Topics: Carbamates; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Piperidines; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
Improving management of type 2 diabetes mellitus: 5. Thiazolidinediones.
Topics: Chromans; Diabetes Mellitus, Type 2; Drug Combinations; Drug Interactions; Drug Monitoring; Humans; Hypoglycemic Agents; Liver Function Tests; Patient Selection; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Failure; Troglitazone | 2000 |
[Physiological function of peroxisome proliferator-activated receptor].
Topics: Animals; Blood Cells; Cell Differentiation; Cell Division; Colonic Neoplasms; Diabetes Mellitus, Type 2; Humans; Insulin Resistance; Ligands; Lipoprotein Lipase; Obesity; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic | 1999 |
Research advances in the treatment of type 2 diabetes mellitus.
Topics: Chemistry, Pharmaceutical; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Peptide Fragments; Protein Kinase C; Protein Precursors; Research; Thiazoles; Thiazolidinediones | 1999 |
Hepatic injury due to troglitazone.
Topics: Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liver; Middle Aged; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
[Insulin resistance and cytokine, cytokine receptor].
Topics: Adipocytes; Animals; Diabetes Mellitus, Type 2; Humans; Insulin Resistance; Obesity; Receptors, Tumor Necrosis Factor; Thiazoles; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2000 |
[The development of thiazolidinedione drugs as anti-diabetic agents].
Topics: Animals; Chemical and Drug Induced Liver Injury; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Mice; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
[Mechanisms of thiazolidinedione derivatives for hypoglycemic and insulin sensitizing effects].
Topics: Animals; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Necrosis Factor-alpha | 2000 |
[Clinical effect and side effect of troglitazone].
Topics: Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Liver Function Tests; Male; Middle Aged; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2000 |
[Proper usage of thiazolidinediones].
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Liver Failure, Acute; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
[Troglitazone].
Topics: Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin Resistance; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
[Clinical evaluation of pioglitazone].
Topics: Animals; Blood Glucose; Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipid Metabolism; Male; Pioglitazone; Thiazoles; Thiazolidinediones | 2000 |
[Rosiglitazone (BRL-49653)].
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides | 2000 |
[Diabetes mellitus].
Topics: Blood Coagulation; Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones | 2000 |
[Insulin sensitizer and urate metabolism].
Topics: Chromans; Diabetes Mellitus, Type 2; Female; Glucose; Gout; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Insulin Resistance; Male; Obesity; Syndrome; Thiazoles; Thiazolidinediones; Troglitazone; Uric Acid | 2000 |
[Cardiovascular effects of the thiazolidinedione troglitazone].
Topics: Animals; Arteriosclerosis; Cardiovascular Diseases; Cardiovascular System; Chromans; Diabetes Mellitus, Type 2; Humans; Hyperinsulinism; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Insulin Resistance; Risk Factors; Syndrome; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
[Kidney disease and insulin resistance--clinical impact of thiazolidinedione compounds for kidney disease].
Topics: Animals; Chromans; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Kidney Diseases; Protein Kinase C; Rats; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
[Skeletal effects of thiazolidinediones].
Topics: Adipocytes; Bone Marrow Cells; Bone Resorption; Cell Differentiation; Cells, Cultured; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Osteoclasts; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2000 |
[Thiazolidinediones].
Topics: Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
New agents for Type 2 diabetes.
Topics: Anti-Obesity Agents; Carbamates; Chromans; Diabetes Mellitus, Type 2; Drug Design; Humans; Hypoglycemic Agents; Insulin Resistance; Piperidines; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
The thiazolidinediones or "glitazones" a treatment option for type 2 diabetes mellitus.
Topics: Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Synergism; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome; Troglitazone | 2000 |
[Hypoglycemic agents to improve insulin resistance].
Topics: Adipocytes; Animals; Cell Differentiation; Chromans; Diabetes Mellitus, Type 2; Disease Models, Animal; Humans; Hyperglycemia; Hyperinsulinism; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Obesity; Pioglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Potential new treatments for type 2 diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Islets of Langerhans; Thiazoles; Thiazolidinediones | 2000 |
The glitazones: proceed with caution.
Topics: Chromans; Diabetes Mellitus, Type 2; Drug Evaluation; Humans; Hypoglycemic Agents; Liver; Pioglitazone; Prognosis; Rosiglitazone; Safety; Thiazoles; Thiazolidinediones; Troglitazone; Weight Gain | 2000 |
Management of drugs affecting blood glucose in diabetic patients with renal failure.
Topics: Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Hypoglycemic Agents; Insulin; Kidney Failure, Chronic; Sulfonylurea Compounds; Thiazoles | 2000 |
Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus.
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine; Pioglitazone; Piperidines; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists.
Topics: Animals; Chromans; Diabetes Mellitus, Type 2; Humans; Insulin Resistance; Islets of Langerhans; Mice; Mice, Knockout; Models, Biological; Mutation; Obesity; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2000 |
New approaches in the treatment of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Hypoglycemic Agents; Liver; Molecular Structure; Peptide Fragments; Protein Precursors; Protein Tyrosine Phosphatases; Receptor, Insulin; Receptors, Cytoplasmic and Nuclear; Receptors, Glucagon; Thiazoles; Thiazolidinediones; Transcription Factors | 2000 |
Insulin sensitiser drugs.
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Thiazoles | 2000 |
Troglitazone and related compounds: therapeutic potential beyond diabetes.
Topics: Animals; Antioxidants; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Microvascular Angina; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2000 |
Thiazolidinediones--a means to endpoint intervention.
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Thiazoles; Treatment Outcome | 2000 |
[Glitazones (thiazolidinedione)].
Topics: Animals; Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Gluconeogenesis; Humans; Hypoglycemic Agents; Insulin Resistance; Rats; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors | 2000 |
Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review.
Topics: Aged; Area Under Curve; Biological Availability; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Interactions; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Metformin; Middle Aged; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer.
Topics: Animals; Diabetes Mellitus, Type 2; DNA-Binding Proteins; Humans; Inflammation; Ligands; Neoplasms; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors | 2000 |
Antidiabetic drugs present and future: will improving insulin resistance benefit cardiovascular risk in type 2 diabetes mellitus?
Topics: Biguanides; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Insulin Resistance; Risk Factors; Thiazoles | 2000 |
New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers.
Topics: Cardiovascular Diseases; Chromans; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome; Troglitazone | 2001 |
Nonhypoglycemic effects of thiazolidinediones.
Topics: Body Weight; Cardiovascular Diseases; Cardiovascular System; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Hemostasis; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Liver Failure; Oxidation-Reduction; Pancreas; Polycystic Ovary Syndrome; Risk Factors; Thiazoles | 2001 |
Diabetes in elderly adults.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Diet Therapy; Exercise; Female; Glyburide; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; United States | 2001 |
The association between insulin resistance and endotheliopathy.
Topics: Diabetes Mellitus, Type 2; Endothelium, Vascular; Humans; Hyperglycemia; Hyperlipidemias; Hypertension; Insulin Resistance; Syndrome; Thiazoles; Vasodilation | 1999 |
Promising new approaches.
Topics: Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Obesity; Thiazoles; Weight Loss | 1999 |
Using dose-response characteristics of therapeutics agents for treatment decisions in type 2 diabetes.
Topics: Acarbose; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Pioglitazone.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Pioglitazone; Thiazoles; Thiazolidinediones | 2000 |
New pharmacological development (alpha glucosidase inhibitors, amylin analogues, GLP-1, thiozolidinediones, short acting insulin analogues).
Topics: Amyloid; Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Islet Amyloid Polypeptide; Peptide Fragments; Protein Precursors; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
Combination therapy in type 2 diabetes: the role of repaglinide.
Topics: Carbamates; Chromans; Diabetes Mellitus, Type 2; Drug Synergism; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin, Isophane; Metformin; Piperidines; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
Insulin resistance and its treatment by thiazolidinediones.
Topics: Adipose Tissue; Binding Sites; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dimerization; Drug Interactions; Endothelium, Vascular; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Male; Models, Biological; Muscle, Smooth; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Sex Factors; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2001 |
Peroxisome proliferator-activated receptor gamma, the ultimate liaison between fat and transcription.
Topics: Adipose Tissue; Cell Differentiation; Diabetes Mellitus, Type 2; Humans; Leptin; Obesity; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Necrosis Factor-alpha | 2000 |
[Update on new oral treatment for diabetes].
Topics: Administration, Oral; Biguanides; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Incidence; Sulfonylurea Compounds; Thiazoles | 2001 |
[PPARgamma and thiazolidinediones, something more than a treatment for diabetes].
Topics: Arteriosclerosis; Cell Differentiation; Cell Transformation, Neoplastic; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Hypoglycemic Agents; Ligands; Male; Polycystic Ovary Syndrome; Protein Isoforms; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors | 2000 |
Using thiazolidinediones: rosiglitazone and pioglitazone in clinical practice.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Education, Continuing; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Pioglitazone; Polycystic Ovary Syndrome; Thiazoles; Thiazolidinediones; United States | 2001 |
[Glitazones. Profile of a new class of substances].
Topics: Albuminuria; Animals; Anticholesteremic Agents; Chromans; Cytochrome P-450 Enzyme System; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Germany; Humans; Hypoglycemic Agents; Isoenzymes; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; United States | 2001 |
Rosiglitazone.
Topics: Animals; Blood Pressure; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Interactions; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Islets of Langerhans; Metformin; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
Oral agents in the management of type 2 diabetes mellitus.
Topics: Benzamides; Biguanides; Diabetes Mellitus, Type 2; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones | 2001 |
Enhancing insulin action: from chemical elements to thiazolidinediones.
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Minerals; Thiazoles | 2001 |
[Current and future aspects of oral antidiabetic agents in type 2 diabetes].
Topics: Administration, Oral; Biguanides; Diabetes Mellitus, Type 2; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones | 2001 |
Lessons from the glitazones: a story of drug development.
Topics: Adverse Drug Reaction Reporting Systems; Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 2; Drug Approval; Drug Therapy, Combination; Europe; Humans; Hypoglycemic Agents; Liver Failure; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; United States | 2001 |
Type 2 diabetes. How new insights, new drugs are changing clinical practice.
Topics: Acarbose; Aged; Biguanides; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Interactions; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Thiazoles; Thiazolidinediones; Treatment Outcome | 2001 |
Oral agents for the treatment of type 2 diabetes mellitus: pharmacology, toxicity, and treatment.
Topics: Administration, Oral; Benzoates; Biguanides; Blood Glucose; Diabetes Mellitus, Type 2; Drug Interactions; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Metabolic Clearance Rate; Safety; Sulfonylurea Compounds; Thiazoles; Time Factors; Treatment Outcome | 2001 |
Management of type 2 diabetes. Evolving strategies for treatment.
Topics: Comorbidity; Diabetes Mellitus, Type 2; Exercise Therapy; Glycoside Hydrolase Inhibitors; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin; Metformin; Sulfonylurea Compounds; Thiazoles | 2001 |
Thiazolidinediones and liver toxicity.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Incidence; Liver; Liver Failure; Thiazoles; United States; United States Food and Drug Administration | 2001 |
[Insulin resistance: why is it important to treat?].
Topics: Adipose Tissue; Blood Glucose; Coronary Disease; Diabetes Mellitus, Type 2; Glucose; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipids; Muscles; Syndrome; Thiazoles | 2001 |
[Thiazolidinediones: clinical data and perspectives].
Topics: Animals; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
[Mechanisms of action of thiazolidinediones].
Topics: Adipose Tissue; Animals; Diabetes Mellitus, Type 2; Gene Expression; Glucose; Humans; Hypoglycemic Agents; Insulin Resistance; Muscle, Skeletal; Receptors, Cytoplasmic and Nuclear; Thiazoles; Transcription Factors | 2001 |
[Type 2 diabetes mellitus: Which place for thiazolidinediones in the therapeutic strategy?].
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Europe; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Metformin; Sulfonylurea Compounds; Thiazoles | 2001 |
Thiazolidinediones: a comparative review of approved uses.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Gene Expression Regulation; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; United States; United States Food and Drug Administration | 2000 |
Safety of drugs commonly used to treat hypertension, dyslipidemia, and Type 2 diabetes (the metabolic syndrome): part 2.
Topics: Acarbose; Cardiovascular Diseases; Chromans; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Insulin; Metformin; Safety; Sulfonylurea Compounds; Syndrome; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Current views on the mechanism of action of thiazolidinedione insulin sensitizers.
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Models, Biological; Thiazoles | 1999 |
Actos (pioglitazone): a new treatment for type 2 diabetes.
Topics: Adult; Aged; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Pioglitazone; Randomized Controlled Trials as Topic; Thiazoles; Thiazolidinediones; Triglycerides | 2001 |
[Thiazolidinediones--a new class of oral antidiabetic drugs].
Topics: Animals; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metabolic Syndrome; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2001 |
[Peroxisome proliferator-activated receptors (PPARs) in the vessel wall: new regulators of gene expression in vascular cells].
Topics: Animals; Arteriosclerosis; Chromans; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Female; Fenofibrate; Gemfibrozil; Gene Expression Regulation; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Inflammation; Ligands; Male; Mice; Muscle, Smooth, Vascular; Peroxisome Proliferators; Rats; Research; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2001 |
[Glitazone--a new class of drugs for the treatment of type 2 diabetes].
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
[The thiazolidinedione derivates: a new class of oral blood glucose lowering agents].
Topics: Administration, Oral; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2001 |
[Objectives and therapeutic strategy in type 2 diabetes mellitus].
Topics: Carbamates; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Piperidines; Thiazoles | 2001 |
Therapeutic perspectives for type 2 diabetes mellitus: molecular and clinical insights.
Topics: Diabetes Mellitus, Type 2; Enzyme Inhibitors; Genetic Therapy; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Thiazoles | 2001 |
PPARS, insulin resistance and type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Metabolic Syndrome; Receptors, Cytoplasmic and Nuclear; Thiazoles; Transcription Factors | 2001 |
A review of rosiglitazone in type 2 diabetes mellitus.
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
[Antidiabetic effect of thiazolidinediones].
Topics: Adipose Tissue; Animals; Diabetes Mellitus, Type 2; Glucose; Humans; Insulin Resistance; Muscle, Skeletal; Receptors, Cytoplasmic and Nuclear; Thiazoles; Transcription Factors | 2001 |
Pioglitazone and rosiglitazone for diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
Pharmacokinetics and clinical efficacy of pioglitazone.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic Agents; Pioglitazone; Risk Factors; Thiazoles; Thiazolidinediones; Treatment Outcome | 2001 |
The reality of type 2 diabetes treatment today.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic Agents; Patient Compliance; Polypharmacy; Thiazoles; Thiazolidinediones | 2001 |
Pioglitazone: the future.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Forecasting; Humans; Hypoglycemic Agents; Pioglitazone; Thiazoles; Thiazolidinediones | 2001 |
Insulin resistance and insulin sensitizers.
Topics: Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertension; Insulin; Insulin Resistance; Insulin Secretion; Thiazoles | 2001 |
Beta-cell deterioration--prospects for reversal or prevention.
Topics: Animals; Blood Glucose; Cell Death; Diabetes Mellitus, Type 2; Humans; Insulin Resistance; Islets of Langerhans; Lipids; Rats; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
Insulin resistance and beta-cell function--a clinical perspective.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
PPAR gamma agonists in type 2 diabetes: how far have we come in 'preventing the inevitable'? A review of the metabolic effects of rosiglitazone.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
The clinical effectiveness and cost-effectiveness of pioglitazone for type 2 diabetes mellitus: a rapid and systematic review.
Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Pioglitazone; Thiazoles; Thiazolidinediones | 2001 |
[Insulin sensitizer drugs, thiazolidinediones: current state and prospect].
Topics: Adipocytes; Animals; Blood Glucose; Depression, Chemical; Diabetes Mellitus, Type 2; Drug Design; Fatty Acids, Nonesterified; Humans; Insulin; Insulin Resistance; Insulin Secretion; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Necrosis Factor-alpha | 2001 |
[Evaluation of a thiazolidinedione compound as a new antidiabetic drug].
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
[Clinical difference between thiazolidinediones and biguanides].
Topics: Biguanides; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin Resistance; Thiazoles; Thiazolidinediones | 2001 |
[Clinical usefulness of combination treatment with thiazolidinedione and insulin].
Topics: Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Multicenter Studies as Topic; Pioglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
[Thiazolidinediones--a new class of oral antidiabetics].
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Receptors, Cytoplasmic and Nuclear; Thiazoles | 2001 |
Hepatotoxicity with thiazolidinediones: is it a class effect?
Topics: Aged; Chemical and Drug Induced Liver Injury; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Rosiglitazone; Structure-Activity Relationship; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
Toxicological consequences of altered peroxisome proliferator-activated receptor gamma (PPARgamma) expression in the liver: insights from models of obesity and type 2 diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Liver; Mice; Obesity; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
Mechanism of action of thiazolidinediones.
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Thiazoles; Thiazolidinediones | 2001 |
A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome | 2001 |
Oral antihyperglycemic therapy for type 2 diabetes: scientific review.
Topics: Administration, Oral; Biguanides; Blood Glucose; Carbamates; Chromans; Diabetes Mellitus, Type 2; Diet; Drug Therapy, Combination; Enzyme Inhibitors; Exercise; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Metformin; Piperidines; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
[Thiazolidinediones--new antidiabetic agents. Why don't we know how to use them?].
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Thiazoles | 2001 |
Treatment of type 2 diabetes mellitus: pharmacologic intervention.
Topics: Benzamides; Biguanides; Diabetes Mellitus, Type 2; Glucosidases; Humans; Hypoglycemic Agents; Insulin; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones | 2002 |
Pharmacological treatment of insulin resistance in obesity.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Humans; Hypoglycemic Agents; Insulin Resistance; Obesity; Rats; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
[Thiazolidinediones and PPARgamma system in repair of liver damage].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antioxidants; Arteriosclerosis; Chromans; Diabetes Mellitus, Type 2; Eicosanoids; Fatty Acids; Forecasting; Humans; Hypoglycemic Agents; In Vitro Techniques; Inflammation; Liver Cirrhosis; Neoplasms; Obesity; Receptors, Cytoplasmic and Nuclear; Research; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2002 |
Type 2 diabetes management: a comprehensive clinical review of oral medications.
Topics: Benzamides; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Metformin; Piperidines; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones | 2002 |
Pioglitazone: a review of Japanese clinical studies.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Interactions; Humans; Hypoglycemic Agents; Japan; Pioglitazone; Thiazoles; Thiazolidinediones | 2001 |
Type 2 diabetes therapy. A pathophysiologically based approach.
Topics: alpha-Glucosidases; Benzamides; Biguanides; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones | 2002 |
Thiazolidinedione hepatotoxicity: a class effect?
Topics: Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Prevention of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Thiazoles | 2000 |
Prevention of coronary heart disease in type 2 diabetes.
Topics: Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic Agents; Risk Factors; Thiazoles | 2000 |
Current treatment of insulin resistance in type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Thiazoles; Thiazolidinediones | 2000 |
Novel insulin sensitizers: pharmacogenomic aspects.
Topics: Diabetes Mellitus, Type 2; DNA-Binding Proteins; Genetic Variation; Humans; Hypoglycemic Agents; Insulin; Polymorphism, Genetic; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Thiazoles; Thiazolidinediones; Tissue Distribution; Transcription Factors; Transcription, Genetic | 2002 |
[Metformin. Mode of action and effect of monotherapy and combination therapy on glucose metabolism in type 2 diabetes].
Topics: Acarbose; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Metformin; Thiazoles; Treatment Outcome | 2002 |
Thiazolidinediones in the treatment of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |
Clinical inquiries. How beneficial are thiazolidinediones for diabetes mellitus?
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Thiazoles; Thiazolidinediones | 2002 |
Polycystic ovary syndrome. Long term sequelae and management.
Topics: Adult; Blood Glucose; Cardiovascular Diseases; Contraceptives, Oral; Diabetes Mellitus, Type 2; Diagnosis, Differential; Endometrial Neoplasms; Female; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Metformin; Obesity; Polycystic Ovary Syndrome; Pregnancy; Progestins; Randomized Controlled Trials as Topic; Risk Factors; Thiazoles; Thiazolidinediones | 2002 |
New solutions for type 2 diabetes mellitus: the role of pioglitazone.
Topics: Diabetes Mellitus, Type 2; Glycated Hemoglobin; Half-Life; Humans; Hypoglycemic Agents; Insulin Resistance; Intestinal Absorption; Pioglitazone; Randomized Controlled Trials as Topic; Thiazoles; Thiazolidinediones | 2002 |
The role of models within economic analysis: focus on type 2 diabetes mellitus.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Economics, Pharmaceutical; Humans; Hypoglycemic Agents; Models, Economic; Pioglitazone; Thiazoles; Thiazolidinediones | 2002 |
Applications of economic models in healthcare: the introduction of pioglitazone in Sweden.
Topics: Diabetes Mellitus, Type 2; Economics, Pharmaceutical; Health Care Sector; Humans; Hypoglycemic Agents; Models, Economic; Pioglitazone; Prevalence; Sweden; Thiazoles; Thiazolidinediones | 2002 |
[PPARgamma and insulin resistance].
Topics: Adipose Tissue; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Muscle, Skeletal; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
[Rosiglitazone: clinical data].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Rosiglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones | 2002 |
[Rosiglitazone: a clinical development focused on cardio-vascular prevention].
Topics: Albuminuria; Animals; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Endothelium, Vascular; Humans; Hypoglycemic Agents; Plasminogen Activator Inhibitor 1; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |
[Glitazones and weight gain].
Topics: Adipose Tissue; Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Risk Factors; Thiazoles; Thiazolidinediones; Weight Gain | 2002 |
[Precautions for use and contraindications of thiazolidinediones. A cardiologist opinion].
Topics: Cardiology; Cardiovascular Diseases; Contraindications; Diabetes Mellitus, Type 2; Echocardiography; Heart; Humans; Hypoglycemic Agents; Thiazoles; Thiazolidinediones | 2002 |
[Is a new therapeutic class justified in the treatment of type 2 diabetes?].
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Thiazoles; Thiazolidinediones | 2002 |
Thiazolidinediones and type 2 diabetes: new drugs for an old disease.
Topics: Adult; Aged; Australia; Clinical Trials as Topic; Contraindications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |
PPAR(gamma) and glucose homeostasis.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Gene Expression Regulation; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Mice; Mice, Knockout; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic | 2002 |
[Against insulin resistance. Insulin sensitizers].
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Thiazoles; Thiazolidinediones | 2002 |
[Medication of the month. Rosiglitazone (Avandia)].
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Prognosis; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; Weight Gain | 2002 |
Impaired ('diabetic') insulin signaling and action occur in fat cells long before glucose intolerance--is insulin resistance initiated in the adipose tissue?
Topics: Adipocytes; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucose Intolerance; Humans; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Intracellular Signaling Peptides and Proteins; Phosphoproteins; Signal Transduction; Thiazoles; Thiazolidinediones | 2002 |
Metabolic and additional vascular effects of thiazolidinediones.
Topics: Animals; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Humans; Hypoglycemic Agents; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Vasodilation | 2002 |
New oral thiazolidinedione antidiabetic agents act as insulin sensitizers.
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Pioglitazone; Thiazoles; Thiazolidinediones | 1992 |
165 trial(s) available for thiazoles and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Consumption of Beverages Containing Low-Calorie Sweeteners, Diet, and Cardiometabolic Health in Youth With Type 2 Diabetes.
Topics: Adolescent; Beverages; Body Mass Index; Cardiometabolic Risk Factors; Child; Diabetes Mellitus, Type 2; Diet; Diet Records; Dietary Sugars; Drug Combinations; Energy Intake; Female; Humans; Life Style; Longitudinal Studies; Male; Metformin; Rosiglitazone; Surveys and Questionnaires; Sweetening Agents; Thiazoles | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses | 2021 |
Changes in Visceral and Subcutaneous Fat in Youth With Type 2 Diabetes in the TODAY Study.
Topics: Adiposity; Adolescent; Blood Glucose; Body Fat Distribution; Child; Combined Modality Therapy; Diabetes Mellitus, Type 2; Drug Combinations; Exercise Therapy; Female; Humans; Insulin Resistance; Intra-Abdominal Fat; Life Style; Male; Metformin; Obesity; Sex Factors; Subcutaneous Fat; Thiazoles | 2019 |
Evaluation of the impact of UGT polymorphism on the pharmacokinetics and pharmacodynamics of the novel PPAR agonist sipoglitazar.
Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Female; Genotype; Glucuronosyltransferase; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Models, Biological; Peroxisome Proliferator-Activated Receptors; Polymorphism, Genetic; Propionates; Thiazoles; Young Adult | 2013 |
Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and β-cell function in TODAY.
Topics: Adolescent; Child; Diabetes Mellitus, Type 2; Drug Combinations; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Life Style; Male; Metformin; Thiazoles | 2013 |
Treatment effects on measures of body composition in the TODAY clinical trial.
Topics: Adolescent; Body Composition; Body Mass Index; Child; Diabetes Mellitus, Type 2; Drug Combinations; Female; Glycated Hemoglobin; Humans; Life Style; Male; Metformin; Thiazoles | 2013 |
Safety and tolerability of the treatment of youth-onset type 2 diabetes: the TODAY experience.
Topics: Adolescent; Blood Glucose; Child; Diabetes Mellitus, Type 2; Drug Combinations; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Thiazoles | 2013 |
Impact of sex on the heart's metabolic and functional responses to diabetic therapies.
Topics: Analysis of Variance; Chi-Square Distribution; Diabetes Mellitus, Type 2; Diastole; Dietary Supplements; Docosahexaenoic Acids; Double-Blind Method; Drug Combinations; Echocardiography, Doppler; Eicosapentaenoic Acid; Energy Metabolism; Fatty Acids; Fatty Acids, Omega-3; Female; Health Status Disparities; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Missouri; Myocardium; Positron-Emission Tomography; Recovery of Function; Sex Factors; Stroke Volume; Thiazoles; Time Factors; Treatment Outcome; Triglycerides; Ventricular Function, Left; Ventricular Pressure | 2013 |
A model-based approach to analyze the influence of UGT2B15 polymorphism driven pharmacokinetic differences on the pharmacodynamic response of the PPAR agonist sipoglitazar.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Genotype; Glucuronosyltransferase; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Models, Biological; Peroxisome Proliferator-Activated Receptors; Polymorphism, Genetic; Propionates; Rosiglitazone; Thiazoles; Thiazolidinediones | 2014 |
Efficacy and safety of avandamet or uptitrated metformin treatment in patients with type 2 diabetes inadequately controlled with metformin alone: a multicenter, randomized, controlled trial.
Topics: Adult; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Type 2; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Thiazoles | 2015 |
Weight change in the management of youth-onset type 2 diabetes: the TODAY clinical trial experience.
Topics: Adolescent; Anthropometry; Blood Glucose; Body Weight; Child; Diabetes Mellitus, Type 2; Drug Combinations; Female; Humans; Hypoglycemic Agents; Life Style; Male; Metformin; Risk Factors; Thiazoles; Treatment Outcome | 2017 |
Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
Topics: Adult; Central Nervous System Diseases; Dental Enamel; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Febuxostat; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Japan; Kidney Diseases, Cystic; Male; Middle Aged; Thiazoles; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2011 |
A randomized, parallel group, double-blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long-term glycaemic control and bone mineral density after 80 weeks of treatment in drug-naïve type 2 d
Topics: Adolescent; Adult; Aged; Biomarkers; Blood Glucose; Bone Density; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Thiazoles; Treatment Outcome; Young Adult | 2011 |
Discordant effects on central obesity, hepatic insulin resistance, and alanine aminotransferase of low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance.
Topics: Alanine Transaminase; Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Fatty Liver; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Metformin; Obesity, Abdominal; Thiazoles; Waist-Hip Ratio | 2012 |
[The efficacy and safety of pioglitazone hydrochloride in combination with sulphonylureas and metfomin in the treatment of type 2 diabetes mellitus a 12-week randomized multi-centres placebo-controlled parallel study].
Topics: Blood Pressure; Body Weight; Cholesterol; Consumer Product Safety; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Heart Rate; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Pioglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Time Factors; Treatment Outcome; Triglycerides | 2002 |
High glucose concentrations abolish the superoxide dismutase response of leukocytes to ascorbic acid or troglitazone in type 2 diabetes mellitus.
Topics: Aged; Albuminuria; Antioxidants; Ascorbic Acid; Chromans; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diabetic Retinopathy; Dose-Response Relationship, Drug; Electron Spin Resonance Spectroscopy; Female; Glucose; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Leukocytes; Male; Middle Aged; Superoxide Dismutase; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
Topics: Biomarkers; Body Weight; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Humans; Interleukin-6; Leukocyte Count; Male; Matrix Metalloproteinase 9; Middle Aged; Receptors, Cytoplasmic and Nuclear; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes.
Topics: Adult; Aged; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Phenylalanine; Thiazoles; Thiazolidinediones; Treatment Outcome | 2002 |
Troglitazone treatment increases protein kinase B phosphorylation in skeletal muscle of normoglycemic subjects at risk for the development of type 2 diabetes.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Adult; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin; Male; Muscle, Skeletal; Osmolar Concentration; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Reference Values; Risk Factors; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women.
Topics: Adult; Chromans; Diabetes Mellitus, Type 2; Diabetes, Gestational; Double-Blind Method; Female; Glucose Tolerance Test; Hispanic or Latino; Humans; Incidence; Insulin; Insulin Resistance; Islets of Langerhans; Medical Records; Pregnancy; Risk Factors; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects.
Topics: Adiponectin; Adult; Animals; Body Weight; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Lipids; Male; Middle Aged; Obesity; Proteins; Rats; Thiazoles; Thiazolidinediones | 2002 |
Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes.
Topics: Adult; Age of Onset; Aged; Body Mass Index; C-Peptide; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Lipoproteins; Male; Metformin; Middle Aged; Racial Groups; Texas; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes.
Topics: Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Disease Progression; Double-Blind Method; Glyburide; Humans; Hypoglycemic Agents; Metformin; Research Design; Rosiglitazone; Safety; Thiazoles; Thiazolidinediones; Time Factors; Treatment Failure; Treatment Outcome | 2002 |
Troglitazone improves cardiac function in patients with congestive heart failure.
Topics: Blood Pressure; Cardiac Output; Catecholamines; Chromans; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Stroke Volume; Thiazoles; Thiazolidinediones; Time Factors; Troglitazone; Vasodilator Agents; Ventricular Function, Left | 2002 |
Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected].
Topics: Absorptiometry, Photon; Adipose Tissue; Adult; Aged; Aged, 80 and over; Blood Glucose; Body Composition; Cholesterol; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids, Nonesterified; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipoproteins; Liver; Magnetic Resonance Imaging; Male; Middle Aged; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides | 2002 |
Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Evaluation; Drug Therapy, Combination; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Hypolipidemic Agents; Male; Middle Aged; North America; Pyrroles; Rosiglitazone; Safety; Thiazoles; Thiazolidinediones; Time Factors; Treatment Outcome | 2002 |
A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Mass Index; Cardiovascular Physiological Phenomena; Cardiovascular System; Diabetes Mellitus, Type 2; Female; Glyburide; Glycated Hemoglobin; Hemodynamics; Humans; Hypoglycemic Agents; Male; Middle Aged; Placebos; Racial Groups; Rosiglitazone; Safety; Thiazoles; Thiazolidinediones; Time Factors; Ventricular Function, Left | 2002 |
Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled study.
Topics: Adult; Aged; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Thiazoles; Thiazolidinediones | 2002 |
Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Exercise; Fasting; Female; Glucose; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Leg; Male; Metformin; Middle Aged; Muscle, Skeletal; Oxygen Consumption; Radionuclide Imaging; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |
Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects.
Topics: Adipose Tissue; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Fluorodeoxyglucose F18; Glucose; Humans; Hypoglycemic Agents; Insulin; Kinetics; Lactates; Lipids; Male; Metformin; Middle Aged; Placebos; Radiopharmaceuticals; Rosiglitazone; Thiazoles; Thiazolidinediones; Tomography, Emission-Computed; Weight Loss | 2003 |
Clinical evaluation of pioglitazone in patients with type 2 diabetes using alpha-glucosidase inhibitor and examination of its efficacy profile.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin Resistance; Leptin; Lipids; Male; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Treatment Failure; Treatment Outcome | 2003 |
An international study of the effects of rosiglitazone plus sulphonylurea in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Developing Countries; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Treatment Outcome | 2002 |
Rosiglitazone reduces urinary albumin excretion in type II diabetes.
Topics: Administration, Oral; Aged; Albuminuria; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Kidney Function Tests; Male; Middle Aged; Reference Values; Rosiglitazone; Sensitivity and Specificity; Thiazoles; Thiazolidinediones; Treatment Outcome | 2003 |
Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease.
Topics: Adult; Aged; Anti-Inflammatory Agents; Apolipoproteins; Biomarkers; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 8; Matrix Metalloproteinase 9; Middle Aged; Randomized Controlled Trials as Topic; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Serum Amyloid A Protein; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Necrosis Factor-alpha | 2003 |
The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial.
Topics: Chromans; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Fasting; Female; Follow-Up Studies; Humans; Insulin; Male; Middle Aged; Placebos; Thiazoles; Thiazolidinediones; Time Factors; Troglitazone | 2003 |
Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy.
Topics: Adipocytes; Adiponectin; Adipose Tissue; Adult; Aged; Biopsy; Chromans; Culture Media, Conditioned; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Hypoglycemic Agents; Intercellular Signaling Peptides and Proteins; Male; Metformin; Middle Aged; Molecular Weight; Obesity; Proteins; Thiazoles; Thiazolidinediones; Tissue Distribution; Troglitazone | 2003 |
Nocturnal and postprandial free fatty acid kinetics in normal and type 2 diabetic subjects: effects of insulin sensitization therapy.
Topics: Adult; Blood Glucose; C-Peptide; Chromans; Circadian Rhythm; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Food; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Kinetics; Lipolysis; Male; Metformin; Middle Aged; Placebos; Thiazoles; Thiazolidinediones; Troglitazone | 2003 |
Analysis of the relationship between the Pro12Ala variant in the PPAR-gamma2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes.
Topics: Aged; Alanine; Blood Glucose; Diabetes Mellitus, Type 2; Female; Genotype; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Proline; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Treatment Outcome | 2003 |
Effects of pioglitazone on diabetes-related outcomes in Hispanic patients.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Hispanic or Latino; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Retrospective Studies; Thiazoles; Thiazolidinediones; Time Factors; Treatment Outcome; Triglycerides; United States | 2003 |
Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes.
Topics: Adult; Apolipoproteins B; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Glycated Hemoglobin; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metformin; Middle Aged; Pioglitazone; Thiazoles; Thiazolidinediones; Triglycerides | 2003 |
Usefulness of troglitazone administration to obese hyperglycaemic patients with near-normoglycaemia.
Topics: Adult; Aged; Blood Glucose; Chromans; Deoxyglucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Obesity; Thiazoles; Thiazolidinediones; Troglitazone | 2003 |
Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease.
Topics: Adult; Aged; Biomarkers; Blood Glucose; CD40 Ligand; Coronary Artery Disease; Diabetes Mellitus, Type 2; E-Selectin; Female; Fibrinolytic Agents; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Receptors, Cytoplasmic and Nuclear; Receptors, Interleukin-2; Reference Values; Rosiglitazone; Solubility; Thiazoles; Thiazolidinediones; Time; Transcription Factors; Treatment Outcome; Vasodilator Agents | 2003 |
Addition of rosiglitazone to existing sulfonylurea treatment in chinese patients with type 2 diabetes and exposure to hepatitis B or C.
Topics: Adult; Asian People; Blood Glucose; China; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Environmental Exposure; Female; Gliclazide; Glyburide; Glycated Hemoglobin; Hepatitis B; Hepatitis C; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones | 2003 |
Long-term cardiovascular effects of insulin sensitizer troglitazone on non-diabetic individuals with insulin resistance: double blind, prospective randomized study.
Topics: Adult; Aorta; Blood Flow Velocity; Blood Pressure; Cardiovascular Diseases; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Male; Middle Aged; Prospective Studies; Thiazoles; Thiazolidinediones; Troglitazone | 2003 |
Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones.
Topics: Acute Disease; Adult; Aged; Arteriosclerosis; Body Mass Index; CD40 Ligand; Chromans; Chronic Disease; Cross-Sectional Studies; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Longitudinal Studies; Male; Metformin; Pilot Projects; Receptors, Cytoplasmic and Nuclear; Reference Values; Risk Factors; Solubility; Spain; Thiazoles; Thiazolidinediones; Transcription Factors; Treatment Outcome; Troglitazone | 2003 |
Regulation of skeletal muscle morphology in type 2 diabetic subjects by troglitazone and metformin: relationship to glucose disposal.
Topics: Adult; Aged; Biopsy; Capillaries; Chromans; Diabetes Mellitus, Type 2; Female; Glucose; Histocytochemistry; Humans; Hypoglycemic Agents; Lipid Metabolism; Male; Metformin; Microscopy, Electron; Middle Aged; Muscle Fibers, Skeletal; Muscle, Skeletal; Regional Blood Flow; Thiazoles; Thiazolidinediones; Troglitazone | 2003 |
The Diabetes Prevention Program.
Topics: Adult; Cardiovascular Diseases; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic Agents; Incidence; Life Style; Metformin; Morbidity; Risk Factors; Thiazoles; Thiazolidinediones; Troglitazone | 2003 |
The effect of rosiglitazone on serum lipoprotein(a) levels in Korean patients with type 2 diabetes mellitus.
Topics: Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Korea; Lipids; Lipoprotein(a); Male; Middle Aged; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Are the metabolic effects of rosiglitazone influenced by baseline glycaemic control?
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Middle Aged; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin; Lipids; Male; Middle Aged; Pioglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome | 2003 |
A "futile cycle" induced by thiazolidinediones in human adipose tissue?
Topics: Adipocytes; Adipose Tissue; Animals; Blood Glucose; Carrier Proteins; Cells, Cultured; Diabetes Mellitus, Type 2; Enzyme Activation; Fasting; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Fatty Acids, Nonesterified; Glycerol; Glycerol Kinase; Humans; Hypoglycemic Agents; Insulin; Mice; Middle Aged; Neoplasm Proteins; Nerve Tissue Proteins; Rosiglitazone; Thiazoles; Thiazolidinediones; Tumor Suppressor Proteins | 2003 |
Efficacy and safety of a combination of metformin and rosiglitaone in patients with type 2 diabetes mellitus--a postmarketing study.
Topics: Adult; Aged; Analysis of Variance; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Product Surveillance, Postmarketing; Prospective Studies; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome | 2003 |
Efffect of addition of low-dose rosiglitazone to sulphonylurea therapy on glycemic control in type 2 diabetic patients.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones | 2003 |
Activation of protein kinase C-zeta by insulin and phosphatidylinositol-3,4,5-(PO4)3 is defective in muscle in type 2 diabetes and impaired glucose tolerance: amelioration by rosiglitazone and exercise.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Exercise; Fatty Acids, Nonesterified; Female; Glucose Intolerance; Glucose Transporter Type 4; Humans; Hypoglycemic Agents; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Isoenzymes; Male; Middle Aged; Monosaccharide Transport Proteins; Muscle Proteins; Muscle, Skeletal; Phosphatidylinositol 3-Kinases; Phosphatidylinositol Phosphates; Phosphoproteins; Phosphorylation; Protein Kinase C; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones | 2003 |
Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients.
Topics: Biopsy; Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucose Clamp Technique; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin; Insulin Receptor Substrate Proteins; Insulin Secretion; Male; Middle Aged; Muscle, Skeletal; Phosphoproteins; Phosphorylation; Receptor, Insulin; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones; Tyrosine | 2003 |
Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study.
Topics: Aged; Angioplasty, Balloon, Coronary; Blood Glucose; Coronary Angiography; Coronary Disease; Coronary Restenosis; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Pioglitazone; Stents; Thiazoles; Thiazolidinediones; Tunica Intima; Ultrasonography, Interventional | 2003 |
Influence of rosiglitazone treatment on beta-cell function in type 2 diabetes: evidence of an increased ability of glucose to entrain high-frequency insulin pulsatility.
Topics: Arginine; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Entropy; Female; Glucose; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Insulin; Islets of Langerhans; Male; Middle Aged; Rosiglitazone; Stimulation, Chemical; Thiazoles; Thiazolidinediones | 2003 |
Plasma BNP levels in the treatment of type 2 diabetes with pioglitazone.
Topics: Aged; Atrial Natriuretic Factor; Body Mass Index; Buformin; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Heart Failure; Humans; Hypoglycemic Agents; Male; Middle Aged; Natriuretic Peptide, Brain; Pioglitazone; Stroke Volume; Thiazoles; Thiazolidinediones | 2003 |
The impact of an insulin sensitizer, troglitazone, on glucose metabolism in African Americans at risk for type 2 diabetes mellitus: a placebo-controlled, 24-month randomized study.
Topics: Adult; Black People; Blood Glucose; Body Constitution; Body Mass Index; C-Peptide; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Genetic Predisposition to Disease; Glucose Intolerance; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipids; Male; Placebos; Skinfold Thickness; Thiazoles; Thiazolidinediones; Troglitazone | 2003 |
Cardiac abnormalities in diabetic patients with neuropathy: effects of aldose reductase inhibitor administration.
Topics: Aldehyde Reductase; Benzothiazoles; Cardiac Output; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Double-Blind Method; Enzyme Inhibitors; Exercise Test; Female; Heart; Heart Conduction System; Heart Rate; Humans; Male; Middle Aged; Phthalazines; Placebos; Stroke Volume; Thiazoles; Ventricular Function, Left | 2004 |
Improvement in glycaemic control with rosiglitazone/metformin fixed-dose combination therapy in patients with type 2 diabetes with very poor glycaemic control.
Topics: Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Combinations; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Male; Metformin; Middle Aged; Thiazoles; Treatment Outcome | 2006 |
Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipids; Male; Metformin; Middle Aged; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome | 2006 |
A double-blind randomized study comparing the effects of continuing or not continuing rosiglitazone + metformin therapy when starting insulin therapy in people with Type 2 diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Europe; Female; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Thiazoles; Treatment Outcome | 2007 |
Role of AMP kinase and PPARdelta in the regulation of lipid and glucose metabolism in human skeletal muscle.
Topics: Adenylate Kinase; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Gene Expression Regulation; Glucose; Humans; Insulin; Lipid Metabolism; Muscle Cells; Muscle, Skeletal; Oxidation-Reduction; Phosphorylation; PPAR delta; RNA, Small Interfering; Thiazoles | 2007 |
Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives.
Topics: Aged; Blood Glucose; Blood Pressure; Chromans; Diabetes Mellitus, Type 2; Female; Heart Rate; Hemoglobin A; Humans; Hypertension; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Renin; Single-Blind Method; Thiazoles; Thiazolidinediones; Troglitazone | 1995 |
Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.
Topics: Adult; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Tolerance Test; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Lipids; Male; Obesity; Thiazoles; Thiazolidinediones; Troglitazone | 1994 |
Topical aldose reductase inhibitor for correcting corneal endothelial changes in diabetic patients.
Topics: Administration, Topical; Aged; Aldehyde Reductase; Cell Size; Corneal Diseases; Diabetes Mellitus, Type 2; Endothelium, Corneal; Humans; Middle Aged; Thiazoles; Thiazolidinediones | 1995 |
Metabolic effects of darglitazone, an insulin sensitizer, in NIDDM subjects.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids, Nonesterified; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Obesity; Thiazoles; Thiazolidinediones | 1995 |
Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy.
Topics: Adult; Aged; Aged, 80 and over; Blood Pressure; Body Weight; Cholesterol; Chromans; Diabetes Mellitus, Type 2; Diet, Diabetic; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Placebos; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 1996 |
Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Cholesterol; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Fatty Acids, Nonesterified; Female; Fructosamine; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Leukocyte Count; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Neutrophils; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 1996 |
Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM.
Topics: Adult; Blood Glucose; Blood Pressure; Body Mass Index; California; Cholesterol, HDL; Cholesterol, LDL; Chromans; Diabetes Mellitus, Type 2; Diabetes, Gestational; Dose-Response Relationship, Drug; Fatty Acids, Nonesterified; Female; Glucose Intolerance; Glucose Tolerance Test; Hispanic or Latino; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Placebos; Pregnancy; Risk Assessment; Risk Factors; Thiazoles; Thiazolidinediones; Tolbutamide; Triglycerides; Troglitazone | 1996 |
Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group.
Topics: Blood Glucose; C-Peptide; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Chromans; Confidence Intervals; Diabetes Mellitus, Type 2; Echocardiography; Female; Glyburide; Glycated Hemoglobin; Heart; Heart Function Tests; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Stroke Volume; Thiazoles; Thiazolidinediones; Time Factors; Triglycerides; Troglitazone | 1997 |
Effect of combination therapy of troglitazone and sulphonylureas in patients with Type 2 diabetes who were poorly controlled by sulphonylurea therapy alone.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Blood Glucose; Chromans; Demography; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Lipids; Middle Aged; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Treatment Outcome; Troglitazone | 1996 |
Trivalent chromium and the diabetes prevention program.
Topics: Chromans; Chromium; Clinical Protocols; Complementary Therapies; Diabetes Mellitus, Type 2; Diet; Exercise; Glucose Intolerance; Humans; Hypoglycemic Agents; Metformin; Safety; Thiazoles; Thiazolidinediones; Troglitazone | 1997 |
Efficacy of troglitazone measured by insulin resistance index.
Topics: Chromans; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Thiazoles; Thiazolidinediones; Treatment Outcome; Troglitazone | 1997 |
Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes.
Topics: Administration, Oral; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipids; Male; Middle Aged; Potassium; Risk Factors; Thiazoles; Thiazolidinediones; Troglitazone | 1997 |
Good metabolic and safety profile of troglitazone alone and following alcohol in NIDDM subjects.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Chromans; Creatinine; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Ethanol; Fasting; Female; Humans; Hydrocortisone; Hypoglycemic Agents; Insulin; Lipids; Male; Middle Aged; Proinsulin; Thiazoles; Thiazolidinediones; Troglitazone | 1997 |
Increase of lipoprotein (a) with troglitazone.
Topics: Chromans; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Lipoprotein(a); Male; Middle Aged; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Troglitazone | 1997 |
Troglitazone reduces LDL oxidation and lowers plasma E-selectin concentration in NIDDM patients.
Topics: Analysis of Variance; Arteriosclerosis; Cholesterol, LDL; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; E-Selectin; Endothelium, Vascular; Female; Fluorescence; Humans; Hypoglycemic Agents; Male; Middle Aged; Oxidation-Reduction; Peroxides; Thiazoles; Thiazolidinediones; Thiobarbituric Acid Reactive Substances; Troglitazone; Vitamin E | 1998 |
Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Analysis of Variance; Blood Glucose; C-Peptide; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Male; Middle Aged; Placebos; Regression Analysis; Thiazoles; Thiazolidinediones; Troglitazone | 1998 |
Effect of troglitazone on B cell function, insulin sensitivity, and glycemic control in subjects with type 2 diabetes mellitus.
Topics: Aged; Aged, 80 and over; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Male; Middle Aged; Regression Analysis; Thiazoles; Thiazolidinediones; Troglitazone | 1998 |
Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.
Topics: Administration, Oral; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucose; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Thiazoles; Thiazolidinediones; Troglitazone | 1998 |
Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.
Topics: Administration, Oral; Adult; Aged; Blood Glucose; Cholesterol; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 1998 |
Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM. AD-4833 Glucose Clamp Study Group, Japan.
Topics: Administration, Oral; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Pioglitazone; Thiazoles; Thiazolidinediones | 1997 |
TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus.
Topics: Adolescent; Adult; Blood Glucose; Carotid Stenosis; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up Studies; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Infant, Newborn; Middle Aged; Pregnancy; Pregnancy in Diabetics; Quality of Life; Recurrence; Risk Factors; Thiazoles; Thiazolidinediones; Treatment Outcome; Troglitazone | 1998 |
Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro.
Topics: Adipose Tissue; Animals; Arteries; Chromans; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Humans; Hypoglycemic Agents; Male; Rats; Rats, Wistar; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; Vasodilator Agents | 1998 |
Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes.
Topics: Carotid Arteries; Chromans; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 1998 |
Establishing the dose response curve for metabolic control with troglitazone, an insulin action enhancer, in type 2 diabetes patients.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Fatty Acids, Nonesterified; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Middle Aged; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 1998 |
Troglitazone use in insulin-treated type 2 diabetic patients. The Troglitazone Insulin Study Group.
Topics: Adult; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Thiazoles; Thiazolidinediones; Troglitazone | 1998 |
Troglitazone reduces plasma leptin concentration but increases hunger in NIDDM patients.
Topics: Blood Glucose; Body Mass Index; Chromans; Diabetes Mellitus, Type 2; Energy Intake; Feeding Behavior; Glycated Hemoglobin; Humans; Hunger; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Leptin; Lipids; Middle Aged; Proteins; Thiazoles; Thiazolidinediones; Troglitazone | 1998 |
Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group.
Topics: Blood Glucose; Body Weight; C-Peptide; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Treatment Outcome; Troglitazone | 1998 |
Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients.
Topics: Aged; Aged, 80 and over; Alanine Transaminase; Aspartate Aminotransferases; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Fasting; Fatigue; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipids; Male; Thiazoles; Thiazolidinediones; Treatment Outcome; Troglitazone; Vomiting | 1998 |
Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group.
Topics: Aged; Blood Glucose; C-Peptide; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Placebos; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Troglitazone | 1998 |
Pioglitazone enhances splanchnic glucose uptake as well as peripheral glucose uptake in non-insulin-dependent diabetes mellitus. AD-4833 Clamp-OGL Study Group.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Pioglitazone; Thiazoles; Thiazolidinediones | 1998 |
Pharmacokinetics of troglitazone, a PPAR-gamma agonist, in patients with hepatic insufficiency.
Topics: Adult; Aged; Chromans; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liver Diseases; Male; Middle Aged; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 1998 |
Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy.
Topics: Aged; Albuminuria; Blood Glucose; Blood Pressure; C-Peptide; Cholesterol; Cholesterol, HDL; Chromans; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 1998 |
The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Cardiovascular Diseases; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Energy Intake; Exercise Therapy; Female; Glucose Tolerance Test; Health Policy; Humans; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Life Style; Liver; Male; Metformin; Middle Aged; Obesity; Outcome and Process Assessment, Health Care; Quality of Life; Research Design; Risk Factors; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
Troglitazone in combination with sulphonylurea improves glycaemic control in Type 2 diabetic patients inadequately controlled by sulphonylurea therapy alone. Troglitazone Study Group.
Topics: Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
Troglitazone's effect on lipoprotein(a) levels.
Topics: Chromans; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Lipoprotein(a); Male; Middle Aged; Thiazoles; Thiazolidinediones; Time Factors; Troglitazone | 1999 |
Troglitazone directly increases HDL cholesterol levels.
Topics: Blood Glucose; Cholesterol, HDL; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
Effect of troglitazone on body fat distribution in type 2 diabetic patients.
Topics: Abdomen; Adipose Tissue; Blood Glucose; Blood Pressure; Body Mass Index; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucose Tolerance Test; Glyburide; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Skin; Thiazoles; Thiazolidinediones; Tomography, X-Ray Computed; Troglitazone; Viscera | 1999 |
Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus.
Topics: Adult; Blood Pressure; Chromans; Diabetes Mellitus, Type 2; Female; Glyburide; Hemodynamics; Humans; Hypoglycemic Agents; Male; Middle Aged; Reference Values; Rest; Stress, Psychological; Thiazoles; Thiazolidinediones; Troglitazone; Vasodilation | 1999 |
Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes.
Topics: Adipose Tissue; Adult; Blood Glucose; Blood Pressure; Body Mass Index; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin-Like Growth Factor I; Male; Middle Aged; Thiazoles; Thiazolidinediones; Tomography, X-Ray Computed; Troglitazone | 1999 |
Effect of troglitazone on lipoprotein(a) levels in obese subjects.
Topics: Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Hypoglycemic Agents; Insulin Resistance; Lipoprotein(a); Obesity; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients.
Topics: Blood Glucose; Body Weight; C-Peptide; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Chromans; Circadian Rhythm; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Nonesterified; Female; Fructosamine; Humans; Hypoglycemic Agents; Insulin; Insulin Infusion Systems; Male; Metformin; Middle Aged; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 1999 |
Lack of effects of the beta3-adrenoreceptor agonist UL-TG 307 on insulin sensitivity and insulin secretion in Type 2 diabetic patients.
Topics: Adrenergic beta-Agonists; Adult; Body Weight; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids, Nonesterified; Glycerol; Humans; Insulin; Insulin Resistance; Insulin Secretion; Lipids; Male; Middle Aged; Thiazoles | 1999 |
Troglitazone reduces hyperglycaemia and selectively acute-phase serum proteins in patients with Type II diabetes.
Topics: Acute-Phase Proteins; Aged; Blood Glucose; Body Mass Index; C-Reactive Protein; Chromans; Complement C3; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Middle Aged; Orosomucoid; Placebos; Serum Amyloid A Protein; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Chromans; Cohort Studies; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Costs; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Models, Economic; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Troglitazone; United States | 2000 |
Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Europe; Female; Fructosamine; Gliclazide; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Rosiglitazone; Safety; Thiazoles; Thiazolidinediones; Triglycerides | 2000 |
Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Metformin; Middle Aged; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Eating; Fasting; Female; Fructosamine; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors | 2000 |
Rosiglitazone taken once daily provides effective glycaemic control in patients with Type 2 diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Europe; Female; Fructosamine; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Placebos; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors | 2000 |
Improvement by the insulin-sensitizing agent, troglitazone, of abnormal fibrinolysis in type 2 diabetes mellitus.
Topics: Aged; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Female; Fibrinolysis; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones.
Topics: Body Weight; Cholesterol, LDL; Chromans; Diabetes Mellitus, Type 2; Edema; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 2000 |
Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects.
Topics: Adult; Blood Glucose; Body Mass Index; C-Peptide; Cholesterol; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucose; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Obesity; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans.
Topics: Adult; Aged; Biological Availability; Chromatography, High Pressure Liquid; Cross-Over Studies; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Middle Aged; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
Long-term effects of troglitazone: open-label extension studies in type 2 diabetic patients.
Topics: Blood Glucose; C-Peptide; Chromans; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Lipoproteins, HDL; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Carbamates; Chromans; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Piperidines; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Response of pancreatic beta-cells to improved insulin sensitivity in women at high risk for type 2 diabetes.
Topics: Adult; Chromans; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Glucose; Glucose Intolerance; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Pregnancy; Risk Factors; Thiazoles; Thiazolidinediones; Tolbutamide; Troglitazone | 2000 |
Troglitazone decreases serum uric acid concentrations in type II diabetic patients and non-diabetics.
Topics: Blood Glucose; Chromans; Creatinine; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Middle Aged; Reference Values; Thiazoles; Thiazolidinediones; Troglitazone; Uric Acid | 2000 |
Troglitazone or metformin in combination with sulfonylureas for patients with type 2 diabetes?
Topics: Adult; Aged; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
Efficacy of troglitazone on body fat distribution in type 2 diabetes.
Topics: Adipose Tissue; Body Mass Index; C-Peptide; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Middle Aged; Obesity; Sex Characteristics; Thiazoles; Thiazolidinediones; Tomography, X-Ray Computed; Troglitazone; Viscera; Weight Gain | 2000 |
Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study.
Topics: Cell Division; Chromans; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Stents; Thiazoles; Thiazolidinediones; Troglitazone; Tunica Intima; Ultrasonography, Interventional | 2000 |
Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Ethnicity; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Placebos; Racial Groups; Thiazoles; Thiazolidinediones; United States | 2000 |
Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Pioglitazone; Placebos; Thiazoles; Thiazolidinediones | 2000 |
Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; C-Peptide; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Male; Middle Aged; Placebos; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides | 2001 |
Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Body Weight; C-Peptide; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fructosamine; Glycated Hemoglobin; Humans; Insulin; Lipids; Male; Middle Aged; Placebos; Rosiglitazone; Thiazoles; Thiazolidinediones | 1999 |
Concentration of the complement activation product, acylation-stimulating protein, is related to C-reactive protein in patients with type 2 diabetes.
Topics: Acute-Phase Proteins; Blood Glucose; Blood Proteins; C-Reactive Protein; Complement Activation; Complement C3; Complement C3a; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Osmolar Concentration; Pioglitazone; Thiazoles; Thiazolidinediones | 2001 |
Rosiglitazone monotherapy is effective in patients with type 2 diabetes.
Topics: Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Islets of Langerhans; Male; Middle Aged; Rosiglitazone; Single-Blind Method; Thiazoles; Thiazolidinediones | 2001 |
Effects of troglitazone in patients with type 2 diabetes mellitus not adequately controlled by sulfonylureas.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Mass Index; C-Peptide; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Middle Aged; Sulfonylurea Compounds; Thailand; Thiazoles; Thiazolidinediones; Time Factors; Troglitazone | 2001 |
Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy--a randomized controlled trial.
Topics: Adipose Tissue; Aged; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fatty Liver; Female; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Obesity; Pilot Projects; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.
Topics: Adipose Tissue; Adult; Aged; Blood Glucose; Body Mass Index; C-Peptide; Cholesterol; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids, Nonesterified; Glucose Clamp Technique; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Infusions, Intravenous; Insulin; Middle Aged; Pioglitazone; Placebos; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Triglycerides | 2001 |
The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial.
Topics: Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Treatment Failure; Triglycerides; Troglitazone | 2001 |
The oral insulin sensitizer, thiazolidinedione, increases plasma vascular endothelial growth factor in type 2 diabetic patients.
Topics: Diabetes Mellitus, Type 2; Endothelial Growth Factors; Enzyme-Linked Immunosorbent Assay; Humans; Hypoglycemic Agents; Lymphokines; Metformin; Pioglitazone; Thiazoles; Thiazolidinediones; Time Factors; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2001 |
Beneficial effect of troglitazone, an insulin-sensitizing antidiabetic agent, on coronary circulation in patients with non-insulin-dependent diabetes mellitus.
Topics: Adenosine Triphosphate; Aged; Blood Glucose; Case-Control Studies; Chromans; Coronary Circulation; Diabetes Mellitus, Type 2; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Thallium Radioisotopes; Thiazoles; Thiazolidinediones; Troglitazone; Vasodilator Agents | 2001 |
A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ethnicity; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Placebos; Rosiglitazone; Safety; Thiazoles; Thiazolidinediones; Triglycerides; United States | 2001 |
Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in Type 2 diabetic patients with microalbuminuria or macroalbuminuria.
Topics: Albuminuria; Animals; Blood Pressure; Chromans; Collagen; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Reference Values; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action?
Topics: Adult; Anti-Inflammatory Agents; Blood Glucose; C-Reactive Protein; Chemokine CCL2; Cholesterol; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Humans; I-kappa B Proteins; Insulin; Intercellular Adhesion Molecule-1; Leukocytes, Mononuclear; Linoleic Acid; Linoleic Acids; Linoleic Acids, Conjugated; Male; Middle Aged; NADPH Oxidases; Neutrophils; NF-kappa B; Obesity; Phenylalanine; Phosphoproteins; Plasminogen Activator Inhibitor 1; Reactive Oxygen Species; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone; Tyrosine | 2001 |
Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes.
Topics: Arteriosclerosis; Blood Pressure; Carotid Arteries; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Pioglitazone; Thiazoles; Thiazolidinediones | 2001 |
Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.
Topics: Adult; Aged; Analysis of Variance; Blood Glucose; C-Peptide; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Time Factors; Treatment Outcome; Triglycerides; United States | 2001 |
Serum leptin level as an indicator to predict the clinical efficacy of troglitazone in patients with type 2 diabetes mellitus.
Topics: Biomarkers; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Fasting; Female; Glycated Hemoglobin; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Leptin; Male; Middle Aged; Models, Biological; Predictive Value of Tests; Regression Analysis; Thiazoles; Thiazolidinediones; Time Factors; Troglitazone | 2001 |
The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Arteriosclerosis; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Endpoint Determination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin; Insulin Resistance; Islets of Langerhans; Lipids; Lipoproteins; Male; Middle Aged; Pioglitazone; Single-Blind Method; Thiazoles; Thiazolidinediones; Treatment Outcome; United States | 2001 |
Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria.
Topics: Albuminuria; Blood Glucose; Cytoskeletal Proteins; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Thiazoles; Thiazolidinediones | 2001 |
Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control.
Topics: Analysis of Variance; Arteriosclerosis; Blood Coagulation; Blood Coagulation Tests; Chromans; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Diabetic; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Predictive Value of Tests; Thiazoles; Thiazolidinediones; Thrombosis; Troglitazone | 2001 |
Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects.
Topics: Adipocytes; Adipose Tissue; Adult; Aged; Body Composition; Cells, Cultured; Chromans; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Signal Transduction; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
Effect of pioglitazone on dyslipidemia in hemodialysis patients with type 2 diabetes.
Topics: Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Glyburide; Glycated Hemoglobin; Humans; Hyperlipidemias; Hypoglycemic Agents; Kidney Failure, Chronic; Male; Middle Aged; Pioglitazone; Renal Dialysis; Thiazoles; Thiazolidinediones; Triglycerides | 2001 |
Further insight on the hypoglycemic and nonhypoglycemic effects of troglitazone 400 or 600 mg/d: effects on the very-low-density and high-density lipoprotein particle distribution.
Topics: Aged; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Fatty Acids, Nonesterified; Female; Fibrinogen; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Lipoproteins; Lipoproteins, HDL; Lipoproteins, VLDL; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids, Nonesterified; Glucose; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Middle Aged; Osmolar Concentration; Oxidation-Reduction; Regression Analysis; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
Impact of troglitazone on coronary stent implantation using small stents in patients with type 2 diabetes mellitus.
Topics: Aged; Angioplasty, Balloon, Coronary; Chromans; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Stents; Thiazoles; Thiazolidinediones; Treatment Outcome; Troglitazone | 2002 |
Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects.
Topics: Adult; Aged; Chromans; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Isoenzymes; Male; Metformin; Middle Aged; Muscle, Skeletal; Phosphatidylinositol 3-Kinases; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients.
Topics: Adiponectin; Adipose Tissue; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Multivariate Analysis; Proteins; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization.
Topics: 3T3 Cells; Adipocytes; Adiponectin; Animals; Blood Proteins; Cross-Over Studies; Diabetes Mellitus, Type 2; Electrophoresis, Polyacrylamide Gel; Hypoglycemic Agents; Insulin; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Male; Metformin; Mice; Mice, Inbred C57BL; Pilot Projects; Proteins; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
Clinical evidence of thiazolidinedione-induced improvement of pancreatic beta-cell function in patients with type 2 diabetes mellitus.
Topics: Biomarkers; Blood Glucose; Body Mass Index; C-Peptide; Case-Control Studies; Diabetes Mellitus, Type 2; Eating; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Islets of Langerhans; Middle Aged; Postprandial Period; Thiazoles; Thiazolidinediones | 2002 |
Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes.
Topics: Adult; Blood Glucose; Body Mass Index; Cholesterol; Diabetes Mellitus, Type 2; Diet, Diabetic; Dose-Response Relationship, Drug; Ethnicity; Fasting; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Middle Aged; Pioglitazone; Thiazoles; Thiazolidinediones | 2002 |
Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.
Topics: Blood Glucose; Blood Pressure; C-Reactive Protein; Cardiovascular Diseases; Cholesterol; Chromans; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Lipoproteins, LDL; Male; Metformin; Middle Aged; Plasminogen Activator Inhibitor 1; Risk Factors; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
Cardiac hypertrophy in diabetes patients with and without hypertension: effects of troglitazone, a novel antidiabetic drug, on diastolic function.
Topics: Cardiomegaly; Chromans; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diastole; Female; Humans; Hypertension; Hypoglycemic Agents; Male; Middle Aged; Reference Values; Thiazoles; Thiazolidinediones; Troglitazone; Ventricular Function, Left | 2001 |
A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone.
Topics: Adult; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin; Male; Metformin; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 2002 |
Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Liver Failure; Liver Function Tests; Male; Metformin; Middle Aged; Reference Values; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |
Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy.
Topics: Adult; Aged; Analysis of Variance; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Pioglitazone; Thiazoles; Thiazolidinediones; Triglycerides | 2002 |
Rosiglitazone in combination with glimepiride plus metformin in type 2 diabetic patients.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones | 2002 |
Rosiglitazone amplifies the benefits of lifestyle intervention measures in long-standing type 2 diabetes mellitus.
Topics: Biomarkers; Blood Pressure; Body Constitution; Body Mass Index; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Life Style; Obesity; Placebos; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides; Weight Loss | 2002 |
Antihypoxic treatment at an early stage of diabetic neuropathy: an electrophysiological study with sabeluzole.
Topics: Adult; Aged; Autonomic Nervous System Diseases; Cell Hypoxia; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Double-Blind Method; Electromyography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Nerve Degeneration; Neurologic Examination; Peripheral Nerves; Piperidines; Sensory Thresholds; Synaptic Transmission; Thiazoles | 1992 |
Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM.
Topics: Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Middle Aged; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Troglitazone | 1991 |
A pilot clinical trial of a new oral hypoglycemic agent, CS-045, in patients with non-insulin dependent diabetes mellitus.
Topics: Biomarkers; Blood Glucose; Body Mass Index; Chromans; Diabetes Mellitus, Type 2; Diet, Diabetic; Female; Fructosamine; Glycated Hemoglobin; Hexosamines; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Pilot Projects; Thiazoles; Thiazolidinediones; Troglitazone | 1991 |
387 other study(ies) available for thiazoles and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Nitazoxanide Exerts Immunomodulatory Effects on Peripheral Blood Mononuclear Cells from Type 2 Diabetes Patients.
Topics: Adult; Diabetes Mellitus, Type 2; Humans; Leukocytes, Mononuclear; MicroRNAs; Nitro Compounds; Thiazoles | 2021 |
Synthesis of Arylidenehydrazinyl-4-methoxyphenylthiazole Derivatives: Docking Studies, Probing Type II Diabetes Complication Management Agents.
Topics: alpha-Amylases; Diabetes Complications; Diabetes Mellitus, Type 2; Humans; Molecular Docking Simulation; Molecular Structure; Spectroscopy, Fourier Transform Infrared; Structure-Activity Relationship; Thiazoles | 2022 |
Synthesis of new phenoxymethylcoumarin clubbed 4-arylthiazolylhydrazines as α-glucosidase inhibitors and their kinetics and molecular docking studies.
Topics: alpha-Glucosidases; Diabetes Mellitus, Type 2; Glycoside Hydrolase Inhibitors; Humans; Kinetics; Molecular Docking Simulation; Molecular Structure; Spectroscopy, Fourier Transform Infrared; Structure-Activity Relationship; Thiazoles | 2023 |
Synthesis and biological evaluation of 2,5-disubstituted furan derivatives containing 1,3-thiazole moiety as potential α-glucosidase inhibitors.
Topics: alpha-Glucosidases; Diabetes Mellitus, Type 2; Furans; Glycoside Hydrolase Inhibitors; HEK293 Cells; Humans; Kinetics; Molecular Docking Simulation; Molecular Structure; Structure-Activity Relationship; Thiazoles | 2023 |
A Novel TNF-α Converting Enzyme (TACE) Selective Inhibitor JTP-96193 Prevents Insulin Resistance in KK-A
Topics: ADAM17 Protein; Adipose Tissue; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Mice, Inbred ICR; Rats; Rats, Inbred Lew; Thiazoles; Tumor Necrosis Factor-alpha | 2019 |
Design, synthesis, and pharmacological evaluation of 2-(4-sulfonylphenyl)-2-[(E)-pyrrolidin-1-ylimino]-N-thiazoleacetamides as glucokinase activators.
Topics: Acetamides; Administration, Oral; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Design; Glucokinase; Hypoglycemic Agents; Mice; Mice, Inbred C57BL; Molecular Structure; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Thiazoles | 2020 |
Enhancing insulin sensitivity by dual PPARγ partial agonist, β-catenin inhibitor: Design, synthesis of new αphthalimido-o-toluoyl2-aminothiazole hybrids.
Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Adiponectin; Animals; beta Catenin; Cell Differentiation; Diabetes Mellitus, Type 2; Gene Expression; Glucose; Insulin; Insulin Resistance; Mice; Molecular Docking Simulation; Phthalimides; PPAR gamma; Rosiglitazone; Thiazoles; Thiazolidinediones | 2020 |
Multimodal imaging Gd-nanoparticles functionalized with Pittsburgh compound B or a nanobody for amyloid plaques targeting.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Aniline Compounds; Animals; Brain; Diabetes Mellitus, Type 2; Gadolinium; Humans; Immunohistochemistry; Islet Amyloid Polypeptide; Mice; Multimodal Imaging; Nanoparticles; Plaque, Amyloid; Single-Domain Antibodies; Thiazoles | 2017 |
Discovery of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific glucokinase activators: Design, synthesis, and biological evaluation.
Topics: Animals; Apoptosis; Benzamides; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Discovery; Enzyme Activation; Enzyme Activators; Glucokinase; Glucose Tolerance Test; Insulin-Secreting Cells; Male; Mice; Mice, Inbred C57BL; Models, Molecular; Molecular Structure; Streptozocin; Structure-Activity Relationship; Thiazoles | 2017 |
Lysophosphatidylcholine modulates the aggregation of human islet amyloid polypeptide.
Topics: alpha-Synuclein; Benzothiazoles; Diabetes Mellitus, Type 2; Humans; Insulin-Secreting Cells; Islet Amyloid Polypeptide; Kinetics; Lysophosphatidylcholines; Microscopy, Electron, Transmission; Molecular Dynamics Simulation; Thiazoles | 2017 |
Lower risk of dementia with pioglitazone, compared with other second-line treatments, in metformin-based dual therapy: a population-based longitudinal study.
Topics: Aged; Dementia; Diabetes Mellitus, Type 2; Drug Combinations; Female; Humans; Hypoglycemic Agents; Longitudinal Studies; Male; Metformin; Pioglitazone; Thiazoles; Thiazolidinediones | 2018 |
Evaluation of 4-methyl-2-[(2-methylbenzyl) amino]-1,3-thiazole-5-carboxylic acid against hyperglycemia, insulin sensitivity, and oxidative stress-induced inflammatory responses and β-cell damage in the pancreas of streptozotocin-induced diabetic rats.
Topics: Animals; Biomarkers; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glycated Hemoglobin; Hypoglycemic Agents; Inflammation Mediators; Insulin; Insulin Resistance; Insulin-Secreting Cells; Interleukin-6; Oxidative Stress; Rats, Wistar; Streptozocin; Thiazoles; Tumor Necrosis Factor-alpha | 2018 |
Amyloid and Tau Positron Emission Tomography in Suggested Diabetesrelated Dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid; Aniline Compounds; Benzothiazoles; Dementia; Diabetes Mellitus, Type 2; Female; Humans; Magnetic Resonance Imaging; Male; Neuropsychological Tests; Positron-Emission Tomography; Psychiatric Status Rating Scales; tau Proteins; Thiazoles; Tomography, Emission-Computed, Single-Photon | 2018 |
DS-8500a, an Orally Available G Protein-Coupled Receptor 119 Agonist, Upregulates Glucagon-Like Peptide-1 and Enhances Glucose-Dependent Insulin Secretion and Improves Glucose Homeostasis in Type 2 Diabetic Rats.
Topics: Animals; Benzamides; CHO Cells; Cricetulus; Cyclopropanes; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Glucose; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Male; Mesylates; Mice; Oxadiazoles; Rats; Rats, Sprague-Dawley; Rats, Zucker; Receptors, G-Protein-Coupled; Tetrazoles; Thiazoles; Up-Regulation | 2018 |
Discovery of first-in-class thiazole-based dual FFA1/PPARδ agonists as potential anti-diabetic agents.
Topics: Animals; Diabetes Mellitus, Type 2; Drug Discovery; Glucose Tolerance Test; Hypoglycemic Agents; Mice; PPAR delta; Receptors, G-Protein-Coupled; Thiazoles | 2019 |
Discovery and biological evaluation of novel G protein-coupled receptor 119 agonists for type 2 diabetes.
Topics: Animals; Blood Glucose; CHO Cells; Cricetinae; Cricetulus; Cyclic AMP; Diabetes Mellitus, Type 2; Drug Design; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Male; Mice; Mice, Inbred ICR; Receptors, G-Protein-Coupled; Structure-Activity Relationship; Tetrazoles; Thiazoles | 2019 |
Adipose tissue macrophage-derived exosomal miR-29a regulates obesity-associated insulin resistance.
Topics: Adipocytes; Adipose Tissue; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Exosomes; Gene Knockdown Techniques; Hepatocytes; In Vitro Techniques; Insulin Resistance; Macrophages; Male; Mice; Mice, Inbred C57BL; MicroRNAs; Muscle Cells; Obesity; Receptors, Cytoplasmic and Nuclear; Thiazoles | 2019 |
Inhibition of human islet amyloid polypeptide or amylin aggregation by two manganese-salen derivatives.
Topics: Amyloid; Anilino Naphthalenesulfonates; Antioxidants; Benzothiazoles; Cell Line, Tumor; Cell Survival; Diabetes Mellitus, Type 2; Ethylenediamines; Fluorescent Dyes; Humans; Islet Amyloid Polypeptide; Microscopy, Electron, Transmission; Molecular Docking Simulation; Neuroblastoma; Organometallic Compounds; Salicylates; Thiazoles | 2013 |
Molecular characterization of the hetero-assembly of β-amyloid peptide with islet amyloid polypeptide.
Topics: Alzheimer Disease; Amino Acid Sequence; Amyloid; Amyloid beta-Peptides; Amyloidosis; Animals; Benzothiazoles; Cell Survival; Circular Dichroism; Diabetes Mellitus, Type 2; Islet Amyloid Polypeptide; Kinetics; Microscopy, Electron, Transmission; Molecular Sequence Data; PC12 Cells; Peptide Fragments; Protein Binding; Protein Folding; Protein Multimerization; Rats; Spectrometry, Fluorescence; Thiazoles | 2014 |
Identification of a new class of glucokinase activators through structure-based design.
Topics: Allosteric Regulation; Aminopyridines; Animals; Diabetes Mellitus, Type 2; Enzyme Activators; Glucokinase; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Mice; Mice, Inbred C57BL; Rats; Rats, Zucker; Structure-Activity Relationship; Thiazoles; Young Adult | 2013 |
Identification of PPARγ ligands with One-dimensional Drug Profile Matching.
Topics: Animals; Benzophenones; Blood Glucose; Bromobenzenes; Cell Line, Tumor; Computer Simulation; Databases, Pharmaceutical; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Design; Drugs, Generic; Glucose Clamp Technique; Humans; Insulin; Ligands; Male; Nitro Compounds; PPAR gamma; Rats; Rats, Wistar; Thiazoles; Time Factors | 2013 |
Islet amyloid polypeptide toxicity and membrane interactions.
Topics: Amino Acid Sequence; Amyloid; Animals; Benzothiazoles; Biophysics; Diabetes Mellitus, Type 2; Humans; Islet Amyloid Polypeptide; Membranes, Artificial; Microscopy, Electron, Transmission; Molecular Sequence Data; Oxazines; Rats; Species Specificity; Thiazoles; Xanthenes | 2013 |
Comment on: TODAY Study Group. Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and β-cell function in TODAY. Diabetes Care 2013;36:1749-1757.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Life Style; Male; Metformin; Thiazoles | 2013 |
Optimization of brain penetrant 11β-hydroxysteroid dehydrogenase type I inhibitors and in vivo testing in diet-induced obese mice.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adamantane; Animals; Blood Glucose; Body Weight; Brain; Crystallography, X-Ray; Cyclopropanes; Diabetes Mellitus, Type 2; Dietary Fats; Humans; Hypoglycemic Agents; Insulin; Isoenzymes; Liver; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Mice, Obese; Models, Molecular; Pyrazoles; Rats; Stereoisomerism; Structure-Activity Relationship; Thiazoles | 2014 |
Prevention of comorbidity and acute attack of gout by uric acid lowering therapy.
Topics: Adult; Allopurinol; Antimetabolites; Benzbromarone; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hypertension; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Thiazoles; Uric Acid; Uricosuric Agents; Urolithiasis | 2014 |
Pharmacological effects of JTT-551, a novel protein tyrosine phosphatase 1B inhibitor, in diet-induced obesity mice.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose; Glycine; Hypothalamus; Leptin; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Protein Tyrosine Phosphatases; Signal Transduction; STAT3 Transcription Factor; Thiazoles | 2014 |
SIRT1 activation ameliorates hyperglycaemia by inducing a torpor-like state in an obese mouse model of type 2 diabetes.
Topics: Angiopoietin-Like Protein 8; Angiopoietin-like Proteins; Anilides; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Enzyme Activation; Enzyme Activators; Hepatocytes; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Secreting Cells; Male; Mice, Mutant Strains; Obesity; Peptide Hormones; Signal Transduction; Sirtuin 1; Thiazoles; Time Factors; Torpor | 2015 |
A Comparison of Three Fluorophores for the Detection of Amyloid Fibers and Prefibrillar Oligomeric Assemblies. ThT (Thioflavin T); ANS (1-Anilinonaphthalene-8-sulfonic Acid); and bisANS (4,4'-Dianilino-1,1'-binaphthyl-5,5'-disulfonic Acid).
Topics: Alzheimer Disease; Amino Acid Sequence; Amyloid; Amyloid beta-Peptides; Anilino Naphthalenesulfonates; Benzothiazoles; Diabetes Mellitus, Type 2; Fluorescent Dyes; Humans; Islet Amyloid Polypeptide; Molecular Sequence Data; Spectrometry, Fluorescence; Thiazoles | 2015 |
Retinoic acid receptor β2 agonists restore glycaemic control in diabetes and reduce steatosis.
Topics: Animals; Benzoates; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diet, High-Fat; Drugs, Investigational; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Kidney; Lipid Peroxidation; Liver; Male; Mice, Inbred C57BL; Mice, Mutant Strains; Muscle, Skeletal; Non-alcoholic Fatty Liver Disease; Obesity; Oxidative Stress; Pancreas; Receptors, Retinoic Acid; Thiazoles | 2016 |
Development of PPAR-agonist GW0742 as antidiabetic drug: study in animals.
Topics: Animals; Biomarkers; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Discovery; Fructose; Glucose Transporter Type 4; Homeostasis; Hypoglycemic Agents; Insulin; Insulin Resistance; Intracellular Signaling Peptides and Proteins; Liver; Male; Muscle, Skeletal; Phosphoenolpyruvate Carboxykinase (GTP); PPAR alpha; Rats, Wistar; Streptozocin; Thiazoles; Time Factors | 2015 |
Reactions of 1,3-Diketones with a Dipeptide Isothiazolidin-3-one: Toward Agents That Covalently Capture Oxidized Protein Tyrosine Phosphatase 1B.
Topics: Amides; Diabetes Mellitus, Type 2; Dipeptides; Enzyme Inhibitors; Ketones; Oxidation-Reduction; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Thiazoles | 2015 |
Design, synthesis and Structure-activity relationship studies of new thiazole-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes.
Topics: Animals; Blood Glucose; CHO Cells; Cricetulus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Design; Humans; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Models, Molecular; Molecular Structure; Receptors, G-Protein-Coupled; Structure-Activity Relationship; Thiazoles | 2016 |
Adiponectin, Insulin Sensitivity, β-Cell Function, and Racial/Ethnic Disparity in Treatment Failure Rates in TODAY.
Topics: Adiponectin; Adolescent; Black People; Blood Glucose; C-Peptide; Child; Diabetes Mellitus, Type 2; Drug Combinations; Ethnicity; Female; Glucose Tolerance Test; Health Status Disparities; Hispanic or Latino; Humans; Hypoglycemic Agents; Insulin Resistance; Life Style; Male; Metformin; Thiazoles; Treatment Failure; White People | 2017 |
Cognitive deficits in non-demented diabetic elderly appear independent of brain amyloidosis.
Topics: Aged; Amyloidosis; Aniline Compounds; Brain; Case-Control Studies; Cognition Disorders; Diabetes Mellitus, Type 2; Female; Humans; Independent Living; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Positron-Emission Tomography; Thiazoles | 2017 |
2-[(4-Chlorobenzyl) amino]-4-methyl-1,3-thiazole-5-carboxylic acid exhibits antidiabetic potential and raises insulin sensitivity via amelioration of oxidative enzymes and inflammatory cytokines in streptozotocin-induced diabetic rats.
Topics: Animals; Animals, Newborn; Blood Glucose; Cytokines; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose Tolerance Test; Glycated Hemoglobin; Hypoglycemic Agents; Insulin Resistance; Lipid Metabolism; Oxidative Stress; Pancreas; Rats; Rats, Wistar; Thiazoles | 2017 |
Platelet hyperprocoagulant activity in Type 2 diabetes mellitus: attenuation by glycoprotein IIb/IIIa inhibition.
Topics: Benzylamines; Blood Platelets; Case-Control Studies; Diabetes Mellitus, Type 2; Humans; Phosphatidylserines; Piperidines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Receptors, Thrombin; Thiazoles; Thrombophilia | 2008 |
Amyloid oligomers in diabetic and nondiabetic human pancreas.
Topics: Aged; Amyloid; Apoptosis; Benzothiazoles; Biomarkers; Blotting, Western; Caspase 3; Diabetes Mellitus, Type 2; Female; Fluorescent Antibody Technique, Indirect; Humans; Insulin; Islet Amyloid Polypeptide; Islets of Langerhans; Male; Protein Multimerization; Thiazoles | 2009 |
[Avandia and avandamet in the treatment of patients with diabetes mellitus type 2: effects on secretion of some fat tissue hormones].
Topics: Adiponectin; Adipose Tissue; Diabetes Mellitus, Type 2; Drug Combinations; Female; Fibrinolytic Agents; Ghrelin; Humans; Hypoglycemic Agents; Insulin; Leptin; Male; Metformin; Middle Aged; Resistin; Rosiglitazone; Thiazoles; Thiazolidinediones | 2008 |
Nano-scale imaging and dynamics of amylin-membrane interactions and its implication in type II diabetes mellitus.
Topics: Aluminum Silicates; Amyloid; Animals; Benzothiazoles; Biological Assay; Cell Membrane; Cholesterol; Circular Dichroism; Diabetes Mellitus, Type 2; Fluorescence; Humans; Imaging, Three-Dimensional; Islet Amyloid Polypeptide; Liposomes; Microscopy, Atomic Force; Models, Biological; Nanotechnology; Phase Transition; Phospholipids; Protein Structure, Quaternary; Protein Structure, Secondary; Rats; Solutions; Surface Properties; Thiazoles | 2008 |
Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Enzyme Activators; Hypoglycemic Agents; Imidazoles; Mice; Quinoxalines; Rats; Rats, Zucker; Sirtuin 1; Structure-Activity Relationship; Thiazoles | 2009 |
Design, synthesis, and structure-activity relationship of substrate competitive, selective, and in vivo active triazole and thiadiazole inhibitors of the c-Jun N-terminal kinase.
Topics: Activating Transcription Factor 2; Animals; Binding Sites; Diabetes Mellitus, Type 2; Drug Design; HeLa Cells; Humans; Hypoglycemic Agents; Insulin Resistance; JNK Mitogen-Activated Protein Kinases; Male; Mice; Phosphorylation; Protein Binding; Structure-Activity Relationship; Substrate Specificity; Thiadiazoles; Thiazoles; Triazoles | 2009 |
Human glucagon receptor antagonists with thiazole cores. A novel series with superior pharmacokinetic properties.
Topics: Administration, Oral; Animals; Cell Line; Diabetes Mellitus, Type 2; Drug Design; Half-Life; Humans; Receptors, Glucagon; Species Specificity; Thiazoles | 2009 |
Rosiglitazone maleate + metformin hydrochloride extend: review of an emerging compound.
Topics: Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Drug Combinations; Gluconeogenesis; Humans; Hypoglycemic Agents; Metformin; Molecular Structure; Thiazoles; Treatment Outcome | 2009 |
Sulfonylureido thiazoles as fructose-1,6-bisphosphatase inhibitors for the treatment of type-2 diabetes.
Topics: Animals; Binding Sites; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Disease Models, Animal; Fructose-Bisphosphatase; High-Throughput Screening Assays; Humans; Hypoglycemic Agents; Mice; Structure-Activity Relationship; Sulfonylurea Compounds; Thiazoles | 2010 |
Pharmacological profiles of a novel protein tyrosine phosphatase 1B inhibitor, JTT-551.
Topics: Animals; Blood Glucose; Cell Line; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glycine; Hypoglycemic Agents; Liver; Male; Mice; Mice, Obese; Phosphorylation; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Rats; Receptor, Insulin; Signal Transduction; Thiazoles | 2010 |
Discovery, structure-activity relationships, pharmacokinetics, and efficacy of glucokinase activator (2R)-3-cyclopentyl-2-(4-methanesulfonylphenyl)-N-thiazol-2-yl-propionamide (RO0281675).
Topics: Animals; Blood Glucose; Cell Line; Cytotoxins; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Discovery; Glucokinase; Humans; Hypoglycemic Agents; Insulin; Male; Mice; Pharmacokinetics; Structure-Activity Relationship; Sulfones; Thiazoles | 2010 |
Design, synthesis, and pharmacological evaluation of N-(4-mono and 4,5-disubstituted thiazol-2-yl)-2-aryl-3-(tetrahydro-2H-pyran-4-yl)propanamides as glucokinase activators.
Topics: Acetamides; Administration, Oral; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Design; Glucokinase; Glucose; Glycoside Hydrolases; Hepatocytes; Hypoglycemic Agents; Mice; Mice, Inbred Strains; Rats; Thiazoles | 2010 |
Self-assembling pathway of HiApp fibrils within lipid bilayers.
Topics: Benzothiazoles; Diabetes Mellitus, Type 2; Fluoresceins; Humans; Islet Amyloid Polypeptide; Lipid Bilayers; Microscopy, Atomic Force; Spectrometry, Fluorescence; Thiazoles | 2010 |
The flavanol (-)-epigallocatechin 3-gallate inhibits amyloid formation by islet amyloid polypeptide, disaggregates amyloid fibrils, and protects cultured cells against IAPP-induced toxicity.
Topics: alpha-Synuclein; Amyloid; Amyloid beta-Protein Precursor; Animals; Benzothiazoles; Catechin; Cell Culture Techniques; Diabetes Mellitus, Type 2; Flavonoids; Islet Amyloid Polypeptide; Microscopy, Electron, Transmission; Phenols; Polyphenols; Protease Nexins; Rats; Receptors, Cell Surface; Thiazoles | 2010 |
Fructose-1,6-bisphosphatase regulates glucose-stimulated insulin secretion of mouse pancreatic beta-cells.
Topics: Alanine; Animals; Cells, Cultured; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Fructose-Bisphosphatase; Gene Knockdown Techniques; Glucose; Insulin; Insulin Secretion; Insulin-Secreting Cells; Mice; Mice, Inbred C57BL; Organophosphonates; Organophosphorus Compounds; RNA, Small Interfering; Thiazoles; Transfection; Up-Regulation | 2010 |
Design and synthesis of a new class of malonyl-CoA decarboxylase inhibitors with anti-obesity and anti-diabetic activities.
Topics: Animals; Anti-Obesity Agents; Blood Glucose; Body Weight; Carboxy-Lyases; Diabetes Mellitus, Type 2; Drug Design; Eating; Humans; Hypoglycemic Agents; Mice; Mice, Inbred C57BL; Obesity; Propanols; Thiazoles | 2010 |
Discovery of a series of phosphonic acid-containing thiazoles and orally bioavailable diamide prodrugs that lower glucose in diabetic animals through inhibition of fructose-1,6-bisphosphatase.
Topics: Administration, Oral; Alanine; Amides; Animals; Biological Availability; Blood Proteins; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fructose-Bisphosphatase; Humans; Hypoglycemic Agents; Male; Mice; Organophosphonates; Prodrugs; Protein Binding; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Thiazoles | 2011 |
Interference of low-molecular substances with the thioflavin-T fluorescence assay of amyloid fibrils.
Topics: Amyloid; Amyloid beta-Peptides; Azure Stains; Benzothiazoles; Biological Assay; Diabetes Mellitus, Type 2; False Positive Reactions; Fluorescent Dyes; Humans; Insulin; Kinetics; Neurodegenerative Diseases; Protein Structure, Secondary; Spectrometry, Fluorescence; Tannins; Thiazoles | 2012 |
Solid-state NMR reveals differences in the packing arrangements of peptide aggregates derived from the aortic amyloid polypeptide medin.
Topics: Amino Acid Sequence; Amyloid; Amyloidosis; Antigens, Surface; Aorta; Benzothiazoles; Biomarkers; Diabetes Mellitus, Type 2; Humans; Magnetic Resonance Spectroscopy; Microscopy, Electron; Milk Proteins; Molecular Sequence Data; Neurodegenerative Diseases; Peptide Fragments; Protein Structure, Secondary; Protein Structure, Tertiary; Spectrometry, Fluorescence; Thiazoles | 2012 |
In silico identification of structure requirement for novel thiazole and oxazole derivatives as potent fructose 1,6-bisphosphatase inhibitors.
Topics: Computer Simulation; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Fructose-Bisphosphatase; Hydrogen Bonding; Models, Molecular; Molecular Docking Simulation; Molecular Dynamics Simulation; Oxazoles; Quantitative Structure-Activity Relationship; Sequence Alignment; Thiazoles | 2011 |
Ziprasidone's effect on metabolic markers in patients with diabetes and chronic schizophrenia.
Topics: Analysis of Variance; Antipsychotic Agents; Biomarkers; Blood Glucose; Body Mass Index; Body Weight; Chronic Disease; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Insulin; Lipids; Male; Metabolic Syndrome; Middle Aged; Piperazines; Polypharmacy; Prospective Studies; Psychiatric Status Rating Scales; Schizophrenia; Thiazoles; Treatment Outcome | 2012 |
Postmarketing pharmacovigilance of adverse drug reactions: the case of rosiglitazone in Mexico.
Topics: Administration, Oral; Adult; Aged; Diabetes Mellitus, Type 2; Drug Combinations; Edema; Female; Follow-Up Studies; Glyburide; Humans; Hypoglycemic Agents; Male; Medication Adherence; Metformin; Mexico; Middle Aged; Pharmacovigilance; Prospective Studies; Rosiglitazone; Thiazoles; Thiazolidinediones; Weight Gain | 2012 |
The AGE-breaker ALT-711 restores high blood flow-dependent remodeling in mesenteric resistance arteries in a rat model of type 2 diabetes.
Topics: Animals; Blood Pressure; Diabetes Mellitus, Type 2; Endothelium, Vascular; Glycation End Products, Advanced; Male; Mesenteric Arteries; Rats; Rats, Zucker; Thiazoles; Vascular Resistance; Vasodilation | 2012 |
Anemia due to coadministration of renin-angiotensin-system inhibitors and PPARγ agonists in uncomplicated diabetic patients.
Topics: Aged; Anemia; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Body Mass Index; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Hematocrit; Hemoglobins; Humans; Male; Middle Aged; PPAR gamma; Renin-Angiotensin System; Thiazoles | 2012 |
Design, synthesis and biological evaluation of thiazole- and indole-based derivatives for the treatment of type II diabetes.
Topics: Administration, Oral; Alanine Transaminase; Animals; Blood Glucose; Body Weight; Cell Line; Cholesterol; Diabetes Mellitus, Type 2; Drug Design; Fatty Acid-Binding Proteins; Hypoglycemic Agents; Indoles; Insulin; Lipopolysaccharides; Male; Mice; Models, Molecular; Protein Conformation; Rats; Structure-Activity Relationship; Thiazoles; Triglycerides; Tumor Necrosis Factor-alpha | 2012 |
Enzyme inhibitory and antioxidant activities of traditional medicinal plants: potential application in the management of hyperglycemia.
Topics: alpha-Amylases; Antioxidants; Australia; Benzothiazoles; Biphenyl Compounds; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Ferric Compounds; Flavonoids; Glycoside Hydrolase Inhibitors; Hyperglycemia; India; Magnoliopsida; Medicine, Ayurvedic; Oxidative Stress; Phenols; Phytotherapy; Picrates; Plant Extracts; Plants, Medicinal; Sulfonic Acids; Thiazoles | 2012 |
Peroxisome proliferator-activated receptor-δ activation ameliorates albuminuria by preventing nephrin loss and restoring podocyte integrity in type 2 diabetes.
Topics: Albuminuria; Animals; Blotting, Western; Cell Culture Techniques; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Immunohistochemistry; Membrane Proteins; Podocytes; PPAR gamma; Rats; Rats, Inbred OLETF; Real-Time Polymerase Chain Reaction; Thiazoles | 2012 |
Rapid amelioration of hyperglycemia facilitated by dasatinib in a chronic myeloid leukemia patient with type 2 diabetes mellitus.
Topics: Antineoplastic Agents; Benzamides; Blood Glucose; Dasatinib; Diabetes Mellitus, Type 2; Drug Resistance, Neoplasm; Humans; Hyperglycemia; Hypoglycemic Agents; Imatinib Mesylate; Insulin; Leukemia, Myeloid, Accelerated Phase; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2012 |
Reversal of the deleterious effects of chronic dietary HFCS-55 intake by PPAR-δ agonism correlates with impaired NLRP3 inflammasome activation.
Topics: Animals; Carrier Proteins; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dietary Carbohydrates; Disease Models, Animal; Fructokinases; Fructose; Glucose; Hypoglycemic Agents; Inflammasomes; Kidney; Liver; Male; Mice; Mice, Inbred C57BL; NLR Family, Pyrin Domain-Containing 3 Protein; PPAR gamma; Seeds; Thiazoles; Zea mays | 2013 |
Macrophage migration inhibitory factor (MIF) enhances palmitic acid- and glucose-induced murine beta cell dysfunction and destruction in vitro.
Topics: Animals; Apoptosis; Caspase 3; Cell Line; Cytokines; Diabetes Mellitus, Type 2; DNA Fragmentation; Gene Expression Profiling; Glucose; In Vitro Techniques; Insulin-Secreting Cells; Macrophage Migration-Inhibitory Factors; Male; Mice; Mice, Inbred C57BL; Palmitic Acid; Tetrazolium Salts; Thiazoles | 2012 |
Bisphenol A accelerates toxic amyloid formation of human islet amyloid polypeptide: a possible link between bisphenol A exposure and type 2 diabetes.
Topics: Air Pollutants, Occupational; Amino Acid Sequence; Animals; Benzhydryl Compounds; Benzothiazoles; Cell Line, Tumor; Cell Membrane; Circular Dichroism; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Humans; Insulin-Secreting Cells; Islet Amyloid Polypeptide; Microscopy, Electron, Transmission; Molecular Sequence Annotation; Oxidative Stress; Phenols; Protein Folding; Protein Structure, Secondary; Rats; Thiazoles | 2013 |
Understanding insulin-resistance in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; DNA-Binding Proteins; Humans; Insulin Resistance; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
[Prevention of arteriosclerosis with the insulin sensitizer pioglitazone. Early intervention in diabetic patients compensates "cell ignorance"].
Topics: Arteriosclerosis; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Thiazoles; Thiazolidinediones | 2002 |
[Early effect of therapy with pioglitazone. Vascular damage significantly reduced].
Topics: Arteriosclerosis; Carotid Stenosis; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic Agents; Pioglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome | 2002 |
Rhabdomyolysis, pancreatitis, and hyperglycemia with ziprasidone.
Topics: Antipsychotic Agents; Diabetes Mellitus, Type 2; Diagnosis, Differential; Female; Fever; Humans; Hyperglycemia; Middle Aged; Muscle Rigidity; Neuroleptic Malignant Syndrome; Pancreatitis; Piperazines; Psychotic Disorders; Rhabdomyolysis; Thiazoles | 2002 |
Rosiglitazone--useful drug but has side effects.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Lipids; Rosiglitazone; Thiazoles; Thiazolidinediones; Weight Gain | 2002 |
PMT13, a pyrimidone analogue of thiazolidinedione improves insulin resistance-associated disorders in animal models of type 2 diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Hypoglycemic Agents; Insulin Resistance; Liver; Mice; Mice, Obese; Pyrimidines; Pyrimidinones; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
Effect of pioglitazone on blood proinsulin levels in patients with type 2 diabetes mellitus.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Gliclazide; Glycated Hemoglobin; Humans; Insulin; Male; Middle Aged; Pioglitazone; Proinsulin; Thiazoles; Thiazolidinediones | 2002 |
Ziprasidone alternative for olanzapine-induced hyperglycemia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Male; Olanzapine; Piperazines; Pirenzepine; Schizophrenia, Paranoid; Thiazoles; Treatment Outcome | 2002 |
Effective use of thiazolidinediones for the treatment of glucocorticoid-induced diabetes.
Topics: Administration, Oral; Adult; Biomarkers; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Fructosamine; Glucocorticoids; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Leptin; Middle Aged; Prednisone; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
[Diabetes therapy. Blood vessel oriented rather than glucose-centered].
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hyperlipidemias; Hypoglycemic Agents; Thiazoles | 2002 |
Possible vascular-protective effects of antidiabetic agents such as the thiazolidinediones (TZDs).
Topics: Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Thiazoles; Thiazolidinediones | 2002 |
Rosiglitazone in the management of older patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Hemoglobins; Humans; Hypoglycemic Agents; Male; Middle Aged; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome | 2002 |
Seeking sweet relief for diabetes.
Topics: Behavior Control; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diet; Exercise; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Metformin; Obesity; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Treatment Outcome; United States | 2002 |
A futile metabolic cycle activated in adipocytes by antidiabetic agents.
Topics: Adipocytes; Animals; Cell Line; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Gene Expression Regulation; Glycerol; Glycerol Kinase; Humans; Hypoglycemic Agents; Ligands; Mice; Mice, Inbred C57BL; Mice, Obese; Rats; Rats, Sprague-Dawley; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Substrate Cycling; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides | 2002 |
APC-dependent suppression of colon carcinogenesis by PPARgamma.
Topics: Animals; Azoxymethane; beta Catenin; Carcinogens; Colonic Neoplasms; Cytoskeletal Proteins; Diabetes Mellitus, Type 2; Gene Silencing; Genes, APC; Humans; Hypoglycemic Agents; Male; Mice; Mice, Knockout; Mutation; Receptors, Cytoplasmic and Nuclear; Thiazoles; Trans-Activators; Transcription Factors | 2002 |
[Severe electrolyte imbalance and edema in therapy with rosiglitazone].
Topics: Chemical and Drug Induced Liver Injury; Contraindications; Diabetes Mellitus, Type 2; Edema; Humans; Hypoglycemic Agents; Liver Diseases, Alcoholic; Liver Function Tests; Male; Middle Aged; Rosiglitazone; Thiazoles; Thiazolidinediones; Water-Electrolyte Imbalance | 2002 |
Lipid metabolome-wide effects of the PPARgamma agonist rosiglitazone.
Topics: Adipose Tissue; Animals; Diabetes Mellitus, Type 2; Gene Expression; Heart; Lipid Metabolism; Lipids; Liver; Male; Mice; Mice, Obese; Myocardium; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Weight Gain | 2002 |
[Glinides and glitazones in diabetes treatment. Are they really effective?].
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Nateglinide; Phenylalanine; Pioglitazone; Piperidines; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome | 2002 |
[Vascular damage decides prognosis of type 2 diabetic patients. Lowering blood glucose is not enough].
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic Agents; Pioglitazone; Prognosis; Thiazoles; Thiazolidinediones | 2002 |
Severe but reversible cholestatic liver injury after pioglitazone therapy.
Topics: Cholestasis; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Middle Aged; Pioglitazone; Thiazoles; Thiazolidinediones | 2002 |
[Meta-analysis shows: insulin sensitizer is safe for the liver].
Topics: Chemical and Drug Induced Liver Injury; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
Differences in lipid profiles of patients given rosiglitazone followed by pioglitazone.
Topics: Adult; Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Retrospective Studies; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors; Triglycerides | 2002 |
Rosiglitazone and pioglitazone: new preparations. Two new oral antidiabetics both poorly assessed.
Topics: Administration, Oral; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Approval; Drug Evaluation; Europe; Evaluation Studies as Topic; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sulfonylurea Compounds; Thiazoles | 2002 |
Dual PPARalpha /gamma activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats.
Topics: Animals; Body Composition; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Eating; Fatty Acids, Nonesterified; Glucose Clamp Technique; Glycated Hemoglobin; Glycogen; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Liver; Male; Oxazines; Phenylpropionates; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2003 |
Are thiazolidinediones first-line agents?
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Sensitivity and Specificity; Thiazoles | 2002 |
[News on diabetes and public health perspectives].
Topics: Administration, Oral; Adult; Chromans; Clinical Trials as Topic; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetes, Gestational; Exercise; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Infant, Newborn; Insulin; Metformin; Obesity; Pancreas Transplantation; Patient Education as Topic; Pregnancy; Public Health; Risk Factors; Thiazoles; Thiazolidinediones; Time Factors; Troglitazone | 2002 |
Metaglip and Avandamet for type 2 diabetes.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Fees, Pharmaceutical; Glipizide; Humans; Hypoglycemic Agents; Metformin; Thiazoles | 2002 |
Intramyocellular lipid and insulin resistance: a longitudinal in vivo 1H-spectroscopic study in Zucker diabetic fatty rats.
Topics: Adipose Tissue; Animals; Diabetes Mellitus; Diabetes Mellitus, Type 2; Insulin Resistance; Lipid Metabolism; Liver; Longitudinal Studies; Magnetic Resonance Spectroscopy; Male; Muscle, Skeletal; Obesity; Organ Size; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2003 |
Comparison of glycemic and lipid response to pioglitazone treatment in Mexican-Americans and non-Hispanic Caucasians with type 2 diabetes.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Mexican Americans; Middle Aged; Pioglitazone; Retrospective Studies; Thiazoles; Thiazolidinediones; White People | 2003 |
Pharmacologic treatment of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Exenatide; Gastric Inhibitory Polypeptide; Ghrelin; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Insulin; Insulin Secretion; Monosaccharide Transport Proteins; Obesity; Peptide Fragments; Peptide Hormones; Peptides; Peroxisome Proliferators; Protein Precursors; Receptors, Cell Surface; Thiazoles; Venoms | 2003 |
Effect of thiazolidinediones and metformin on LDL oxidation and aortic endothelium relaxation in diabetic GK rats.
Topics: Acetylcholine; Animals; Aorta, Thoracic; Arteriosclerosis; Cholesterol, LDL; Chromans; Diabetes Mellitus, Type 2; Endothelium, Vascular; Hypoglycemic Agents; Isometric Contraction; Lipid Peroxidation; Lipids; Male; Metformin; Muscle Contraction; Muscle Relaxation; Oxidation-Reduction; Pioglitazone; Rats; Rats, Wistar; Thiazoles; Thiazolidinediones; Troglitazone; Vasodilator Agents | 2003 |
Initial management of glycemia in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Heart Failure; Humans; Hypoglycemic Agents; Insulin; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Amphipathic 3-phenyl-7-propylbenzisoxazoles; human pPaR gamma, delta and alpha agonists.
Topics: Administration, Oral; Animals; Biological Availability; COS Cells; Diabetes Mellitus, Type 2; Disease Models, Animal; Humans; Isoxazoles; Mice; Mice, Mutant Strains; Nuclear Proteins; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2003 |
Improvement of aortic wall distensibility and reduction of oxidative stress by pioglitazone in pre-diabetic stage of Otsuka Long-Evans Tokushima fatty rats.
Topics: Age Factors; Animals; Aorta; Body Weight; Collagen; Diabetes Mellitus, Type 2; Hemodynamics; Hypoglycemic Agents; Male; Oxidative Stress; Pioglitazone; Rats; Rats, Inbred OLETF; Thiazoles; Thiazolidinediones | 2002 |
[Therapy decision based on the glucose triad. Drug treatment of type 2 diabetes].
Topics: 1-Deoxynojirimycin; Acarbose; Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Glucosamine; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Insulin Resistance; Insulin Secretion; Metformin; Obesity; Pioglitazone; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Time Factors | 2003 |
Troglitazone-induced liver failure: a case study.
Topics: Age Distribution; Aged; Chemical and Drug Induced Liver Injury; Chromans; Chronic Disease; Confidence Intervals; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug and Narcotic Control; Female; Humans; Liver Failure; Liver Failure, Acute; Liver Function Tests; Male; Middle Aged; Odds Ratio; Probability; Registries; Risk Assessment; Severity of Illness Index; Sex Distribution; Survival Rate; Thiazoles; Thiazolidinediones; Troglitazone; United States; United States Food and Drug Administration | 2003 |
[A case of drug induced liver injury related pioglitazone].
Topics: Aryl Hydrocarbon Hydroxylases; Chemical and Drug Induced Liver Injury; Cytochrome P-450 CYP2C9; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Middle Aged; Pioglitazone; Thiazoles; Thiazolidinediones | 2003 |
Thiazolidinediones upregulate impaired fatty acid uptake in skeletal muscle of type 2 diabetic subjects.
Topics: Adult; CD36 Antigens; Cells, Cultured; Chromans; Diabetes Mellitus, Type 2; Fatty Acids; Fatty Acids, Nonesterified; Female; Gene Expression; Humans; Insulin Resistance; Male; Membrane Glycoproteins; Middle Aged; Muscle, Skeletal; Organic Anion Transporters; Oxidation-Reduction; Palmitic Acid; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2003 |
Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
Topics: Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Lipids; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus.
Topics: Aged; Alanine Transaminase; Alleles; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; Chromans; Data Collection; Diabetes Mellitus, Type 2; DNA; DNA Primers; Female; Gene Frequency; Genotype; Glutathione Transferase; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Polymorphism, Genetic; Sex Characteristics; Thiazoles; Thiazolidinediones; Troglitazone | 2003 |
Rosiglitazone in Type 2 diabetes mellitus: an evaluation in British Indo-Asian patients.
Topics: Adult; Aged; Asia; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Placebos; Rosiglitazone; Sensitivity and Specificity; Thiazoles; Thiazolidinediones; Treatment Outcome | 2003 |
Marked improvement of glycaemic control with pioglitazone in a Type 2 diabetic patient associated with Charcot-Marie-Tooth disease.
Topics: Body Weight; Charcot-Marie-Tooth Disease; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Pioglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome | 2003 |
Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucose Clamp Technique; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Kinetics; Lipid Metabolism; Male; Middle Aged; Pioglitazone; Racial Groups; Splanchnic Circulation; Texas; Thiazoles; Thiazolidinediones; Triglycerides | 2003 |
Fatty acids modulate the effect of darglitazone on macrophage CD36 expression.
Topics: Arteriosclerosis; CD36 Antigens; Diabetes Mellitus, Type 2; Fatty Acids; Humans; Macrophages; Receptors, Immunologic; Receptors, Scavenger; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thiazoles; Thiazolidinediones | 2003 |
Effect of thiazolidinediones on glucose and fatty acid metabolism in patients with type 2 diabetes.
Topics: Adipocytes; Adiponectin; Blood Glucose; Cell Size; Cross-Over Studies; Diabetes Mellitus, Type 2; Esterification; Fatty Acids; Female; Glucose; Humans; Hypoglycemic Agents; Insulin; Intercellular Signaling Peptides and Proteins; Leptin; Lipolysis; Male; Middle Aged; Oxidation-Reduction; Proteins; Thiazoles | 2003 |
Chronic treatment with the thiazolidinedione, MCC-555, is associated with reductions in nitric oxide synthase activity and beta-cell apoptosis in the pancreas of the Zucker Diabetic Fatty rat.
Topics: Animals; Apoptosis; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Administration Schedule; Insulin; Islets of Langerhans; Male; Nitric Oxide Synthase; Rats; Rats, Zucker; Thiazoles; Thiazolidinediones | 2003 |
[Preventing infarct in the diabetic patient. Lowering blood glucose and HbA1c are not enough].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Myocardial Infarction; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Economic model of first-line drug strategies to achieve recommended glycaemic control in newly diagnosed type 2 diabetes mellitus.
Topics: Carbamates; Cohort Studies; Decision Trees; Diabetes Mellitus, Type 2; Direct Service Costs; Drug Costs; Drug Therapy, Combination; Glipizide; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Managed Care Programs; Markov Chains; Metformin; Models, Economic; Piperidines; Rosiglitazone; Thiazoles; Thiazolidinediones; United States | 2003 |
Allosteric activators of glucokinase: potential role in diabetes therapy.
Topics: Adaptor Proteins, Signal Transducing; Allosteric Regulation; Animals; Blood Glucose; Carrier Proteins; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Enzyme Activation; Enzyme Activators; Glucokinase; Glucose; Glucose Tolerance Test; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Intracellular Signaling Peptides and Proteins; Islets of Langerhans; Keto Acids; Liver; Liver Glycogen; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Proteins; Rats; Rats, Wistar; Recombinant Proteins; Stereoisomerism; Thiazoles | 2003 |
Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation.
Topics: Adipose Tissue; Animals; Basal Metabolism; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fatty Acids; Fenofibrate; Glycogen; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Islets of Langerhans; Male; Muscle, Skeletal; Obesity; Rats; Rats, Inbred OLETF; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides; Viscera | 2003 |
NICE issues guidance on diabetes treatments.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Practice Guidelines as Topic; Thiazoles; Thiazolidinediones; United Kingdom | 2003 |
Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adipose Tissue; Animals; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Disease Models, Animal; Enzyme Inhibitors; Glucose Clamp Technique; Glucose Tolerance Test; Hyperglycemia; Hyperinsulinism; Insulin; Liver; Male; Mice; Mice, Inbred C57BL; Obesity; Piperazines; RNA, Messenger; Sulfonamides; Thiazoles | 2003 |
Do thiazolidinediones cause congestive heart failure?
Topics: Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Pulmonary Edema; Thiazoles; Thiazolidinediones | 2003 |
Thiazolidinedione-associated congestive heart failure and pulmonary edema.
Topics: Aged; Cardiomyopathies; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Kidney Failure, Chronic; Male; Myocardial Ischemia; Pulmonary Edema; Retrospective Studies; Thiazoles; Thiazolidinediones | 2003 |
Rosiglitazone reduces the accelerated neointima formation after arterial injury in a mouse injury model of type 2 diabetes.
Topics: Animals; Blood Glucose; Carotid Arteries; Carotid Artery Injuries; Cells, Cultured; Diabetes Mellitus, Type 2; Diet; Disease Models, Animal; Female; Homozygote; Hyperglycemia; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Resistance; Islets of Langerhans; Lipids; Macrophages; Mice; Mice, Inbred C57BL; Mice, Knockout; Muscle, Smooth, Vascular; Rosiglitazone; Thiazoles; Thiazolidinediones; Tunica Intima | 2003 |
Novel PPARgamma-dependent and independent effects for thiazolidinediones.
Topics: Animals; Bezafibrate; Body Weight; Chromans; Diabetes Mellitus, Type 2; Gene Expression; Humans; Insulin-Like Growth Factor Binding Protein 1; Insulin-Like Growth Factor Binding Proteins; Mice; Monocytes; Pancreas; Pioglitazone; PPAR alpha; PPAR gamma; Pregnancy Proteins; Pregnane X Receptor; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Rosiglitazone; Thiazoles; Thiazolidinediones; Thiazolidines; Troglitazone; Tumor Necrosis Factor-alpha | 2003 |
[Blood sugar inspite of maximal metformin dosage. New fixed combination forces HbA1c down].
Topics: Body Mass Index; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Combinations; Drug Therapy, Combination; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Patient Compliance; Placebos; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors | 2003 |
Use of perospirone for obesity and diabetes mellitus in patients with schizophrenia: three case reports.
Topics: Adult; Antipsychotic Agents; Diabetes Mellitus, Type 2; Humans; Indoles; Isoindoles; Male; Middle Aged; Obesity; Schizophrenia; Thiazoles; Weight Gain | 2004 |
Improvement of glucose tolerance in Zucker diabetic fatty rats by long-term treatment with the dipeptidyl peptidase inhibitor P32/98: comparison with and combination with rosiglitazone.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Drinking; Drug Therapy, Combination; Drug Tolerance; Eating; Glucose Tolerance Test; Hypoglycemic Agents; Insulin; Islets of Langerhans; Male; Obesity; Pentanoic Acids; Rats; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones; Thiazolidines; Time Factors | 2005 |
A computational model to define the molecular causes of type 2 diabetes mellitus.
Topics: Algorithms; Blood Glucose; Computer Simulation; Diabetes Mellitus, Type 2; Gene Expression Regulation; Genome; Humans; Insulin Resistance; Mexican Americans; Models, Statistical; Muscle, Skeletal; Oxidative Phosphorylation; RNA; Scandinavian and Nordic Countries; Thiazoles | 2005 |
Anglo-Swedish Medicinal Chemistry - second symposium.
Topics: Animals; Benzamides; Chemistry, Pharmaceutical; Diabetes Mellitus, Type 2; Enzyme Activators; Glucokinase; Humans; Imatinib Mesylate; JNK Mitogen-Activated Protein Kinases; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, IGF Type 1; Societies, Scientific; src-Family Kinases; Sweden; Thiazoles; United Kingdom | 2005 |
MB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes.
Topics: Adenosine Monophosphate; Alanine; Analysis of Variance; Animals; Carbon Radioisotopes; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Design; Fructose-Bisphosphatase; Gluconeogenesis; Humans; Liver; Male; Molecular Mimicry; Organophosphonates; Organophosphorus Compounds; Rats; Rats, Sprague-Dawley; Rats, Zucker; Spectrophotometry; Thiazoles | 2005 |
A novel glucokinase activator modulates pancreatic islet and hepatocyte function.
Topics: Animals; Blood Glucose; Cells, Cultured; Crystallography; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Enzyme Activators; Glucokinase; Hepatocytes; Humans; Insulin; Insulin Secretion; Islets of Langerhans; Male; Protein Structure, Tertiary; Rats; Rats, Wistar; Sulfones; Thiazoles | 2005 |
Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.
Topics: Animals; Diabetes Mellitus, Type 2; Dipeptidases; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Dogs; Female; Humans; Hypoglycemic Agents; Isoleucine; Isomerism; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Protease Inhibitors; Rats; Recombinant Proteins; Thiazoles | 2005 |
Short-term activation of peroxysome proliferator-activated receptor beta/delta increases fatty acid oxidation but does not restore insulin action in muscle cells from type 2 diabetic patients.
Topics: Cells, Cultured; Diabetes Mellitus, Type 2; Female; Glycogen; Humans; Insulin; Male; Middle Aged; Muscle Cells; Oxidation-Reduction; Palmitic Acid; Phosphorylation; PPAR delta; PPAR-beta; Proto-Oncogene Proteins c-akt; Thiazoles; Time Factors | 2006 |
Oxidizing and reducing responses of granulocytes from type 2 diabetic patients.
Topics: Adult; Aged; Antioxidants; Blood Glucose; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Granulocytes; Humans; Male; Middle Aged; Oxidation-Reduction; Reactive Oxygen Species; Tetrazolium Salts; Thiazoles | 2006 |
Determination of the antioxidant status of plasma from type 2 diabetic patients.
Topics: Antioxidants; Blood Glucose; Body Mass Index; Cholesterol; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Granulocytes; Humans; Oxidation-Reduction; Reactive Oxygen Species; Reference Values; Serum Albumin, Bovine; Tetrazolium Salts; Thiazoles; Triglycerides | 2007 |
Letter to the editor in reference to article titled: Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Combinations; Humans; Hypoglycemic Agents; Metformin; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazoles; Thiazolidinediones | 2007 |
Response to Pokharna and Kanna: initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
Topics: Confounding Factors, Epidemiologic; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Drug Combinations; Humans; Hypoglycemic Agents; Metformin; Rosiglitazone; Thiazoles; Thiazolidinediones | 2008 |
Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib.
Topics: Aged; Antineoplastic Agents; Benzamides; Blood Glucose; Dasatinib; Diabetes Complications; Diabetes Mellitus, Type 2; Fasting; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Accelerated Phase; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Failure | 2008 |
2-amino-1,3-thiazol-4(5H)-ones as potent and selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: enzyme-ligand co-crystal structure and demonstration of pharmacodynamic effects in C57Bl/6 mice.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adamantane; Adipose Tissue; Animals; Cortisone; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Humans; Hydrocortisone; Hypoglycemic Agents; Ligands; Liver; Male; Mice; Mice, Inbred C57BL; Models, Molecular; Molecular Structure; Rats; Stereoisomerism; Structure-Activity Relationship; Thiazoles; Triazoles | 2008 |
The fluorescent amino acid p-cyanophenylalanine provides an intrinsic probe of amyloid formation.
Topics: Alanine; Amino Acid Sequence; Amyloid; Benzothiazoles; Diabetes Mellitus, Type 2; Fluorescence; Fluorescent Dyes; Humans; Islet Amyloid Polypeptide; Kinetics; Molecular Sequence Data; Nitriles; Phenylalanine; Point Mutation; Protein Binding; Thiazoles; Time Factors | 2008 |
New directions in treating insulin resistance.
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Thiazoles; Thiazolidinediones; Troglitazone | 1995 |
The new oral hypoglycemic agent, CS-045, inhibits the lipid peroxidation of human plasma low density lipoprotein in vitro.
Topics: Administration, Oral; Amidines; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Lipid Peroxidation; Lipoproteins, LDL; Thiazoles; Thiazolidinediones; Thiobarbituric Acid Reactive Substances; Time Factors; Troglitazone; Vitamin E | 1995 |
Repeat treatment of obese mice with BRL 49653, a new potent insulin sensitizer, enhances insulin action in white adipocytes. Association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labeling.
Topics: Adipocytes; Adipose Tissue; Affinity Labels; Animals; Azides; Blood Glucose; Cell Membrane; Cholesterol; Diabetes Mellitus, Type 2; Diet; Disaccharides; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Epididymis; Fatty Acids, Nonesterified; Glucose; Glucose Tolerance Test; Glucose Transporter Type 4; Glycosides; Hypoglycemic Agents; Insulin; Kinetics; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Monosaccharide Transport Proteins; Muscle Proteins; Propylamines; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides | 1995 |
An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma).
Topics: Adipocytes; Animals; Cell Differentiation; Cell Line; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Ligands; Mice; Mice, Inbred C3H; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Stem Cells; Thiazoles; Thiazolidinediones; Transcription Factors | 1995 |
Insulin resistance and the prevention of diabetes mellitus.
Topics: Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Obesity; Thiazoles; Thiazolidinediones; Troglitazone | 1994 |
[[omega-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Hemoglobins; Hypoglycemic Agents; Mice; Mice, Inbred C57BL; Structure-Activity Relationship; Thiazoles | 1994 |
Increased insulin responsiveness after CS-045 treatment in diabetes associated with Werner's syndrome.
Topics: Adult; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Thiazoles; Thiazolidinediones; Troglitazone; Werner Syndrome | 1994 |
Altered gene expression for tumor necrosis factor-alpha and its receptors during drug and dietary modulation of insulin resistance.
Topics: Animals; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Gene Expression; Hypoglycemic Agents; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Muscles; Obesity; Pioglitazone; Receptors, Tumor Necrosis Factor; RNA, Messenger; Thiazoles; Thiazolidinediones; Tumor Necrosis Factor-alpha | 1994 |
Effect of pioglitazone on insulin receptors of skeletal muscles from high-fat-fed rats.
Topics: Animals; Diabetes Mellitus, Type 2; Dietary Fats; Electrophoresis, Polyacrylamide Gel; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Male; Muscles; Phosphorylation; Pioglitazone; Precipitin Tests; Protein-Tyrosine Kinases; Rats; Rats, Sprague-Dawley; Receptor, Insulin; Thiazoles; Thiazolidinediones | 1993 |
Hepatic insulin resistance in KKA(y) mice and its amelioration by pioglitazone do not involve alterations in phospholipase C activity.
Topics: Animals; Cell Membrane; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Phosphoinositide Phospholipase C; Phosphoric Diester Hydrolases; Pioglitazone; Thiazoles; Thiazolidinediones | 1993 |
[EMG findings in patients with diabetic polyneuropathy treated with sabeluzole].
Topics: Diabetes Mellitus, Type 2; Diabetic Neuropathies; Electromyography; Humans; Piperidines; Thiazoles | 1993 |
Lipoprotein profile characterization of the KKA(y) mouse, a rodent model of type II diabetes, before and after treatment with the insulin-sensitizing agent pioglitazone.
Topics: Animals; Apolipoprotein A-I; Apolipoproteins B; Carrier Proteins; Cholesterol Ester Transfer Proteins; Diabetes Mellitus, Type 2; Disease Models, Animal; Glycoproteins; Hypoglycemic Agents; Lipoproteins; Lipoproteins, HDL; Male; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Pioglitazone; Thiazoles; Thiazolidinediones | 1993 |
Down-regulation of the expression of the obese gene by an antidiabetic thiazolidinedione in Zucker diabetic fatty rats and db/db mice.
Topics: Adipose Tissue; Amino Acid Sequence; Animals; Base Sequence; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; DNA Primers; DNA Probes; DNA, Complementary; Gene Expression Regulation; Glucose; Homeostasis; Hypoglycemic Agents; Leptin; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Molecular Sequence Data; Obesity; Polymerase Chain Reaction; Protein Biosynthesis; Proteins; Rats; Rats, Zucker; Reference Values; RNA, Messenger; Thiazoles; Thiazolidinediones; Triglycerides | 1996 |
VLDL triglyceride kinetics in Wistar fatty rats, an animal model of NIDDM: effects of dietary fructose alone or in combination with pioglitazone.
Topics: Animals; Body Weight; Cholesterol; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Disease Models, Animal; Energy Intake; Fatty Acids, Nonesterified; Fructose; Hypoglycemic Agents; Lipase; Lipoprotein Lipase; Lipoproteins, VLDL; Liver; Obesity; Pioglitazone; Rats; Rats, Wistar; Thiazoles; Thiazolidinediones; Thinness; Triglycerides | 1996 |
Hypoglycemic activity of a series of alpha-alkylthio and alpha-alkoxy carboxylic acids related to ciglitazone.
Topics: 3T3 Cells; Adipocytes; Animals; Benzofurans; Carboxylic Acids; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Mice; Mice, Mutant Strains; Mice, Obese; Molecular Structure; Oxazoles; Stereoisomerism; Structure-Activity Relationship; Thiazoles; Thiazolidinediones | 1996 |
Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin or troglitazone.
Topics: Age Factors; Animals; Body Weight; Chromans; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Glucose; Hyperglycemia; Insulin; Islets of Langerhans; Male; Metformin; Rats; Rats, Zucker; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 1996 |
"Glitazones", a prospect for non-insulin-dependent diabetes.
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 1997 |
The effect of pioglitazone on hepatic glucose uptake measured with indirect and direct methods in alloxan-induced diabetic dogs.
Topics: Animals; Biological Transport; Blood Pressure; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dogs; Glucagon; Glucose; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Pioglitazone; Thiazoles; Thiazolidinediones | 1997 |
Metabolic effects of troglitazone in the Goto-Kakizaki rat, a non-obese and normolipidemic rodent model of non-insulin-dependent diabetes mellitus.
Topics: Animals; Chromans; Diabetes Mellitus, Type 2; Disease Models, Animal; Female; Glucose; Glucose Clamp Technique; Glucose Tolerance Test; Hypoglycemic Agents; Injections, Intravenous; Insulin Resistance; Male; Rats; Rats, Inbred Strains; Rats, Wistar; Thiazoles; Thiazolidinediones; Troglitazone | 1997 |
Warner Lambert/Sankyo diabetes drug nears market.
Topics: Blood Glucose; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Industry; Hypoglycemic Agents; Thiazoles; Thiazolidinediones; Troglitazone; United States; United States Food and Drug Administration | 1997 |
New diabetes drug targets insulin resistance.
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Thiazoles; Thiazolidinediones; Troglitazone | 1997 |
Glitazones and NIDDM.
Topics: Animals; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Obesity; Thiazoles; Thiazolidinediones; Troglitazone | 1997 |
Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists.
Topics: Animals; Bexarotene; Blood Glucose; Cells, Cultured; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Hypoglycemic Agents; Insulin; Insulin Resistance; Ligands; Mice; Mice, Inbred C57BL; Mice, Obese; Nicotinic Acids; Obesity; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Rosiglitazone; Tetrahydronaphthalenes; Thiazoles; Thiazolidinediones; Transcription Factors; Transfection | 1997 |
Troglitazone for non-insulin-dependent diabetes mellitus.
Topics: Administration, Oral; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Interactions; Humans; Hypercholesterolemia; Hypoglycemic Agents; Obesity; Thiazoles; Thiazolidinediones; Troglitazone | 1997 |
Pioglitazone: in vitro effects on rat hepatoma cells and in vivo liver hypertrophy in KKAy mice.
Topics: Animals; Blood Glucose; Body Weight; Carcinoma, Hepatocellular; Cell Division; Diabetes Mellitus, Type 2; DNA; Dose-Response Relationship, Drug; Drug Synergism; Glyburide; Hypertrophy; Hypoglycemic Agents; Insulin; Liver; Male; Mice; Mice, Inbred C57BL; Organ Size; Pioglitazone; Rats; Thiazoles; Thiazolidinediones; Tumor Cells, Cultured | 1997 |
Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats.
Topics: Animals; Aorta; Arteriosclerosis; Blood Glucose; Blood Pressure; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Epinephrine; Hypertension; Hypoglycemic Agents; Kidney Cortex; Kidney Glomerulus; Male; Norepinephrine; Obesity; Pioglitazone; Proteinuria; Rats; Rats, Inbred WF; Rats, Mutant Strains; Rats, Wistar; Sodium; Thiazoles; Thiazolidinediones; Triglycerides; Tunica Media | 1997 |
Antidiabetic efficacy of BRL 49653, a potent orally active insulin sensitizing agent, assessed in the C57BL/KsJ db/db diabetic mouse by non-invasive 1H NMR studies of urine.
Topics: Administration, Oral; Aging; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycosuria; Hypoglycemic Agents; Magnetic Resonance Spectroscopy; Mice; Mice, Inbred C57BL; Protons; Rosiglitazone; Thiazoles; Thiazolidinediones | 1997 |
Is troglitazone a real indication for obese subjects with impaired glucose tolerance?
Topics: Chromans; Diabetes Mellitus, Type 2; Glucose Intolerance; Humans; Hypoglycemic Agents; Obesity; Thiazoles; Thiazolidinediones; Troglitazone | 1997 |
Troglitazone: a new class of oral antihyperglycemic for the treatment of type II diabetes.
Topics: Administration, Oral; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Thiazoles; Thiazolidinediones; Troglitazone | 1997 |
Pioglitazone and metformin reverse insulin resistance induced by tumor necrosis factor-alpha in liver cells.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Liver; Liver Neoplasms, Experimental; Metformin; Pioglitazone; Rats; Thiazoles; Thiazolidinediones; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1997 |
Insulin resistance.
Topics: Diabetes Mellitus, Type 2; Hexosamines; Humans; Insulin Resistance; Thiazoles; Tumor Necrosis Factor-alpha | 1997 |
American Diabetes Association Annual Meeting, 1997. Type 2 diabetes.
Topics: Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Homeostasis; Humans; Hypoglycemic Agents; Societies, Medical; Thiazoles; Thiazolidinediones; Troglitazone; United States | 1997 |
The antidiabetic agent thiazolidinedione stimulates the interaction between PPAR gamma and CBP.
Topics: 3T3 Cells; Adipocytes; Animals; Carrier Proteins; Cell Differentiation; Citrates; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Mice; Microbodies; Receptors, Cytoplasmic and Nuclear; Thiazoles; Transcription Factors | 1997 |
Troglitazone action is independent of adipose tissue.
Topics: Adipose Tissue; Animals; Blood Glucose; Body Weight; Cholesterol; Chromans; Diabetes Mellitus, Type 2; Eating; Fatty Acids; Glycogen; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Leptin; Lipoproteins, LDL; Lipoproteins, VLDL; Mice; Mice, Transgenic; Organ Size; Proteins; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides; Troglitazone | 1997 |
A miracle of salamization: positive divided by two equals negative.
Topics: Chromans; Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Troglitazone | 1997 |
Novel benzoxazole 2,4-thiazolidinediones as potent hypoglycemic agents. Synthesis and structure-activity relationships.
Topics: Animals; Benzopyrans; Benzoxazoles; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Male; Mice; Obesity; Pioglitazone; Rosiglitazone; Structure-Activity Relationship; Thiazoles; Thiazolidinediones; Troglitazone | 1997 |
New treatment for adult-onset diabetes.
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Thiazoles; Thiazolidinediones; Troglitazone | 1997 |
Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes.
Topics: Animals; Apoptosis; Cells, Cultured; Ceramides; Chromans; Coenzyme A Ligases; Diabetes Mellitus; Diabetes Mellitus, Type 2; DNA Fragmentation; Enzyme Induction; Enzyme Inhibitors; Fatty Acids, Nonesterified; Guanidines; Homozygote; Humans; Hypoglycemic Agents; Islets of Langerhans; Male; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Obesity; Palmitic Acid; Prediabetic State; Rats; Rats, Zucker; Repressor Proteins; RNA, Messenger; Saccharomyces cerevisiae Proteins; Thiazoles; Thiazolidinediones; Transcription, Genetic; Triazenes; Troglitazone | 1998 |
Troglitazone: monotherapy indication.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Chromans; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Humans; Hypertension; Hypoglycemic Agents; Lipids; Thiazoles; Thiazolidinediones; Troglitazone | 1998 |
Lack of effect of type II diabetes on the pharmacokinetics of troglitazone in a multiple-dose study.
Topics: Adult; Aged; Analysis of Variance; Chromans; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Thiazoles; Thiazolidinediones; Troglitazone | 1997 |
Another potential use of troglitazone in noninsulin-dependent diabetes mellitus.
Topics: Carotid Artery, Common; Chromans; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Thiazoles; Thiazolidinediones; Troglitazone; Ultrasonography | 1998 |
A novel antidiabetic drug, troglitazone--reason for hope and concern.
Topics: Administration, Oral; Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Thiazoles; Thiazolidinediones; Troglitazone | 1998 |
A novel assay in vitro of human islet amyloid polypeptide amyloidogenesis and effects of insulin secretory vesicle peptides on amyloid formation.
Topics: Amyloid; Benzothiazoles; C-Peptide; Cytoplasmic Granules; Diabetes Mellitus, Type 2; Fluorescent Dyes; Humans; Hydrogen-Ion Concentration; Insulin; Islets of Langerhans; Kinetics; Microscopy, Electron; Peptide Fragments; Proinsulin; Temperature; Thiazoles | 1998 |
Troglitazone regulation of glucose metabolism in human skeletal muscle cultures from obese type II diabetic subjects.
Topics: Adult; Cells, Cultured; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucose; Glucose Transporter Type 1; Glycogen Synthase; Humans; Hypoglycemic Agents; Insulin; Middle Aged; Monosaccharide Transport Proteins; Muscle, Skeletal; Obesity; RNA, Messenger; Thiazoles; Thiazolidinediones; Troglitazone | 1998 |
A novel biomarker for hyperglycemia, MRX isolated from hydrolysate of glycated proteins.
Topics: Animals; Biomarkers; Cattle; Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 2; Fluorescent Dyes; Glycoproteins; Glycosylation; Hydrolysis; Hyperglycemia; Maillard Reaction; Male; Pyridinium Compounds; Rats; Thiazoles | 1998 |
International Diabetes Federation meeting, 1997. Issues in the treatment of type 2 diabetes; sulfonylureas, metformin, and troglitazone.
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Troglitazone | 1998 |
Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone.
Topics: Adult; Aged; Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Thiazoles; Thiazolidinediones; Troglitazone | 1998 |
Troglitazone-induced hepatic failure leading to liver transplantation. A case report.
Topics: Chromans; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liver Failure; Liver Transplantation; Middle Aged; Thiazoles; Thiazolidinediones; Troglitazone | 1998 |
Troglitazone and small low-density lipoprotein in type 2 diabetes.
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Lipoproteins, LDL; Thiazoles; Thiazolidinediones; Troglitazone | 1998 |
Effect of troglitazone in type 2 diabetes mellitus.
Topics: Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Thiazoles; Thiazolidinediones; Troglitazone | 1998 |
Effect of troglitazone in type 2 diabetes mellitus.
Topics: Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Thiazoles; Thiazolidinediones; Troglitazone; Weight Gain | 1998 |
Troglitazone effects on gene expression in human skeletal muscle of type II diabetes involve up-regulation of peroxisome proliferator-activated receptor-gamma.
Topics: Adult; Carrier Proteins; Cells, Cultured; Chromans; Diabetes Mellitus, Type 2; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Gene Expression; Gene Expression Regulation; Humans; Hypoglycemic Agents; Middle Aged; Muscle, Skeletal; Myelin P2 Protein; Neoplasm Proteins; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone; Tumor Suppressor Proteins; Up-Regulation | 1998 |
Ways of changing sensitivity to insulin.
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Thiazoles; Thiazolidinediones; Troglitazone | 1997 |
Targeted glycemic control in type 2 diabetes.
Topics: Aged; Algorithms; Anti-Obesity Agents; Biguanides; Blood Glucose; Blood Glucose Self-Monitoring; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Nuclear Proteins; Obesity; Receptors, Cytoplasmic and Nuclear; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 1998 |
Baseline factors affecting the efficacy of troglitazone on plasma glucose in Japanese patients with non-insulin-dependent diabetes mellitus.
Topics: Aged; Blood Glucose; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Fasting; Female; Humans; Hypoglycemic Agents; Japan; Lipids; Male; Middle Aged; Regression Analysis; Thiazoles; Thiazolidinediones; Treatment Outcome; Troglitazone | 1998 |
In vivo effects of pioglitazone on uncoupling protein-2 and -3 mRNA levels in skeletal muscle of hyperglycemic KK mice.
Topics: Animals; Carrier Proteins; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Injections, Subcutaneous; Ion Channels; Male; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Mitochondrial Proteins; Muscle, Skeletal; Pioglitazone; Proteins; RNA, Messenger; Thiazoles; Thiazolidinediones; Uncoupling Agents; Uncoupling Protein 2; Uncoupling Protein 3 | 1998 |
Treatment of psoriasis with troglitazone therapy.
Topics: Adult; Aged; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Immunosuppressive Agents; Middle Aged; Platelet Aggregation Inhibitors; Psoriasis; Thiazoles; Thiazolidinediones; Troglitazone | 1998 |
Substituted tetrahydropyrrolo[2,1-b]oxazol-5(6H)-ones and tetrahydropyrrolo[2,1-b]thiazol-5(6H)-ones as hypoglycemic agents.
Topics: Animals; Cell Line; Diabetes Mellitus, Type 2; Drug Evaluation, Preclinical; Glucose; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Muscles; Oxazoles; Pyrroles; Rats; Structure-Activity Relationship; Thiazoles | 1998 |
Actions of novel antidiabetic thiazolidinedione, T-174, in animal models of non-insulin-dependent diabetes mellitus (NIDDM) and in cultured muscle cells.
Topics: Animals; Blood Glucose; Cells, Cultured; Deoxy Sugars; Diabetes Mellitus, Type 2; Hypoglycemic Agents; In Vitro Techniques; Male; Mice; Muscle, Skeletal; Rats; Rats, Zucker; Thiazoles; Thiazolidinediones | 1998 |
The development of overt diabetes in young Zucker Diabetic Fatty (ZDF) rats and the effects of chronic MCC-555 treatment.
Topics: Age Factors; Animals; Body Weight; Diabetes Mellitus, Type 2; Drinking; Glucose; Glucose Intolerance; Hypoglycemic Agents; Male; Rats; Rats, Zucker; Thiazoles; Thiazolidinediones; Time Factors | 1998 |
An autopsy case of troglitazone-induced fulminant hepatitis.
Topics: Alanine Transaminase; Autopsy; Bilirubin; Chromans; Diabetes Mellitus, Type 2; Fatal Outcome; Hepatic Encephalopathy; Humans; Hypoglycemic Agents; Liver; Male; Middle Aged; Prothrombin Time; Thiazoles; Thiazolidinediones; Time Factors; Troglitazone | 1998 |
LDL cholesterol and troglitazone therapy.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Chromans; Coronary Disease; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypoglycemic Agents; Risk Factors; Thiazoles; Thiazolidinediones; Troglitazone | 1998 |
Pleuropulmonary disease in a man with diabetes who was treated with troglitazone.
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Lung Diseases, Interstitial; Male; Middle Aged; Thiazoles; Thiazolidinediones; Troglitazone | 1998 |
From fat-free mice, the skinny on diabetes.
Topics: Adipose Tissue; Animals; Chromans; Diabetes Mellitus, Type 2; Fatty Acids; Humans; Hypoglycemic Agents; Lipodystrophy; Mice; Mice, Transgenic; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides; Troglitazone | 1998 |
Fatal hepatotoxicity associated with troglitazone.
Topics: Aged; Aged, 80 and over; Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Male; Thiazoles; Thiazolidinediones; Troglitazone | 1998 |
Novel euglycemic and hypolipidemic agents: Part-2. Antioxidant moiety as structural motif.
Topics: Animals; Antioxidants; Blood Glucose; Diabetes Mellitus, Type 2; Drug Design; Hypoglycemic Agents; Hypolipidemic Agents; Indicators and Reagents; Mice; Mice, Mutant Strains; Structure-Activity Relationship; Thiazoles; Triglycerides | 1998 |
Significant weight gain with rezulin therapy.
Topics: Chromans; Diabetes Mellitus, Type 2; Edema; Humans; Hypoglycemic Agents; Male; Middle Aged; Thiazoles; Thiazolidinediones; Troglitazone; Weight Gain | 1999 |
Beneficial effect of long-term combined treatment with voglibose and pioglitazone on pancreatic islet function of genetically diabetic GK rats.
Topics: Animals; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Fasting; Glucose Tolerance Test; Glycoside Hydrolase Inhibitors; Hypoglycemic Agents; Inositol; Insulin; Insulin Secretion; Islets of Langerhans; Male; Pioglitazone; Rats; Rats, Mutant Strains; Rats, Wistar; Thiazoles; Thiazolidinediones; Triglycerides | 1998 |
NIH opens conflict-of-interest investigation.
Topics: Biomedical Research; Chromans; Clinical Trials as Topic; Conflict of Interest; Diabetes Mellitus, Type 2; Disclosure; Federal Government; Humans; Hypoglycemic Agents; National Institutes of Health (U.S.); Research Support as Topic; Thiazoles; Thiazolidinediones; Troglitazone; United States | 1999 |
Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative.
Topics: 3T3 Cells; Administration, Oral; Animals; Blood Glucose; Cell Differentiation; Chromans; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glucose; Hyperinsulinism; Hypertriglyceridemia; Hypoglycemic Agents; Insulin; Isoxazoles; Male; Mice; Mice, Inbred Strains; Oxidation-Reduction; Pioglitazone; Rats; Rats, Sprague-Dawley; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides; Troglitazone | 1999 |
Inhibition of LDL oxidation in vitro but not ex vivo by troglitazone.
Topics: Antioxidants; Chromans; Copper; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Humans; Lipoproteins, LDL; Macrophages; Oxidation-Reduction; Probucol; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
Troglitazone and metformin, but not glibenclamide, decrease blood pressure in Otsuka Long Evans Tokushima Fatty rats.
Topics: Animals; Blood Glucose; Blood Pressure; Catecholamines; Chromans; Diabetes Mellitus, Type 2; Glucose Transporter Type 4; Glyburide; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipids; Male; Metformin; Monosaccharide Transport Proteins; Muscle Proteins; Rats; Rats, Inbred OLETF; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
On the need for outcome trials in preventive pharmacology. Lessons from the recent experience with adverse drug reactions.
Topics: Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug-Related Side Effects and Adverse Reactions; Humans; Hypoglycemic Agents; Thiazoles; Thiazolidinediones; Treatment Outcome; Troglitazone | 1999 |
American Diabetes Association Annual Meeting, 1998. Treatment of type 2 diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Nuclear Proteins; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors | 1999 |
Switching insulin-sensitizing agents in patients with type 2 diabetes who require insulin.
Topics: Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
Attenuation of ischemia induced increases in sodium and calcium by the aldose reductase inhibitor zopolrestat.
Topics: Aldehyde Reductase; Analysis of Variance; Animals; Benzothiazoles; Calcium; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Intracellular Fluid; Magnetic Resonance Spectroscopy; Metals; Myocardial Ischemia; Myocardial Reperfusion; Myocardium; Perfusion; Phthalazines; Rats; Rats, Inbred BB; Sodium; Sodium-Potassium-Exchanging ATPase; Thiazoles; Time Factors | 1999 |
From the Food and Drug Administration.
Topics: Diabetes Mellitus, Type 2; Endotoxemia; Gentamicins; Humans; Hypoglycemic Agents; Joint Prosthesis; Pioglitazone; Rosiglitazone; Temporomandibular Joint; Temporomandibular Joint Disorders; Thiazoles; Thiazolidinediones; United States; United States Food and Drug Administration | 1999 |
[Inhibition of incretin degradation--a new therapy principle for treatment of type 2 diabetes?].
Topics: Administration, Oral; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Enzyme Inhibitors; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Isoleucine; Peptide Fragments; Rats; Rats, Zucker; Thiazoles | 1999 |
FDA approves pioglitazone for diabetes.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Thiazoles; Thiazolidinediones; United States; United States Food and Drug Administration | 1999 |
Non-alcoholic steatohepatitis.
Topics: Chromans; Contraindications; Diabetes Mellitus, Type 2; Fatty Liver; Hepatitis; Humans; Hypoglycemic Agents; Metformin; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
Diabetes drug Rezulin: take it, but take precautions.
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Liver Failure; Liver Function Tests; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
[Type II diabetes mellitus. Rosiglitazone is effective against insulin resistance].
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Rosiglitazone; Thiazoles; Thiazolidinediones | 1999 |
The effect of insulin sensitizer, troglitazone, on lipoprotein lipase mass in preheparin serum.
Topics: Adult; Aged; Cholesterol; Cholesterol, HDL; Chromans; Diabetes Mellitus, Type 2; Diet, Diabetic; Female; Glycated Hemoglobin; Heparin; Humans; Hypoglycemic Agents; Insulin; Lipoprotein Lipase; Male; Middle Aged; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
A drug interaction between troglitazone and simvastatin.
Topics: Cholesterol, LDL; Chromans; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Retrospective Studies; Simvastatin; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
Rosiglitazone for type 2 diabetes mellitus.
Topics: Administration, Oral; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Rosiglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones | 1999 |
Effects of troglitazone on collagen accumulation and distensibility of aortic wall in prestage of non-insulin-dependent diabetes mellitus of Otsuka Long-Evans Tokushima Fatty rats.
Topics: Animals; Aorta, Thoracic; Body Weight; Chromans; Collagen; Diabetes Mellitus, Type 2; Glucose Tolerance Test; Hemodynamics; Hydroxyproline; Hypoglycemic Agents; Male; Muscle, Smooth, Vascular; Observer Variation; Rats; Rats, Inbred OLETF; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Deterioration of rheumatoid arthritis with troglitazone: a rare and unexpected adverse effect.
Topics: Arthritis, Rheumatoid; Chromans; Diabetes Mellitus, Type 2; Disease Progression; Female; Humans; Hypoglycemic Agents; Middle Aged; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Hepatic failure in a patient taking rosiglitazone.
Topics: Aged; Combined Modality Therapy; Coronary Disease; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Ischemia; Liver; Liver Failure; Male; Monitoring, Physiologic; Pravastatin; Rosiglitazone; Thiazoles; Thiazolidinediones; Verapamil | 2000 |
Hepatocellular injury in a patient receiving rosiglitazone. A case report.
Topics: Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Liver; Liver Function Tests; Male; Middle Aged; Monitoring, Physiologic; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
Rosiglitazone approved for treatment of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Approval; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazoles; Thiazolidinediones; United States; United States Food and Drug Administration | 1999 |
Subacute hepatic failure associated with a new antidiabetic agent, troglitazone: a case report with autopsy examination.
Topics: Chromans; Diabetes Mellitus, Type 2; Fatal Outcome; Female; Humans; Hypoglycemic Agents; Liver Failure; Middle Aged; Necrosis; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Troglitazone-associated hepatic failure.
Topics: Aged; Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 2; Fatal Outcome; Female; Hepatic Encephalopathy; Humans; Hyperlipidemias; Hypoglycemic Agents; Liver; Liver Failure; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Short-term treatment with troglitazone decreases bone turnover in patients with type 2 diabetes mellitus.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Biomarkers; Blood Glucose; Bone and Bones; Bone Remodeling; Bone Resorption; Chromans; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Thiazoles; Thiazolidinediones; Time Factors; Troglitazone | 1999 |
The novel hypoglycemic agent YM440 normalizes hyperglycemia without changing body fat weight in diabetic db/db mice.
Topics: 3T3 Cells; Adipose Tissue; Animals; Blood Glucose; Cell Differentiation; Chromans; Diabetes Mellitus, Type 2; Hyperglycemia; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Mice, Transgenic; Oxadiazoles; Pioglitazone; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone; Weight Gain | 2000 |
Managing type 2 diabetes. A look at the newer agents.
Topics: Acarbose; Carbamates; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Piperidines; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
Drugs and disease.
Topics: Chromans; Cisapride; Diabetes Mellitus, Type 2; Drug and Narcotic Control; Gastroesophageal Reflux; Gastrointestinal Agents; Humans; Hypoglycemic Agents; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Troglitazone-induced fulminant hepatic failure. Acute Liver Failure Study Group.
Topics: Chromans; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liver; Liver Failure; Middle Aged; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
["Insulin sensitizers" (glitazones), obesity, insulin resistance--is there a connection?].
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Obesity; Peroxisome Proliferators; Thiazoles | 2000 |
Severe but reversible hepatitis induced by troglitazone.
Topics: Biopsy; Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Liver; Liver Function Tests; Male; Middle Aged; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Troglitazone in progesterone derivative-induced impairment of glucose tolerance.
Topics: Aged; Antineoplastic Agents, Hormonal; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Humans; Hyperglycemia; Hypoglycemic Agents; Medroxyprogesterone Acetate; Middle Aged; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Substituting for troglitazone (Rezulin).
Topics: Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Down-regulation by troglitazone of hepatic tumor necrosis factor-alpha and interleukin-6 mRNA expression in a murine model of non-insulin-dependent diabetes.
Topics: Animals; Chromans; Diabetes Mellitus, Type 2; Disease Models, Animal; Down-Regulation; Gene Expression; Hypoglycemic Agents; Interleukin-6; Lipopolysaccharides; Liver; Male; Mice; Mice, Inbred C57BL; RNA, Messenger; Thiazoles; Thiazolidinediones; Troglitazone; Tumor Necrosis Factor-alpha | 2000 |
Down-regulation of orexin gene expression by severe obesity in the rats: studies in Zucker fatty and zucker diabetic fatty rats and effects of rosiglitazone.
Topics: Animals; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Gene Expression Regulation; Hyperglycemia; Hypoglycemic Agents; Hypothalamus; Insulin; Intracellular Signaling Peptides and Proteins; Leptin; Neuropeptides; Obesity; Orexins; Protein Precursors; Rats; Rats, Zucker; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Thinness; Transcription, Genetic | 2000 |
Pioglitazone attenuates basal and postprandial insulin concentrations and blood pressure in the spontaneously hypertensive rat.
Topics: Animals; Area Under Curve; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Glucose; Hyperglycemia; Hyperinsulinism; Hypertension; Hypoglycemic Agents; Insulin; Male; Pioglitazone; Postprandial Period; Rats; Rats, Inbred SHR; Thiazoles; Thiazolidinediones | 2000 |
Dietary troglitazone decreases oxidative stress in early stage type II diabetic rats.
Topics: Animals; Antioxidants; Chromans; Diabetes Mellitus, Type 2; Diet; Hypoglycemic Agents; Lipid Peroxidation; Male; Oxidative Stress; Rats; Rats, Long-Evans; Superoxide Dismutase; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
[New antidiabetic in "virtual reality". Eye to eye with insulin resistance].
Topics: Computer Simulation; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; User-Computer Interface | 2000 |
Late-onset troglitazone-induced hepatic dysfunction.
Topics: Aged; Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Liver Function Tests; Male; Thiazoles; Thiazolidinediones; Time Factors; Treatment Refusal; Troglitazone | 2000 |
Deterioration of glycemic control after long-term treatment with troglitazone in nonobese type 2 diabetic patients.
Topics: Biomarkers; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Thiazoles; Thiazolidinediones; Time Factors; Treatment Failure; Troglitazone | 2000 |
Toward practical prevention of type 2 diabetes.
Topics: alpha-Linolenic Acid; Animals; Biotin; Calcium; Chromans; Coenzymes; Diabetes Mellitus, Type 2; Ethanol; Female; Humans; Liver; Magnesium; Male; Metformin; Rats; Risk Factors; Thiazoles; Thiazolidinediones; Troglitazone; Ubiquinone | 2000 |
Acute rhabdomyolysis associated with troglitazone.
Topics: Chromans; Creatine Kinase; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glyburide; Humans; Hypoglycemic Agents; Isoenzymes; Middle Aged; Rhabdomyolysis; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
v- and t-SNARE protein expression in models of insulin resistance: normalization of glycemia by rosiglitazone treatment corrects overexpression of cellubrevin, vesicle-associated membrane protein-2, and syntaxin 4 in skeletal muscle of Zucker diabetic fat
Topics: Animals; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Gene Expression; Glucose Transporter Type 4; Hypoglycemic Agents; Immunoblotting; Insulin Resistance; Male; Membrane Proteins; Monosaccharide Transport Proteins; Muscle Proteins; Muscle, Skeletal; Obesity; Qa-SNARE Proteins; R-SNARE Proteins; Rats; Rats, Sprague-Dawley; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones; Vesicle-Associated Membrane Protein 3 | 2000 |
Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.
Topics: Adult; Arteriosclerosis; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Female; Fibrinolysis; Glucose Clamp Technique; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Obesity; Plasminogen Activator Inhibitor 1; Thiazoles; Thiazolidinediones; Tissue Plasminogen Activator; Troglitazone | 2000 |
[Tackling insulin resistance. Control of etiology in type 2 diabetes].
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin Resistance; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
Insulin resistance: a problem for clinicians and scientists.
Topics: Aged; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Receptors, Cytoplasmic and Nuclear; Thiazoles; Transcription Factors | 2000 |
Pharmacologic therapy for type 2 diabetes mellitus.
Topics: Algorithms; Diabetes Mellitus, Type 2; Drug Approval; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; United States; United States Food and Drug Administration | 2000 |
Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors.
Topics: Alitretinoin; Amino Acid Sequence; Binding Sites; Crystallography; Diabetes Mellitus, Type 2; Dimerization; Drug Design; Histone Acetyltransferases; Humans; Ligands; Models, Molecular; Molecular Sequence Data; Nuclear Proteins; Nuclear Receptor Coactivator 1; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Rosiglitazone; Sequence Homology, Amino Acid; Surface Properties; Thiazoles; Thiazolidinediones; Transcription Factors; Tretinoin | 2000 |
Oral antidiabetic agents safe with renal disease?
Topics: Aged; Contraindications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Kidney Diseases; Metformin; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
[Troglitazone, an insulin action enhancer--a drug of precision to treat adult-onset diabetes].
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Thiazoles; Thiazolidinediones; Troglitazone | 1997 |
Pharmacokinetics of the insulin-sensitizing agent troglitazone in cats.
Topics: Administration, Oral; Animals; Area Under Curve; Cats; Chromans; Chromatography, High Pressure Liquid; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Half-Life; Hypoglycemic Agents; Injections, Intravenous; Random Allocation; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
[Type 2 diabetes. A new kind of insulin sensitizer at the door].
Topics: Diabetes Mellitus, Type 2; Drugs, Investigational; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazoles; Thiazolidinediones | 1999 |
Mechanism of troglitazone action in type 2 diabetes.
Topics: Body Composition; Chromans; Diabetes Mellitus, Type 2; Female; Glucose; Glucose-6-Phosphate; Glycogen; Hormones; Humans; Hypoglycemic Agents; Intracellular Membranes; Male; Middle Aged; Muscle, Skeletal; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Troglitazone decreases collagen accumulation in prediabetic stage of a type II diabetic rat model.
Topics: Animals; Chromans; Collagen; Diabetes Mellitus, Type 2; Heart Diseases; Hypoglycemic Agents; Male; Rats; Rats, Long-Evans; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
[New insulin sensitizers].
Topics: Adult; Aged; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Middle Aged; Thiazoles | 1999 |
Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials.
Topics: Chemical and Drug Induced Liver Injury; Chromans; Contraindications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
[A 75-year-old type 2 diabetes mellitus case responding strikingly troglitazone: possible mechanism of insulin resistance induced by insulin antibody].
Topics: Aged; Chromans; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Antibodies; Insulin Resistance; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Troglitazone has a reducing effect on thromboxane production.
Topics: Arachidonic Acid; Blood Platelets; Chromans; Diabetes Mellitus, Type 2; Fibrinolytic Agents; Gas Chromatography-Mass Spectrometry; Humans; Leukemia, Erythroblastic, Acute; Rosiglitazone; Thiazoles; Thiazolidinediones; Thromboxane A2; Troglitazone; Tumor Cells, Cultured; Vitamin E | 2000 |
[Thiazolidinediones in type 2 diabetes].
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
Rosiglitazone.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Food-Drug Interactions; Humans; Hypoglycemic Agents; Insulin Resistance; Rosiglitazone; Thiazoles; Thiazolidinediones; United States | 2000 |
[Diabetes therapy related to etiology. Indications, uses and side effects of new insulin sensitizers].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
The rise and fall of troglitazone.
Topics: Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2000 |
Pioglitazone (Actos).
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Liver Function Tests; Pioglitazone; Thiazoles; Thiazolidinediones | 1999 |
Diabetes recall. Though Rezulin's withdrawal is a blow for some patients, there are ways to cope. Here's how.
Topics: Chromans; Diabetes Mellitus, Type 2; Drug Approval; Humans; Hypoglycemic Agents; Thiazoles; Thiazolidinediones; Troglitazone; United States; United States Food and Drug Administration | 2000 |
Troglitazone prevents and reverses dyslipidemia, insulin secretory defects, and histologic abnormalities in a rat model of naturally occurring obese diabetes.
Topics: Adipose Tissue; Aging; Animals; Blood Glucose; Body Weight; Cholesterol; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Eating; Fasting; Fatty Acids, Nonesterified; Glucose Tolerance Test; Hyperlipidemias; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Obesity; Organ Size; Pancreas; Rats; Rats, Inbred Strains; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 2000 |
[First insulin sensitizer approved in Germany. Insulin resistance in type 2 diabetes can be treated].
Topics: Diabetes Mellitus, Type 2; Drug Approval; Germany; Humans; Hypoglycemic Agents; Insulin Resistance; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
[New development in diabetes therapy. 35th Annual Meeting of the German Diabetes Society, Munich, May 5-June 3, 2000].
Topics: Chromans; Diabetes Mellitus, Type 2; Germany; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
[Insulin sensitizer. A new therapy option for type 2 diabetic patients].
Topics: Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Unraveling the mechanism of action of thiazolidinediones.
Topics: Animals; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Troglitazone prevents fatty changes of the liver in obese diabetic rats.
Topics: Age Factors; Alanine Transaminase; Animals; Aspartate Aminotransferases; Blood Glucose; Cholesterol; Chromans; Colon; Colonic Polyps; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Disease Models, Animal; Fatty Liver; Hyperlipidemias; Hypoglycemic Agents; Insulin; Liver; Male; Organ Size; Rats; Rats, Inbred OLETF; Rats, Long-Evans; Thiazoles; Thiazolidinediones; Time Factors; Triglycerides; Troglitazone | 2000 |
[Therapy of type 2 diabetes. Blood lipids should not be neglected!].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Lipids; Pioglitazone; Thiazoles; Thiazolidinediones | 2000 |
Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion.
Topics: Animals; Basement Membrane; Body Weight; Chondroitin Sulfate Proteoglycans; Chromans; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Fibrosis; Glomerular Mesangium; Hyperglycemia; Hyperinsulinism; Hypertriglyceridemia; Hypoglycemic Agents; Islets of Langerhans; Rats; Rats, Zucker; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
UCP3 gene expression does not correlate with muscle oxidation rates in troglitazone-treated Zucker fatty rats.
Topics: Animals; Antioxidants; Body Weight; Carbon Dioxide; Carrier Proteins; Chromans; Diabetes Mellitus, Type 2; Disease Models, Animal; Energy Metabolism; Fatty Acids; Gene Expression Regulation; Glucose; Insulin Resistance; Ion Channels; Mitochondrial Proteins; Muscle, Skeletal; Rats; Rats, Zucker; RNA, Messenger; Thiazoles; Thiazolidinediones; Troglitazone; Uncoupling Protein 3 | 2000 |
Diabetes. Type-righting lessons.
Topics: Cost of Illness; Diabetes Mellitus, Type 2; Drug Costs; Humans; Hypoglycemic Agents; Rosiglitazone; State Medicine; Thiazoles; Thiazolidinediones; United Kingdom | 2000 |
[New prospects for the type 2 diabetic patient. Delaying disease progression].
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Disease Progression; Humans; Hypoglycemic Agents; Insulin Resistance; Prognosis; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
Glitazones and the potential improvement of lipid profiles in diabetes patients at high risk for cardiovascular disease.
Topics: Coronary Disease; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Lipids; Middle Aged; Pioglitazone; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; United States | 2000 |
[Causal therapy of type 2 diabetes. Determining the cause of insulin resistance early].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
Troglitazone, an antidiabetic drug, improves left ventricular mass and diastolic function in normotensive diabetic patients.
Topics: Blood Flow Velocity; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Chromans; Diabetes Mellitus, Type 2; Echocardiography, Doppler; Heart Ventricles; Humans; Hypertension; Hypertrophy, Left Ventricular; Hypoglycemic Agents; Insulin; Middle Aged; Myocardial Contraction; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
Thiazolidinediones for type 2 diabetes. No evidence exists that pioglitazone induces hepatic cytochrome P450 isoform CYP3A4.
Topics: Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Mixed Function Oxygenases; Pioglitazone; Thiazoles; Thiazolidinediones | 2001 |
Effects of troglitazone on cellular differentiation, insulin signaling, and glucose metabolism in cultured human skeletal muscle cells.
Topics: Adipocytes; Base Sequence; Biomarkers; Cell Differentiation; Cells, Cultured; Chromans; Diabetes Mellitus, Type 2; DNA Primers; Gene Expression; Glucose; Glucose Transporter Type 1; Glucose Transporter Type 4; Glycogen; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Monosaccharide Transport Proteins; Muscle Proteins; Muscle, Skeletal; Phosphatidylinositol 3-Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Signal Transduction; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2001 |
Thiazolidinediones in the treatment of type 2 diabetes: a clinician's perspective.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Formularies as Topic; Humans; Hypoglycemia; Hypoglycemic Agents; Managed Care Programs; Thiazoles | 2000 |
Failure to develop hepatic injury from rosiglitazone in a patient with a history of troglitazone-induced hepatitis.
Topics: Adult; Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
Pulmonary edema associated with rosiglitazone and troglitazone.
Topics: Aged; Chromans; Diabetes Mellitus, Type 2; Humans; Male; Pulmonary Edema; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; Vasodilator Agents | 2001 |
Troglitazone has no effect on K(ATP) channel opener induced-relaxations in rat aorta and in human saphenous veins from patients with type 2 diabetes.
Topics: Animals; Aorta; Chromans; Cromakalim; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; In Vitro Techniques; Isometric Contraction; Male; Middle Aged; Muscle, Smooth, Vascular; Nitroprusside; Potassium Channels; Rats; Rats, Wistar; Reference Values; Saphenous Vein; Thiazoles; Thiazolidinediones; Troglitazone; Vasodilation | 2000 |
Honing type 2 diabetes treatment.
Topics: Carbamates; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Piperidines; Thiazoles; Thiazolidinediones | 2001 |
The hormone resistin links obesity to diabetes.
Topics: 3T3 Cells; Adipocytes; Amino Acid Sequence; Animals; Base Sequence; Chromosomes, Human, Pair 19; Cloning, Molecular; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diet; DNA; Female; Gene Expression Regulation; Glucose Intolerance; Hormones; Hormones, Ectopic; Humans; Hypoglycemic Agents; Insulin Antagonists; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Male; Mice; Mice, Inbred C57BL; Molecular Sequence Data; Nerve Growth Factor; Neutralization Tests; Obesity; Proteins; Resistin; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones | 2001 |
Factors associated with the risk of liver enzyme elevation in patients with type 2 diabetes treated with a thiazolidinedione.
Topics: Adult; Age Factors; Aged; Alanine Transaminase; Aspartate Aminotransferases; Chi-Square Distribution; Diabetes Mellitus, Type 2; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Statistics, Nonparametric; Thiazoles; Thiazolidinediones | 2001 |
Does pioglitazone, like troglitazone, increase serum levels of lipoprotein(a) in diabetic patients?
Topics: Chromans; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Lipoprotein(a); Male; Middle Aged; Pioglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
[30-year-old diabetic patients mostly have type 2 diabetes. "Mature" diabetics are becoming increasingly younger].
Topics: Adult; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Pioglitazone; Thiazoles; Thiazolidinediones | 2001 |
Anticipated US approval for rosiglitazone and pioglitazone.
Topics: Diabetes Mellitus, Type 2; Drug Approval; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; United States; United States Food and Drug Administration | 1999 |
FDA reviews troglitazone.
Topics: Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Liver Diseases; Risk Factors; Thiazoles; Thiazolidinediones; Troglitazone; United States; United States Food and Drug Administration | 1999 |
Lipid lowering explains the insulin sensitivity enhancing effects of a thiazolidinedione, 5-(4-(2-(2-phenyl-4-oxazolyl)ethoxy)benzyl)-2,4 thiazolidinedione.
Topics: Animals; Diabetes Mellitus, Type 2; Female; Glucose; Glucose Clamp Technique; Insulin; Insulin Resistance; Liver; Obesity; Rats; Rats, Zucker; Thiazoles; Thiazolidinediones; Triglycerides | 2000 |
Troglitazone reduces plasma levels of tumour necrosis factor-alpha in obese patients with type 2 diabetes.
Topics: Blood Glucose; C-Peptide; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Obesity; Thiazoles; Thiazolidinediones; Troglitazone; Tumor Necrosis Factor-alpha | 2000 |
The failings of NICE. NICE's guidance suggests using rosiglitazone in type 2 diabetes later than is ideal.
Topics: Diabetes Mellitus, Type 2; Drug Administration Schedule; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Rosiglitazone; Technology Assessment, Biomedical; Thiazoles; Thiazolidinediones; United Kingdom | 2001 |
Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat.
Topics: Aging; Animals; Cataract; Diabetes Mellitus, Type 2; Glucagon; Hyperglycemia; Hypoglycemic Agents; Insulin; Islets of Langerhans; Male; Pancreas; Proteinuria; Rats; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones; Thinness; Thirst; Time Factors | 2000 |
Non-thiazolidinedione insulin sensitiser shows promise.
Topics: Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Drug Industry; Humans; Hypoglycemic Agents; Multicenter Studies as Topic; Oxazoles; Thiazoles; Tyrosine | 2000 |
Antihyperglycemic activity of new 1,2,4-oxadiazolidine-3,5-diones.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Female; Hypoglycemic Agents; Insulin; Male; Mice; Mice, Obese; Oxadiazoles; Structure-Activity Relationship; Thiazoles; Thiazolidinediones | 2001 |
Antiatherogenic effects of thiazolidinediones?
Topics: Animals; Arteriosclerosis; Cell Movement; Chromans; Diabetes Mellitus, Type 2; Dietary Fats; Humans; Monocytes; Receptors, LDL; Thiazoles; Thiazolidinediones; Troglitazone; Vasodilator Agents | 2001 |
Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Aorta; Arteriosclerosis; Blood Glucose; Body Weight; Cell Movement; Cells, Cultured; Chemokine CCL2; Chromans; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Dietary Fats; Endothelium, Vascular; Flavonoids; Fructose; Humans; Insulin; Lipids; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Monocytes; Receptors, LDL; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; Tumor Cells, Cultured; Vasodilator Agents | 2001 |
The role of PPARgamma as a thrifty gene both in mice and humans.
Topics: Adipose Tissue; Animals; Case-Control Studies; Diabetes Mellitus, Type 2; Dietary Fats; Humans; Hypertrophy; Insulin Resistance; Leptin; Mice; Mice, Knockout; Models, Biological; Obesity; Polymorphism, Genetic; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors | 2000 |
Effects of type-2 diabetes and troglitazone on the expression patterns of small intestinal sugar transporters and PPAR-gamma in the Zucker diabetic fatty rat.
Topics: Analysis of Variance; Animals; Blotting, Northern; Blotting, Western; Chromans; Diabetes Mellitus, Type 2; Glucose Transporter Type 2; Glucose Transporter Type 5; Hypoglycemic Agents; Immunoenzyme Techniques; Intestinal Mucosa; Membrane Glycoproteins; Monosaccharide Transport Proteins; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Sodium-Glucose Transporter 1; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2001 |
Insulin action enhancers for the management of type 2 diabetes mellitus.
Topics: Animals; Diabetes Mellitus, Type 2; Drug Synergism; Humans; Hypoglycemic Agents; Insulin; Lipids; Thiazoles | 2000 |
Rosiglitazone, insulin treatment, and fasting correct defective activation of protein kinase C-zeta/lambda by insulin in vastus lateralis muscles and adipocytes of diabetic rats.
Topics: Adipocytes; Animals; Blotting, Western; Diabetes Mellitus, Type 2; Enzyme Activators; Fasting; Hypoglycemic Agents; Insulin; Isoenzymes; Mice; Muscle, Skeletal; Phosphatidylinositol 3-Kinases; Protein Kinase C; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Rats; Rats, Wistar; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
Company played down drug's risks, report says.
Topics: Animals; Chemical and Drug Induced Liver Injury; Chromans; Deception; Diabetes Mellitus, Type 2; Drug Industry; Government Regulation; Humans; Hypoglycemic Agents; Legislation, Drug; Thiazoles; Thiazolidinediones; Troglitazone; United States | 2001 |
Lipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover.
Topics: Animals; Apoptosis; Chromans; Diabetes Mellitus, Type 2; Fatty Acids; Hypoglycemic Agents; Islets of Langerhans; Lipid Metabolism; Obesity; Oxidation-Reduction; Rats; Rats, Zucker; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
Guidance on rosiglitazone for type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; England; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Practice Guidelines as Topic; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
2,4-Thiazolidinediones as potent and selective human beta3 agonists.
Topics: Adrenergic beta-3 Receptor Agonists; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Humans; Mice; Mice, Knockout; Mice, Transgenic; Obesity; Structure-Activity Relationship; Thiazoles; Thiazolidinediones | 2001 |
Myositis, microvesicular hepatitis, and progression to cirrhosis from troglitazone added to simvastatin.
Topics: Aged; Anticholesteremic Agents; Antioxidants; Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 2; Disease Progression; Drug Therapy, Combination; Female; Humans; Hypercholesterolemia; Hypoglycemic Agents; Liver Cirrhosis; Myositis; Simvastatin; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
What caused this patient's sudden liver dysfunction?
Topics: Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Middle Aged; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
Troglitazone stimulates pancreatic growth in congenitally CCK-A receptor-deficient OLETF rats.
Topics: Aging; Amylases; Animals; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Fibrosis; Homeostasis; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipase; Male; Pancreas; Rats; Rats, Inbred OLETF; Receptor, Cholecystokinin A; Receptors, Cholecystokinin; Reference Values; Thiazoles; Thiazolidinediones; Troglitazone; Trypsin | 2001 |
Identification of a novel human islet amyloid polypeptide beta-sheet domain and factors influencing fibrillogenesis.
Topics: Amino Acid Sequence; Amino Acid Substitution; Amyloid; Amyloidosis; Animals; Benzothiazoles; Circular Dichroism; Diabetes Mellitus, Type 2; Humans; Hydrogen-Ion Concentration; Islet Amyloid Polypeptide; Islets of Langerhans; Microscopy, Electron; Molecular Sequence Data; Peptide Fragments; Protein Folding; Protein Structure, Secondary; Protein Structure, Tertiary; Rats; Spectroscopy, Fourier Transform Infrared; Thiazoles; X-Ray Diffraction | 2001 |
Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death.
Topics: Aging; Animals; Blood Glucose; Body Weight; Cell Death; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Hypoglycemic Agents; Insulin; Islets of Langerhans; Male; Obesity; Organ Size; Pancreas; Rats; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
Lack of effect of pioglitazone on postprandial triglyceride levels in type 2 diabetes.
Topics: Asian People; Cholesterol; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Pioglitazone; Postprandial Period; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Time Factors; Transcription Factors; Triglycerides | 2001 |
Rosiglitazone and type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
[Value of glitazones in therapy of type 2 diabetes: pro].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Thiazoles; Thiazolidinediones; Treatment Outcome | 2001 |
[Use of glitazones in type 2 diabetes: a critical position].
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic Agents; Risk Factors; Thiazoles; Thiazolidinediones; Treatment Outcome | 2001 |
Insulinoma, type 2 diabetes and plasminogen activator inhibitor type-I.
Topics: Acarbose; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Insulinoma; Pancreatic Neoplasms; Plasminogen Activator Inhibitor 1; Thiazoles | 2001 |
Troglitazone improves whole-body insulin resistance and skeletal muscle glucose use in type II diabetic patients.
Topics: Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Fluorodeoxyglucose F18; Glucose; Humans; Hypertension; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Muscle, Skeletal; Radiopharmaceuticals; Thiazoles; Thiazolidinediones; Tomography, Emission-Computed; Troglitazone | 2001 |
A new era in type 2 diabetes mellitus treatment?
Topics: 1-Deoxynojirimycin; Acarbose; Carbamates; Diabetes Mellitus, Type 2; Glucosamine; Humans; Hypoglycemic Agents; Imino Pyranoses; Multicenter Studies as Topic; Pioglitazone; Piperidines; Randomized Controlled Trials as Topic; Thiazoles; Thiazolidinediones | 2001 |
Rezulin to be withdrawn from the market.
Topics: Chromans; Diabetes Mellitus, Type 2; Drug Industry; Humans; Hypoglycemic Agents; Liver; Safety; Thiazoles; Thiazolidinediones; Troglitazone; United States; United States Food and Drug Administration | 2000 |
Warner-Lambert voluntarily withdraws Rezulin.
Topics: Chromans; Consumer Product Safety; Diabetes Mellitus, Type 2; Drug Industry; Humans; Hypoglycemic Agents; Thiazoles; Thiazolidinediones; Troglitazone; United States | 2000 |
Actos (pioglitazone HCL) provides a safe, effective alternative for patients formerly taking Rezulin.
Topics: Chromans; Clinical Trials as Topic; Consumer Product Safety; Diabetes Mellitus, Type 2; Drug Industry; Humans; Hypoglycemic Agents; Pioglitazone; Thiazoles; Thiazolidinediones; Troglitazone; United States | 2000 |
Avandia, a leading alternative for Rezulin patients, prescribed to more than 700,000 patients.
Topics: Chromans; Consumer Product Safety; Diabetes Mellitus, Type 2; Drug Industry; Humans; Hypoglycemic Agents; Liver; Liver Function Tests; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; United States | 2000 |
Utilization of oral hypoglycemic agents in a drug-insured U.S. population.
Topics: Carbamates; Chromans; Cohort Studies; Databases as Topic; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insurance, Pharmaceutical Services; Longitudinal Studies; Managed Care Programs; Metformin; Piperidines; Retrospective Studies; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Time Factors; Troglitazone; United States | 2001 |
New labeling and use changes for Rezulin.
Topics: Chromans; Consumer Product Safety; Diabetes Mellitus, Type 2; Drug Labeling; Humans; Hypoglycemic Agents; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
Hepatocellular injury in a patient receiving pioglitazone.
Topics: Aged; Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Liver Function Tests; Male; Pioglitazone; Thiazoles; Thiazolidinediones | 2001 |
Differential regulation of adipocytokine mRNAs by rosiglitazone in db/db mice.
Topics: Adiponectin; Adrenergic beta-Agonists; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gene Expression Regulation; Hormones, Ectopic; Hypoglycemic Agents; Intercellular Signaling Peptides and Proteins; Mice; Mice, Obese; Nerve Growth Factor; Phenethylamines; Protein Biosynthesis; Proteins; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Resistin; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Necrosis Factor-alpha | 2001 |
Mechanisms involved in tumor necrosis factor-alpha induction of insulin resistance and its reversal by thiazolidinedione(s).
Topics: Animals; Autoradiography; Carcinoma, Hepatocellular; Chromans; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Insulin Resistance; Ligands; Liver Neoplasms; Rats; Thiazoles; Thiazolidinediones; Troglitazone; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2001 |
[ACE inhibitor plus glitazone. Insulin sensitizer, preventing diabetes?].
Topics: Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Insulin Resistance; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
Cellular mechanisms in the development and progression of diabetic nephropathy: activation of the DAG-PKC-ERK pathway.
Topics: Animals; Chromans; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diacylglycerol Kinase; Disease Progression; Enzyme Activation; Glomerular Mesangium; Isoenzymes; Mice; Mitogen-Activated Protein Kinases; Pioglitazone; Plant Proteins; Protein Kinase C; Protein Kinase C beta; Rats; Signal Transduction; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
Inhibition of RXR and PPARgamma ameliorates diet-induced obesity and type 2 diabetes.
Topics: 3T3 Cells; Adipose Tissue; Animals; Benzhydryl Compounds; Benzoates; Biphenyl Compounds; Diabetes Mellitus, Type 2; Epoxy Compounds; Fatty Acids; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Leptin; Mice; Mice, Knockout; Nicotinic Acids; Obesity; Receptors, Adrenergic, beta-3; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Rosiglitazone; Tetrahydronaphthalenes; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
[New oral hypoglycemic agents].
Topics: Adverse Drug Reaction Reporting Systems; Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Liver; Netherlands; Thiazoles | 2001 |
[Glitazones--a new therapeutic principle in diabetes].
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
[Type 2 diabetes. Regulating insulin according to need].
Topics: Blood Glucose; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Metformin; Nateglinide; Phenylalanine; Thiazoles; Thiazolidinediones | 2001 |
[Diabetology between genetics and pharmacology; report from the 36th annual meeting of the German Diabetes Association, May 23-26, 2001 at Aachen].
Topics: Adult; Child; Contraindications; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Genetic Therapy; Humans; Hypoglycemic Agents; Insulin; Syndrome; Thiazoles | 2001 |
Pioglitazone improves left ventricular diastolic function and decreases collagen accumulation in prediabetic stage of a type II diabetic rat.
Topics: Animals; Blood Glucose; Collagen; Diabetes Mellitus, Type 2; Diastole; Echocardiography, Doppler; Hemodynamics; Hypoglycemic Agents; Insulin; Kinetics; Lipids; Male; Malondialdehyde; Oxidative Stress; Pioglitazone; Prediabetic State; Rats; Rats, Inbred OLETF; Rats, Long-Evans; Thiazoles; Thiazolidinediones; Thiobarbituric Acid Reactive Substances; Ventricular Dysfunction, Left | 2001 |
[A role of the PPAR gamma activation in insulin resistance].
Topics: Adipocytes; Animals; CCAAT-Enhancer-Binding Proteins; Cell Differentiation; Diabetes Mellitus, Type 2; DNA-Binding Proteins; Energy Metabolism; Humans; Insulin Resistance; Mice; Mutation; Receptors, Cytoplasmic and Nuclear; Sterol Regulatory Element Binding Protein 1; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
[Type 2 diabetes--new treatment].
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Thiazoles | 2001 |
Uncoupling protein 3 content is decreased in skeletal muscle of patients with type 2 diabetes.
Topics: Blood Glucose; Body Mass Index; Carrier Proteins; Diabetes Mellitus, Type 2; Fluorescent Antibody Technique; Homeostasis; Humans; Insulin; Ion Channels; Male; Middle Aged; Mitochondrial Proteins; Muscle, Skeletal; RNA, Messenger; Thiazoles; Uncoupling Protein 3 | 2001 |
Increased lymphatic lipid transport in genetically diabetic obese rats.
Topics: Animals; Bile Acids and Salts; Body Weight; Carrier Proteins; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Energy Intake; Fistula; Hypoglycemic Agents; Lymphatic System; Male; Obesity; Phosphatidylcholines; Physical Conditioning, Animal; Rats; Rats, Inbred OLETF; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 2002 |
[Infarct prevention for diabetics. To lower blood sugar is not enough].
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fibrinolytic Agents; Humans; Hypoglycemic Agents; Insulin Resistance; Myocardial Infarction; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; Vasodilator Agents | 2001 |
Oral antihyperglycemic therapy for type 2 diabetes: clinical applications.
Topics: Aged; Biguanides; Comorbidity; Decision Making; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Evidence-Based Medicine; Female; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Patient Education as Topic; Patient Participation; Physician-Patient Relations; Practice Guidelines as Topic; Sulfonylurea Compounds; Thiazoles | 2002 |
[Life expectancy decreased by 1/3rd. Who to sink the vascular risk of type 2 diabetic patients?].
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic Agents; Pioglitazone; Survival Rate; Thiazoles; Thiazolidinediones | 2001 |
Beneficial hepatic effect of troglitazone in a patient with antimitochondrial antibody-negative primary biliary cirrhosis.
Topics: Autoantibodies; Chromans; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liver Cirrhosis, Biliary; Middle Aged; Mitochondria; Thiazoles; Thiazolidinediones; Treatment Outcome; Troglitazone | 2002 |
Troglitazone for Type II Diabetes.
Topics: Canada; Chromans; Cost of Illness; Diabetes Mellitus, Type 2; Drug Costs; Humans; Hypoglycemic Agents; Technology Assessment, Biomedical; Thiazoles | 1997 |
Improvement of asthma after administration of pioglitazone.
Topics: Aged; Asthma; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Pioglitazone; Thiazoles; Thiazolidinediones | 2002 |
Angioneurotic edema as a side effect of pioglitazone.
Topics: Angioedema; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Pioglitazone; Thiazoles; Thiazolidinediones | 2002 |
Thiazolidinediones enhance insulin-mediated suppression of fatty acid flux in type 2 diabetes mellitus.
Topics: Adipose Tissue; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucose; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
Effect of troglitazone on endothelial function in type 2 diabetic patients.
Topics: Aged; Antioxidants; Blood Glucose; Blood Pressure; Chromans; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Glycated Hemoglobin; Heart Rate; Humans; Hypoglycemic Agents; Insulin; Lipids; Lysophosphatidylcholines; Male; Middle Aged; Nitric Oxide; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
[Glitazones--a new class of drugs in treatment of type 2 diabetes].
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Risk Factors; Thiazoles | 2002 |
[Oral therapy in type 2 diabetes. Critical evaluation of glitazones].
Topics: Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Drug Approval; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
Pioglitazone-associated fulminant hepatic failure.
Topics: Aged; Biopsy, Needle; Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Hypoglycemic Agents; Liver Failure; Liver Function Tests; Male; Pioglitazone; Risk Assessment; Thiazoles; Thiazolidinediones | 2002 |
A treatment for Mr WP: thiazolidinediones after troglitazone.
Topics: Aged; Animals; Body Mass Index; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Mice; Mice, Knockout; Obesity; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2002 |
The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes.
Topics: Adipocytes; Adipose Tissue; Blood Glucose; Body Composition; Calorimetry, Indirect; Diabetes Mellitus, Type 2; Fatty Acids; Glucose Clamp Technique; Glycated Hemoglobin; Glycerol; Humans; Hyperinsulinism; Insulin; Kinetics; Lipids; Lipolysis; Liver; Magnetic Resonance Spectroscopy; Microdialysis; Middle Aged; Muscle, Skeletal; Oxidation-Reduction; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides | 2002 |
[A case report. Rosiglitazone treatment was highly effective yet had to be terminated].
Topics: Administration, Oral; Contraindications; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Heart Failure; Humans; Hypoglycemic Agents; Insulin; Middle Aged; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome | 2002 |
Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes.
Topics: Adiponectin; Adipose Tissue; Adult; Asian People; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Intercellular Signaling Peptides and Proteins; Japan; Male; Middle Aged; Pioglitazone; Proteins; Thiazoles; Thiazolidinediones; Time Factors | 2002 |
[The debate on glitazones].
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Thiazoles | 2002 |
Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy.
Topics: Bilirubin; Chemical and Drug Induced Liver Injury; Cholestasis, Intrahepatic; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liver; Middle Aged; Pioglitazone; Thiazoles; Thiazolidinediones; Transaminases | 2002 |
"Did this drug cause my patient's hepatitis?" and related questions.
Topics: Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Internal Medicine; Male; Middle Aged; Patient Care Planning; Physician's Role; Pioglitazone; Thiazoles; Thiazolidinediones | 2002 |
Summary for patients. Liver damage in a person taking the diabetes drug pioglitazone.
Topics: Bilirubin; Chemical and Drug Induced Liver Injury; Cholestasis, Intrahepatic; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Liver; Middle Aged; Pioglitazone; Thiazoles; Thiazolidinediones; Transaminases | 2002 |
A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; DNA-Binding Proteins; Dose-Response Relationship, Drug; Energy Intake; Energy Metabolism; Glucose Tolerance Test; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Male; Metabolic Syndrome; Mice; Mice, Mutant Strains; Organic Chemicals; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
[Type 2 diabetes. How can the infarction risk be reduced?].
Topics: Acarbose; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Myocardial Infarction; Pioglitazone; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors; Vasodilator Agents | 2002 |
[Diabetic dyslipoproteinemia: physiopathological bases and treatment prospects].
Topics: Anticholesteremic Agents; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Chromans; Clinical Trials as Topic; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Humans; Hyperlipoproteinemias; Hypertriglyceridemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Risk Factors; Simvastatin; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
Pioglitazone-induced hepatic injury in a patient previously receiving troglitazone with success.
Topics: Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liver; Middle Aged; Pioglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
Troglitazone improves GLUT4 expression in adipose tissue in an animal model of obese type 2 diabetes mellitus.
Topics: Adipose Tissue; Animals; Blood Glucose; Cholesterol; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Disease Models, Animal; Fatty Acids, Nonesterified; Gene Expression Regulation; Glucose Transporter Type 4; Hypoglycemic Agents; Insulin; Male; Monosaccharide Transport Proteins; Muscle Proteins; Obesity; Rats; Rats, Inbred OLETF; Rats, Long-Evans; Reference Values; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 2002 |
Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Pioglitazone; Retrospective Studies; Rosiglitazone; Sample Size; Thiazoles; Thiazolidinediones | 2002 |
Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury.
Topics: Animals; Cardiotonic Agents; Carrier Proteins; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose; Glucose Transporter Type 4; Hypoglycemic Agents; In Vitro Techniques; Intracellular Signaling Peptides and Proteins; JNK Mitogen-Activated Protein Kinases; Lactic Acid; Male; Mitogen-Activated Protein Kinases; Monosaccharide Transport Proteins; Muscle Proteins; Myocardial Reperfusion Injury; Myocardium; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
Rosiglitazone monotherapy and type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Diabetes, Gestational; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Pregnancy; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
Economic evaluation of pioglitazone hydrochloride in the management of type 2 diabetes mellitus in Canada.
Topics: Canada; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Economics, Pharmaceutical; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Markov Chains; Middle Aged; Pioglitazone; Thiazoles; Thiazolidinediones | 2002 |
Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.
Topics: Abdomen; Adipose Tissue; Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Glucose; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Pioglitazone; Regression Analysis; Thiazoles; Thiazolidinediones | 2002 |
Troglitazone enhances the hepatotoxicity of acetaminophen by inducing CYP3A in rats.
Topics: Acetaminophen; Administration, Oral; Animals; Aryl Hydrocarbon Hydroxylases; Carbon Tetrachloride; Chemical and Drug Induced Liver Injury; Chromans; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Diabetes Mellitus, Type 2; Diet; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Induction; Hypoglycemic Agents; Injections, Intraperitoneal; Male; Oxidoreductases, N-Demethylating; Rats; Rats, Mutant Strains; Rats, Wistar; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
Lipid response to pioglitazone in diabetic patients: clinical observations from a retrospective chart review.
Topics: Anticholesteremic Agents; Blood Glucose; Body Weight; California; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ethnicity; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Pioglitazone; Retrospective Studies; Thiazoles; Thiazolidinediones; Triglycerides | 2002 |
Does hypertriglyceridemia present an indication for pioglitazone therapy in diabetes?
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypertriglyceridemia; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Thiazoles; Thiazolidinediones | 2002 |
Combination of insulin and thiazolidinedione therapy in massively obese patients with Type 2 diabetes.
Topics: Adult; Aged; Body Mass Index; Body Weight; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Edema; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Obesity; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |
Pioglitazone increases insulin sensitivity by activating insulin receptor kinase.
Topics: Administration, Oral; Animals; Diabetes Mellitus, Type 2; Drug Hypersensitivity; Electrophoresis, Polyacrylamide Gel; Enzyme Activation; Female; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Obesity; Phosphorylation; Pioglitazone; Protein-Tyrosine Kinases; Rats; Rats, Inbred Strains; Receptor, Insulin; Thiazoles; Thiazolidinediones | 1992 |
Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects.
Topics: Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Chromans; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucagon; Gluconeogenesis; Glucose Clamp Technique; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Liver; Male; Middle Aged; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 1992 |
Novel thiazolidine-2,4-diones as potent euglycemic agents.
Topics: Alcohols; Animals; Benzopyrans; Blood Glucose; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Ketones; Mice; Mice, Inbred C57BL; Thiazoles; Thiazolidinediones | 1992 |
Glucose transport deficiency in diabetic animals is corrected by treatment with the oral antihyperglycemic agent pioglitazone.
Topics: Administration, Oral; Animals; Biological Transport; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose; Hypoglycemic Agents; Insulin; Male; Mice; Mice, Inbred Strains; Mice, Mutant Strains; Pioglitazone; Rats; Rats, Inbred Strains; Thiazoles; Thiazolidinediones | 1991 |
Effects of pioglitazone on glucose and lipid metabolism in Wistar fatty rats.
Topics: Adipose Tissue; Animals; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucose; Glucose Tolerance Test; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Muscles; Obesity; Pioglitazone; Rats; Rats, Inbred Strains; Thiazoles; Thiazolidinediones | 1990 |
Insulinlike activity of new antidiabetic agent CP 68722 in 3T3-L1 adipocytes.
Topics: Adipose Tissue; Animals; Benzopyrans; Biological Transport; Cell Line; Cells, Cultured; Deoxyglucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glucose; Insulin; Insulin Resistance; Oxidation-Reduction; Receptor, Insulin; Sulfonylurea Compounds; Temperature; Thiazoles; Thiazolidinediones | 1990 |
Synthesis and antihyperglycemic activity of novel 5-(naphthalenylsulfonyl)-2,4-thiazolidinediones.
Topics: Animals; Blood Glucose; Chemical Phenomena; Chemistry; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Lactates; Male; Mice; Naphthalenes; Rats; Rats, Zucker; Structure-Activity Relationship; Thiazoles; Thiazolidinediones | 1990 |